DAY-AT-A-GLANCE PROGRAm - American Diabetes Association

JUNE 25-29, 2010 • ORLANDO, FL 

DAY-AT-A-GLANCE Program 

scientificsessions.diabetes.org

Program Highlights 

Guided Audio Poster Tours 

New this year: Explore the Poster Hall with a Guided 

Audio Poster Tour. Moderators will lead attendees 

on one-hour tours, sharing their perspectives and 

highlighting novel or recent developments in Q&A 

sessions with poster presenters. Select posters from 

all categories will be included in the tours. 

Saturday, June 26, 11:30 a.m.–1:30 p.m. 

Sunday, June 27 and Monday, June 28, 12:00 p.m.–2:00 p.m. 

Hall C 

Presidents Poster Session and Reception 

New this year: Join us for the Presidents Poster 

Session and Reception. This prestigious session will 

showcase 100 posters. Presenters will be available 

during the session to discuss their research. Light 

refreshments and drinks will be served. 

June 24-28, 2011 

San Diego, CA 

SAVE THE DATE 

SAN DIEGO 

Sunday, June 27, 6:30 p.m.–7:45 p.m. 

Hall C 

Special NIDDK 60th Anniversary 

Symposium—Novel Pathways to Treatment 

of Type 2 Diabetes and Obesity 

Saturday, June 26, 4:00 p.m.–6:00 p.m. 

Valencia Ballroom AB 

Opening Reception 

(ticketed function) 

Joint ADA/JDRF Symposium—The Artificial 

Pancreas—A Goal within Reach 


Room 311 

HEALTHY Study—Middle School-Based 

Intervention to Reduce Diabetes Risk 



Late Breaking Clinical Studies 

Tuesday, June 29, 8:00 a.m.–10:00 a.m. 

Valencia Ballroom AB/CD 

Results of the ACCORD Clinical Trial 

Tuesday, June 29, 10:15 a.m.–12:15 p.m. 


Join us Friday, June 25 from 7:30 p.m.-11:00 p.m. 

for the Scientific Sessions Opening Reception at 

Walt Disney World’s Epcot Center. Enjoy a one-hour 

dessert reception, complimentary drink ticket, and 

a private viewing area for the multimedia fireworks 

show Illuminations: Reflections of Earth. After hours 

access to the best rides in the park is also included. 

If you did not purchase a ticket when registering, there 

is still time. Add a ticket to your existing meeting 

registration by using your registration confirmation 

number at https://www.cmrreg.com/ada_2s/ 

under “Already Registered” Only a limited number 

of tickets will be available on site in Orlando.

Table of Contents 

Session Schedule.................................................................................. 1–7 

Friday, June 25.................................................................................... 9–16 

Saturday, June 26............................................................................. 17–32 

Sunday, June 27................................................................................ 33–52 

Monday, June 28............................................................................... 53–68 

Tuesday, June 29............................................................................... 69–72

70 th Scientific Sessions Award Lectures 

The recipients of the American Diabetes Association’s highest scientific and health care 

achievement awards will present lectures at this year’s meeting. Please refer to the Session 

Schedule for times and locations of each lecture. 

Robert A. Rizza, MD, will present the Banting Lecture, The Liver as a Prime Target for 

Individualized Therapy in Diabetes, on Sunday, June 27. 

Martin G. Myers, Jr., MD, PhD, will deliver the Outstanding Scientific Achievement Award 

Lecture, Deconstructing Leptin—From Signals to Circuits, on Monday, June 28. 

Belinda P. Childs, ARNP, MN, CDE, BC-ADM, will give the Outstanding Educator in Diabetes 

Award Lecture, From the Land of Oz—Brains, Heart, Courage, and Power, on Saturday, 

June 26. 

Frank B. Hu, MD, PhD, will present the Kelly West Lecture, Role of Diet, Lifestyle, and Gene- 

Environment Interactions in the Global Epidemic of Type 2 Diabetes, on Sunday, June 27. 

Other key lectures: 

Christine T. Tobin, RN, MBA, CDE, will deliver the President, Health Care & Education Address, 

Unique Challenges in Diabetes Care, on Saturday, June 26. 

Richard M. Bergenstal, MD, will give the President, Medicine & Science Address, Patient- 

Centered Team Diabetes Care in an Era of Health Care Reform—Lessons from Three 

Leaders in the Field, on Sunday, June 27. 

Ira J. Goldberg, MD, will present the Edwin Bierman Lecture, Diabetic Heart Diseases— 

Why, on Monday, June 28 during the Cardiovascular Complications of Diabetes Oral 

Presentation. 

David G. Armstrong, DPM, PhD, will present the Roger Pecoraro Lecture, Healing Wounds and 

Preventing Amputations—A Marriage of Team, Technology, and Tenacity, on Sunday, June 

27 during the Foot Complications Oral Presentation. 

Richard R. Rubin, PhD, CDE, will give the Behavioral Medicine and Psychology Interest 

Group Award and Lectureship for Distinguished Contributions, Reflections on 30 Years of 

Behavioral Medicine in Diabetes, on Saturday, June 26 during the Advancing the Field— 

The Role of Inflammation and Depression and Diabetes Symposium. 

Sylvie Hauguel-de Mouzon, PhD, will present the Norbert Freinkel Lecture, From Insulin to 

Inflammation—Evolving Paths to Fetal Programming, on Saturday, June 26 during the 

Pregnancy and Diabetes Research—A 20-Year Tribute to Norbert Freinkel Symposium.

Friday, June 25, 2010 

Registration Hours: 9:00 a.m.–6:30 p.m. / Bookstore Hours: 10:00 a.m.–6:30 p.m. 

Acute and Chronic 

Complications 

(AC) 

Behavioral Medicine, 

Clinical Nutrition, 

Education, and Exercise 

(BM) 

Clinical Diabetes/ 

Therapeutics 

(CT) 

Epidemiology/ 

Genetics 

(EG) 

Immunology/ 

Transplantation 

(IT) 

Insulin Signaling/ 

Insulin Action 

(IS) 

2:00 p.m.–4:00 p.m. Oral Presentations 

Novel Mechanisms in 

the Development of 

Diabetic Nephropathy 

Room 209 

Symposium 

Lost in Translation 

Room 208 

Symposium 

Clinical Role of TZDs 

in 2010 


Oral Presentations 

Altered Metabolism 

During and After 

Pregnancy Complicated 

by Hyperglycemia 

Room 307 

Obesity and Type 2 

Diabetes in Youth 

Room 312 

Symposium 

Stages of the Lifecycle 

and Risk for Onset and 

Progression of Diabetes 

and Its Complications 

Room 315 

Symposium 

Insulin Action—A 

Molecular View 

Room 304 E 

4:15 p.m.–6:15 p.m. Symposium 

Cardiorenal Issues in 

Diabetes Management 



Hypoglycemia 

Room 207 

Symposia 

Type 2 Diabetes, 

Exercise, and 

Cerebrovascular 

Physiology 

Room 221 

What Influences How 

Much We Eat 

Room 224 

Symposia 

The Implications of U.S. 

Health Care Reform on 

the Care and Prevention 

of Diabetes 

Chapin Theater 

Tailoring Diabetes 

Treatment Priorities 

in the New Age of 

Cardiometabolic Risk 

Management 

Valencia Ballroom CD 


Insulin Therapy 

Room 311 

Symposium 

Beyond the First Phase 

of Genome-Wide 

Association Studies 

(GWAS) 

Room 315 


Signal Transduction 

Room 304 E 

7:30 p.m.–11:00 p.m. Opening Reception—Walt Disney World’s Epcot Center (Ticketed Function) 

Day-at-a-Glance 

Integrated Physiology 

or Obesity 

(IP) 

Symposium 

Brown Adipose Tissue 



Obesity—Human 

Room 314 

Islet Biology/ 

Insulin Secretion 

(IB) 

Symposium 

Pathways to Beta 

Cell Development and 

Differentiation 

Room 304 A 

Symposium 

Transdifferentiation and 

Reprogramming 

Room 304 A 

1


Saturday, June 26, 2010 

Registration Hours: 7:30 a.m.–6:00 p.m. / Bookstore Hours: 8:00 a.m.–6:30 p.m. / Exhibit Hall Hours: 10:00 a.m.–4:00 p.m. / Blood Drive Hours: 10:00 a.m.–4:00 p.m. / Poster Display Hours: 10:00 a.m.–6:00 p.m. 


Complications 

(AC) 




(BM) 


Therapeutics 

(CT) 

Epidemiology/ 

Genetics 

(EG) 

Immunology/ 


(IT) 



(IS) 


or Obesity 

(IP) 



(IB) 

8:00 a.m.–10:00 a.m. Symposium 

Does Diabetes 

Affect the Approach 

to Diagnosis or 

Management of 

Cardiovascular Disease 


Symposia 

Diabetes Prevention and 

Behavioral Interventions 

in Underserved 

Populations 

Room 221 

Prescribing Exercise for 

Severely Obese Patients 

Room 209 

ADA Education 

Recognition 

Program—Assessing 

the Impact of Diabetes 

Education 

Room 207 

Symposia 

Combination Therapies 

for Type 2 Diabetes 

From the Get-Go—Are 

We There Yet 

Room 224 

A1C Targets in Pediatric 

Diabetes—Ideal vs. 

Real 

Room 308 

Joint ADA/The 

Lancet Symposium 



Incretin Comparisons 


Current Issues 

Is Diabetes Really a 


Equivalent 

Room 311 

Symposium 

Novel Insights into 

Insulin Resistance and 

Metabolic Syndrome 

Room 304 E 

Symposium 

Adipose Tissue and 

Inflammation 

Room 414 

Symposium 

Beta Cell Intracellular 

Signaling-1—mTor to 

S6Kinase 

Room 304 A 

10:15 a.m.–11:15 a.m. President, Health Care & Education Address and Outstanding Educator in Diabetes Award Lecture—Room 224 

11:30 a.m.–1:30 p.m. General Poster Session/Guided Audio Poster Tours—Hall C 

12:00 p.m.–1:15 p.m. Interest Group Discussions 



in Diabetes 


Symposium 

Advancing the 

Field—The Role 

of Inflammation 

in Depression and 

Diabetes (Includes 

Behavioral Medicine 

and Psychology 

Interest Group Award 

and Lectureship 

for Distinguished 

Contributions) 



Glycemic Outcomes and 

Acute Complications— 

MDI or the Pump— 

Which Is Best 


Symposium 

Pregnancy and Diabetes 

Research—A 20-Year 

Tribute to Norbert 

Freinkel (Includes 

Norbert Freinkel 

Lecture) 

Room 311 


Pediatric Diabetes— 

Clinical Aspects of Beta 

Cell Function 

Room 312 

Pharmacotherapies for 

the Treatment of Type 

2 Diabetes—From the 

Old to the New 

Room 224 

Symposium 

Clinical Impact of 

the New Genetic 

Discoveries in Diabetes 

Room 315 

Symposium 

Mitochondrial 

Metabolism and 

Substrate Selection 

Room 304 E 

Symposium 

Joint ADA/EASD 

Symposium— 

Glucagon-Like Peptide- 

1—From Secretion to 

Function 

Room 414 


Integrated Physiology— 

Liver 

Room 314 


Islet Development and 

Signal Transduction 

Room 304 A 

2


Diabetic Dyslipidemia 

Room 209 


Novel Approaches to 

Patient and Provider 

Education 

Room 207 

Exercise and Diabetes 

Room 208 


Should New Diabetes 

Drugs Submitted to 

the FDA Have a Higher 

Bar for Cardiovascular 

Safety Than Other 

Drugs 


Symposia 

Diabetes in the New 

Realm of Comparative 

Effectiveness Research 

(CER) 

Room 224 

NIDDK Symposium— 

Novel Pathways to 

Treatment of Type 2 

Diabetes and Obesity 



Continuous Glucose 

Monitoring 

Room 414 


Genetic Risks and Gene 

Specific Studies 

Room 315 



Monitoring and 

Clinical Impact of Islet 


Room 221 


Mitochondria and 

Energy Homeostasis 

Room 304 E 

Symposium 

Central Modulators of 

Obesity 

Room 311 

Symposium 


Signaling-2—PI3Kinase 

and PKCs, and IKKs 

Room 304 A 

3


Sunday, June 27, 2010 

Wear Red to Stop Diabetes SM 

5K@ADA: 6:00 a.m.–7:30 a.m. / Registration Hours: 7:30 a.m.–5:00 p.m. / Poster Display Hours: 7:30 a.m.–7:45 p.m. / Bookstore Hours: 8:00 a.m.–6:00 p.m. / Exhibit Hall Hours: 10:00 a.m.–4:00 p.m. / 

Blood Drive Hours: 10:00 a.m.–4:00 p.m. 


Complications 

(AC) 




(BM) 


Therapeutics 

(CT) 

Epidemiology/ 

Genetics 

(EG) 

Immunology/ 


(IT) 



(IS) 


or Obesity 

(IP) 



(IB) 

8:00 a.m.–10:00 a.m. Symposia 

Lipids—Key Issues in 

the Management of 

Dyslipidemia 


Team Building to 

Prevent Amputations 

Room 208 

Symposia 

Maximizing Diabetes 

Care—Shared Medical 

Appointments 

Room 209 

Dietary Sweeteners 

Containing Fructose— 

Effects on Metabolism 

and Impact in the Food 

Supply 

Room 207 

Symposia 

Controversies Relating 

Cancer with Diabetes, 

Obesity, and Insulin 


A 21st Century Look 

at Genetic Causes 

of Diabetes and Its 

Complications in Youth 

Room 312 

Society for Clinical 

Trials Symposium— 

Issues in the Design, 

Conduct, and Analysis 

of Large Randomized 

Clinical Trials in 

Diabetes 

Room 414 


The Effects of Obesity, 

Excessive Gestational 

Weight Gain, and 

Hyperglycemia on 

Pregnancy Metabolism 

and the Fetus 

Room 307 

Symposium 

The Role of Sex 

Hormones in the 

Epidemiology of 

Type 2 Diabetes and 

Cardiometabolic Risk 

Room 315 


Improving Islet 


Room 221 

Symposium 

Selective Hepatic 

Insulin Resistance 

Room 304 E 

Symposium 

Inflammation in Glucose 

Homeostasis 

Room 311 


Obesity—Animal 

Room 314 


Life and Death in the 

Islet I 

Room 304 A 

10:15 a.m.–12:15 p.m. President, Medicine & Science Address and Banting Lecture—Hall D 

12:00 p.m.–2:00 p.m. General Poster Session/Guided Audio Poster Tours 


4


Complications of 

Diabetes—What Is 

Unique About the 

Retina 

Room 224 


Foot Complications 

(Includes Roger 

Pecoraro Lecture) 

Room 414 

Symposium 

New Technologies for 

Diabetes Education 

Room 208 


Nutrition 

Room 207 

Symposia 

Joint ADA/JDRF 

Symposium—The 

Artificial Pancreas— 

A Goal within Reach 

Room 311 

Managing Insulin 

Therapy in the Obese, 

Extremely Insulin 

Resistant Patient 


Pregnancy Diet and 

Supplements—Needs 

and Concerns 

Room 308 


Targeting and 

Tailoring—Keys to 

Maximizing Health and 

Economic Outcomes 

in Diabetes Care and 

Prevention 

Room 307 

Kelly West Lecture 

(2:00 p.m.–2:45 p.m.) 



Genome-Wide Genetics 

Room 315 


Prediction and Natural 

History of Type 1 


Room 221 


Vascular, Infection, 

Pressure—The VIPs 

of Healing Diabetic 

Wounds 

Room 308 


Ocular 

Room 207 

Cellular Mechanisms 

of Cardiovascular 



Room 209 

Symposium 

Practical Issues in 

Diabetes and Exercise 

Room 224 


Behavioral Interventions 


Room 208 

Symposia 

Tactics and 

Controversies in 

the Management of 

Hyperglycemia in the 

Hospital 


Newer Insulins— 

As They Approach 

Availability What 

Should We Know about 

Them 


HEALTHY Study— 

Middle School-Based 

Intervention to Reduce 

Diabetes Risk 

(4:15 p.m.–5:15 p.m.) 



Deficiencies in Diabetes 

Care and Outcomes— 

Exploring Problem Areas 

and Emerging Solutions 

Room 414 


Epidemiology of Type 1 

and Type 2 Diabetes 

Room 315 

Symposium 

Alternative Cellular 

Sources for Beta Cell 

Replacement Therapy— 

Today and Tomorrow 

Room 221 

6:30 p.m.–7:45 p.m. Presidents Poster Session and Reception—Hall C 



Mechanisms of In Vivo 


Room 304 E 

Symposium 

Clues to Mechanisms 

of Insulin Resistance 

from Other Human 

Syndromes 

Room 304 E 

Symposium 

Bile Acids as Metabolic 

Regulators 

Room 314 


Insulin Secretion— 

In Vivo 

Room 312 


Incretin and Leptin 

Biology 

Room 314 

Symposium 


Signaling-3— 

A Potpourri 

Room 304 A 


Beta Cell Stimulus- 

Secretion Coupling and 

Metabolism 

Room 304 A 

5


Monday, June 28, 2010 

Poster Display Hours: 7:30 a.m.–2:00 p.m. / Registration Hours: 7:30 a.m.–4:00 p.m. / Bookstore Hours: 8:00 a.m.–5:00 p.m. / Exhibit Hall Hours: 10:00 a.m.–2:00 p.m. / Blood Drive Hours: 10:00 a.m.–3:00 p.m. 


Complications 

(AC) 




(BM) 


Therapeutics 

(CT) 

Epidemiology/ 

Genetics 

(EG) 

Immunology/ 


(IT) 



(IS) 


or Obesity 

(IP) 



(IB) 


Update on Diabetic 

Peripheral Neuropathy 

Room 414 


Cardiovascular 



(Includes Edwin 

Bierman Lecture) 


Symposium 

NDEP Symposium— 

Translating New 

Research into a Public 

Health Campaign and 

Tools for Supporting 

Behavior Change 

Room 224 

Symposia 

Intensive Insulin Therapy 

at the Onset of Type 

2 Diabetes—Can We 

Preserve Beta Cell Function 

and Reverse Diabetes 


Drug Therapy during 

Pregnancy—Safety and 

Effectiveness 

Room 308 


Pediatric Diabetes— 

New Clinical Measurements, 

Approaches, and 

Outcomes 

Room 307 

Symposium 

From Genetic 

Association to 

Molecular Mechanism 

Room 315 

Symposium 

Nanotechnology and 

Tissue Engineering for 

Beta Cell Replacement 

Therapy 

Room 221 

Symposium 

Cross-Talk in Insulin 

Signaling at the Cellular 

Level 

Room 304 E 

Symposium 

Nutrient-Gut-Brain 

Modulators 

Room 311 


Integrated Physiology— 

Muscle 

Room 314 

Symposium 

Does Autoimmunity 

Influence Beta Cell 

Regeneration 

Room 304 A 

10:15 a.m.–11:45 a.m. National Scientific & Health Care Achievement Awards Presentation and Outstanding Scientific Achievement Award Lecture—Hall D 

12:00 p.m.–2:00 p.m. General Poster Session/Guided Audio Poster Tours—Hall C 


2:15 p.m.–4:15 p.m. Symposia 

Controversies in 

Blockade of the 

Renin-Angiotensin- 

Aldosterone System 

(RAAS) 

Room 224 

Implications of the 

NAVIGATOR Trial for 

Prevention of Diabetes 

and Cardiovascular 

Disease in Subjects 

with Impaired Glucose 

Tolerance 


Symposium 

Integrating 

Complementary 

Practices into Diabetes 

Care—Herbs, 

Supplements, and 

Mindful Meditation 

Room 209 

Symposia 

Updates on GLP-1 

Agonists 


Pediatric Diabetes Trends— 

Epidemiology 2010 

Room 308 

Joint ADA/AACC 

Symposium—Point 

of Care Devices for 

Glucose and HbA1C— 

Are They Up to the Task 

Room 311 


Update on BARI 2D— 

Treatment of Insulin 

Resistance 

Room 307 


Diabetes Outcomes and 

Related Conditions 

Room 315 


Antigen-Specific 

and Non-Specific 

Mechanisms and 

Treatment of Diabetes 

Room 221 

Symposium 

Thyroid Hormone 

Signaling in Insulin 

Action and Metabolism 

Room 304 E 

Symposium 

Beta Cell Failure—The 

Key to Unlocking Type 2 

Diabetes Mellitus 

Room 414 


Life and Death in the 

Islet II 

Room 304 A 


Neuropathy 

Room 208 

Symposia 

From Children to Adults— 

Models of Transition Care 

in Youth with Diabetes 

Room 207 


and Diabetes— 

Nutrition Update 

Room 224 


Will DPP-4 Inhibitors 

Replace Sulfonylureas 



Insulin Delivery Systems 

Room 311 


Etiology of Type 2 


Room 315 

Symposium 

Novel Immune 

Mechanisms in 


Room 221 


Molecular Mechanisms 

of Insulin Resistance/ 

Action 

Room 304 E 

Symposium 

Epigenetics and 

Metabolic Disease 

Room 312 



Pathophysiology and 

Treatment 

Room 314 

Symposium 

Mitochondria, 

Endoplasmic Reticulum 

(ER) and Oxidative 

Stress, and Beta Cell 

Survival 

Room 304 A 

6

Registration Hours: 7:30 a.m.–10:00 a.m. / Bookstore Hours: 8:00 a.m.–12:00 p.m. 

Tuesday, June 29, 2010 


Complications 

(AC) 




(BM) 


Therapeutics 

(CT) 

Epidemiology/ 

Genetics 

(EG) 

Immunology/ 


(IT) 


Cardiovascular Risks of 

Hypoglycemia 

Room 209 

Symposium 

The Art and Science of 

Gestational Diabetes 

Counseling 

Room 207 


Is the Patient with 

Well-Managed Type 

1 Diabetes Still at 

Increased Risk for 


Room 224 

Symposia 

The Potential of SGLT-2 

Inhibitors for Diabetes 

Management 

Room 311 

Late Breaking Clinical 

Studies 


Symposium 

Diabetes Diagnosis 

Based on the A1C 


Symposium 

B Cells in Type 1 


Room 221 

10:15 a.m.–12:15 p.m. Symposium 

Physiological Aspects of 

Hypoglycemia 

Room 208 

Symposium 

Non-Caloric/Non- 

Nutritive Sweeteners— 

What’s New 

Room 224 

Symposium 

Results of the ACCORD 

Clinical Trial 





(IS) 

Symposium 

Control of Adipose 

Tissue Development and 

Function 

Room 304 E 


or Obesity 

(IP) 

Symposium 

Role of the Kidney in the 

Pathogenesis of Type 2 


Room 414 

Symposium 

What Has Genetics 

Taught Us From Gene 

to Human Physiology 

Room 311 



(IB) 

Symposium 


Room 304 A 

7

Take the meeting home with you! 

Webcasts of the presentations at this year’s Scientific Sessions will be available for 

purchase, so you can take the meeting home with you! From symposia to major lectures to 

oral abstract presentations, every session will be available, subject to individual speaker 

authorization. Presentations may be purchased for access either online only or online plus 

a USB Flash Drive. 

With so many concurrent sessions, even the most athletic attendee can’t make it to all 

of the sessions he or she is interested in. These convenient webcast presentations give 

you the chance to catch up on what you missed, and the sound and image quality are 

excellent—giving you a prime seat for every lecture. 

Purchasing webcasts this year is even easier, with credit card or cash payments accepted 

at the sales kiosk located in front of Hall C. Take advantage of the onsite discount and 

save $80 over the post-meeting price. After the meeting, webcasts may be purchased 

online at scientificsessions.diabetes.org. 

8

SCIENTIFIC SESSIONS PROGRAM SCHEDULE 

FRIDAY, JUNE 25 

Scientific Sessions 

2:00 p.m.–4:00 p.m. 

Symposia 

Lost in Translation 

Room 208 

Chair: Marjorie Cypress, PhD, C-ANP, CDE 

2:00 p.m.–2:40 p.m. Health Literacy—Assessing Vulnerable Populations 

Andrea S. Wallace, PhD, ND, APRN, BC-ADM 

2:40 p.m.–3:20 p.m. Health Literacy—Interventions that Work 

Darren A. DeWalt, MD 

3:20 p.m.–4:00 p.m. Health Numeracy—Strategies that Count 

Kathleen I. Wolff, MSN, RN 

FRIDAY—PROGRAM 

Clinical Role of TZDs in 2010 


Chair: Sunder Mudaliar, MD 

2:00 p.m.–2:30 p.m. Beta Cell Benefits, Slowing of Disease Progression, Persistence of Glucose Lowering 

Thomas A. Buchanan, MD 

2:30 p.m.–3:00 p.m. The “Warts”—Effects on the Bone 

Andrew B. Grey, MD 

3:00 p.m.–3:30 p.m. Has the Dust Settled What is the Effect of TZDs on Cardiovascular Disease Risk After All 

Philip D. Home, DM, DPhil 

3:30 p.m.–4:00 p.m. Clinical Use and Monitoring of TZDs 

Ian Blumer, MD 

Stages of the Lifecycle and Risk for Onset and Progression of Diabetes and Its Complications 

Room 315 

Chair: Edward J. Boyko, MD 

2:00 p.m.–2:30 p.m. In Utero and Early Childhood 

Janet Rich-Edwards, ScD 

2:30 p.m.–3:00 p.m. Puberty in Relation to Risk and Complications of Diabetes 

Cuilin Zhang, MD, PhD 

3:00 p.m.–3:30 p.m. Breastfeeding 

Erica P. Gunderson, PhD 

3:30 p.m.–4:00 p.m. Menopause 

John F. Randolph, Jr., MD 

Insulin Action—A Molecular View 

Room 304 E 

Chair: Timothy E. McGraw, PhD 

2:00 p.m.–2:30 p.m. Insulin Signaling 

C. Ronald Kahn, MD 

2:30 p.m.–3:00 p.m. Atomic Studies of Insulin Receptor Activation 

Stevan R. Hubbard, PhD 

3:00 p.m.–3:30 p.m. Tyrosine Phosphatases in the Control of Insulin Signaling 

Kendra K. Bence, PhD 

3:30 p.m.–4:00 p.m. mTor Signaling 

Roberto Zoncu, PhD 

9




2:00 p.m.–4:00 p.m. 

(continued) 

Brown Adipose Tissue 


Chair: Eric Ravussin, PhD 

2:00 p.m.–2:30 p.m. Molecular Regulation of Brown Fat Development—Implications for Human Obesity 

Bruce M. Spiegelman, PhD 

2:30 p.m.–3:00 p.m. Cold Activated Brown Adipose Tissue in Healthy Men—Metabolic Implications 

Wouter D. van Marken Lichtenbelt, PhD 

3:00 p.m.–3:30 p.m. Brown Adipose Tissue—Sexual Dimorphism and Relationship to Body Fat 

Aaron M. Cypess, MD, PhD 

3:30 p.m.–4:00 p.m. Brown Adipose Tissue—Relationship to Age-Related Accumulation of Visceral Fat 

Masayuki Saito, MD 

Pathways to Beta Cell Development and Differentiation 

Room 304 A 

Chair: Lori Sussel, PhD 

2:00 p.m.–2:30 p.m. Sox9 Cells as Adult Beta Cell Progenitors 

Maike Sander, MD 

2:30 p.m.–3:00 p.m. NGN3 Downstream Targets and Beta Cell Development 

Stuart B. Smith, PhD 

3:00 p.m.–3:30 p.m. Small Molecules that Regulate Endoderm Differentiation 

Malgorzata Borowiak, PhD 

3:30 p.m.–4:00 p.m. Small Molecules that Regulate Pluripotency and Stem Cell Differentiation 

Sheng Ding, PhD 


Novel Mechanisms in the Development of Diabetic Nephropathy...............................................................Abstracts 1-OR to 8-OR 

Room 209 

Chair: Robert D. Toto, MD 

Altered Metabolism During and After Pregnancy Complicated by Hyperglycemia................................Abstracts 9-OR to 16-OR 

Room 307 

Co-Chairs: Patrick M. Catalano, MD and Catherine Kim, MD 

Obesity and Type 2 Diabetes in Youth.............................................................................................................Abstracts 17-OR to 24-OR 

Room 312 

Co-Chairs: Sanjeev Mehta, MD and Andrew W. Norris, MD, PhD 

4:15 p.m.–6:15 p.m. 

Symposia 

Cardiorenal Issues in Diabetes Management 

Supported by an unrestricted educational grant from Boehringer Ingelheim Pharmaceuticals, Inc. 


Chair: George Bakris, MD 

4:15 p.m.–4:45 p.m. Controlling Glycemia in Chronic Kidney Disease—What Are the Targets and How to Achieve Them 

Mark E. Molitch, MD 

4:45 p.m.–5:15 p.m. The Role of Uric Acid in Vascular Disease Risk in the Kidney 

Linda H. Ficociello, DSc 

5:15 p.m.–5:45 p.m. Parathyroid Hormone, Vitamin D, and Cardiovascular Risk 

Tamara J. Vokes, MD 

5:45 p.m.–6:15 p.m. Proteinuria as a Surrogate Outcome in Chronic Kidney Disease 

Katherine R. Tuttle, MD 

10



4:15 p.m.–6:15 p.m. 

(continued) 

Type 2 Diabetes, Exercise, and Cerebrovascular Physiology 

Room 221 

Chair: Johannes J. van Lieshout, MD, PhD 

4:15 p.m.–4:45 p.m. Evaluation and Determinant of Perfusion, Oxygenation, Autoregulation, and Metabolism of the 

Brain in Humans 

Johannes J. van Lieshout, MD, PhD 

4:45 p.m.–5:15 p.m. Influence of Exercise on Brain Perfusion, Oxygenation, and Metabolism in Healthy Individuals 

Niels H. Secher, MD, PhD 

5:15 p.m.–5:45 p.m. Cerebral Perfusion and Metabolism in Type 2 Diabetes during Exercise 

Patrice Brassard, PhD 

5:45 p.m.–6:15 p.m. Type 2 Diabetes, Dementia, Exercise, and Brain Health—Is Brain-Derived Neurotrophic Factor the Target 

Karen S. Krabbe, PhD 


What Influences How Much We Eat 

Room 224 

Chair: Alison Evert, MS, RD, CDE 

4:15 p.m.–5:00 p.m. Emotion and Stress-Related Eating—Moving Beyond the Calorie Balance Equation 

Amy D. Ozier, PhD, RD, LDN 

5:00 p.m.–5:45 p.m. Portion Size—Can We Tell How Much Is Too Much 

Brian Wansink, PhD 

5:45 p.m.–6:15 p.m. The Relationship between Dietary Energy Density and Energy Intake 

Barbara J. Rolls, PhD 

The Implications of U.S. Health Care Reform on the Care and Prevention of Diabetes 


Chair: Ronald T. Ackermann, MD 

4:15 p.m.–4:45 p.m. Prevention of Diabetes and Other Chronic Illnesses—The Need for Health Care Reform 

TBD 

4:45 p.m.–5:15 p.m. Impact on Access and Affordability—The Patient Perspective 

Shereen Arent, JD 

5:15 p.m.–5:45 p.m. Implications of Reform on Diabetes Care Delivery—Patient Centered Medical Home and Impact 

on Professional Roles 

Steven H. Woolf, MD 

5:45 p.m.–6:15 p.m. U.S. Health Reform and the Coverage, Payment, and Delivery of Services for Diabetes Care 

and Prevention—Implications and Opportunities 

Deneen Vojta, MD 

Tailoring Diabetes Treatment Priorities in the New Age of Cardiometabolic Risk Management 

Supported by an unrestricted educational grant from Amylin/Lilly 


Chair: TBD 

4:15 p.m.–4:45 p.m. Overview of Treatment Targets and Goals for Care in Diabetes 

Craig D. Williams, PharmD 

4:45 p.m.–5:15 p.m. Intensification at a Cost—Where Is the Biggest Bang for the Buck 

Brian T. Denton, PhD 

5:15 p.m.–5:45 p.m. Tailoring of Risk Factor Modification Goals—Implications for Clinical Guidelines 

Patrick J. O’Connor, MD 

5:45 p.m.–6:15 p.m. Moving Towards Customized Diabetes Care—Use of EMR-Based Clinical Decision Support 

Richard W. Grant, MD 

11




4:15 p.m.–6:15 p.m. 

(continued) 

Beyond the First Phase of Genome-Wide Association Studies (GWAS) 

Room 315 

Chair: Donald W. Bowden, PhD 

4:15 p.m.–4:45 p.m. Rare Variants of the IFIH1 Gene and Type 1 Diabetes 

Sergey Nejentsev, MD, PhD 

4:45 p.m.–5:15 p.m. Copy Number Variants and Crohn’s Disease 

TBD 

5:15 p.m.–5:45 p.m. Quantitive Glycemic Traits—MAGIC and Other Consortia 

Jose C. Florez, MD, PhD 

5:45 p.m.–6:15 p.m. Linking Gene Expression to GWAS 

Clifton Bogardus III, MD 

Transdifferentiation and Reprogramming 

Room 304 A 

Chair: Maike Sander, MD 

4:15 p.m.–4:45 p.m. PAX4 in the Alpha Cell to Beta Cell Transition 

Ahmed Mansouri, PhD 

4:45 p.m.–5:15 p.m. Spontaneous Reprogramming of Adult Alpha Cells into Beta Cells 

Fabrizio Thorel, PhD 

5:15 p.m.–5:45 p.m. Transdifferentiation within Endocrine Cells 

Christopher V.E. Wright, DPhil 

5:45 p.m.–6:15 p.m. Nkx2.2—Transdifferentiation from Beta to Alpha Cells 

Lori Sussel, PhD 


Hypoglycemia...................................................................................................................................................... Abstracts 25-OR to 32-OR 

Room 207 

Chair: Carmine G. Fanelli, MD, PhD 

Insulin Therapy.................................................................................................................................................... Abstracts 33-OR to 40-OR 

Room 311 

Chair: Julio Rosenstock, MD 

Signal Transduction............................................................................................................................................ Abstracts 41-OR to 48-OR 

Room 304 E 

Chair: Ann Louise Olson, PhD 

Obesity—Human................................................................................................................................................. Abstracts 49-OR to 56-OR 

Room 314 

Chair: Louis J. Aronne, MD 

Opening Reception 

7:30 p.m.–11:00 p.m. 

Walt Disney World’s Epcot Center (Ticketed Function) 

Buses will depart from Hall F of the Orange County Convention Center 

between 7:15 p.m.–8:00 p.m. 

12

ORAL PRESENTATIONS 

FRIDAY, JUNE June 25 5 

2:00 p.m.–4:00 p.m. 

Session: Novel Mechanisms in the Development of Diabetic Nephropathy 

Room 209 

Chair: Robert D. Toto, MD 

1-OR 

2-OR 

3-OR 

4-OR 

5-OR 

6-OR 

7-OR 

8-OR 

2:00 p.m.–2:15 p.m. 

Mild Mitochondrial Dysfunction Increases Type I Diabetic Renal and 

Cardiac Damage 

ANDRZEJ S. JANUSZEWSKI, BEN MA, YUAN ZHANG, RACHEL BLAKE, 

IAN TROUNCE, CARL A. PINKERT, DARREN J. KELLY, ALICIA J. JENKINS, 

Melbourne, Australia, Auburn, AL 

2:15 p.m.–2:30 p.m. 

PDGFR-β Deletion Improves Diabetic Nephropathy in CaM Kinase IIα 

(Thr286Asp) Transgenic Mice 

HIKARI SUZUKI, ISAO USUI, ICHIRO KATO, YUKIKO KANATANI, YU 

YAMAZAKI, SHIHO FUJISAKA, SATOKO SENDA, MASAHARU URAKAZE, 

SHIN TAKASAWA, HIROSHI OKAMOTO, MASAKIYO SASAHARA, 

MASASHI KOBAYASHI, KAZUYUKI TOBE, Toyama, Japan, Nara, Japan, 

Miyagi, Japan 

2:30 p.m.–2:45 p.m. 

Aberrant Expression of CD68 in Podocytes Precedes Inflammatory 

Markers in STZ-Induced Diabetic Nephropathy 

MAGALI ARAUJO, AUDREY LEE, CECILIA COURREGES, NANCY KOLES, 

KAREN T. COSCHIGANO, SONIA Q. DOI, Bethesda, MD, Athens, OH 

2:45 p.m.–3:00 p.m. 

Characterization of the Plasmacytoma Variant Translocation 1 Gene 

(PVT1) as a Mediator of Diabetic Kidney Disease 

M. LUCRECIA ALVAREZ, JOHANNA K. DISTEFANO, Phoenix, AZ 

3:00 p.m.–3:15 p.m. 

The rs7204609 Polymorphism in the FTO Gene Is Positively Associated 

with Central Obesity and Microalbuminuria in Patients with Type 2 


THAIS STEEMBURGO, MIRELA J. AZEVEDO, JORGE L. GROSS, FERMÍN 

MILAGRO, JAVIER CAMPION, JOSE ALFREDO MARTÍNEZ, Porto Alegre, 

Brazil, Navarra, Spain 

3:15 p.m.–3:30 p.m. 

Urinary Type IV Collagen as Well as Urinary Albumin Is an Important 

Prognostic Factor for Glomerular Filtration Rate Decline in Young 

Patients with Type 1 Diabetes Mellitus 

MIWA MORITA, YASUKO UCHIGATA, KO HANAI, YOHEI OGAWA, 

YASUHIKO IWAMOTO, Izumo, Japan, Shinjuku, Japan, Niigata, Japan 

3:30 p.m.–3:45 p.m. 

Increased Axl Receptor Tyrosine Kinase and Its Ligand in Glycoxidized- 

LDL-Induced Mesangial Cells and Diabetic Kidney 

YOUNG SOOK KIM, EUN JIN SOHN, OHN SOON KIM, JUNGHYUN KIM, 

JIN SOOK KIM, Daejeon, Republic of Korea 

3:45 p.m.–4:00 p.m. 

Effect of Intrauterine Diabetes Exposure on the Incidence of End-Stage 

Renal Disease in Young Adults with Type 2 Diabetes 

ROBERT G. NELSON, ROBERT L. HANSON, MEDA E. PAVKOV, WILLIAM 

C. KNOWLER, Phoenix, AZ, Atlanta, GA 

2:00 p.m.–4:00 p.m. 

Session: Altered Metabolism During and After Pregnancy Complicated by 

Hyperglycemia 

Room 307 

Co-Chairs: Patrick M. Catalano, MD and Catherine Kim, MD 

9-OR 

10-OR 

11-OR 

12-OR 

13-OR 

14-OR 

15-OR 

16-OR 

2:00 p.m.–2:15 p.m. 

Is There a Link between Elevated Serum Selenium Concentrations and 

Gestational Diabetes 

ZOLTAN GARAMVOLGYI, KRISZTIAN BALOGH, MIKLOS MEZES, NORA 

ADANYI, NORBERT SOLYMOSI, JANOS RIGO, JR., JEANNETTE MOLNAR, 

Budapest, Hungary, Godollo, Hungary 

2:15 p.m.–2:30 p.m. 

Gestational Diabetes Mellitus (GDM) May Reflect GLP-1 Resistance 

JENNIFER HONE, DAVID J. PETTITT, ANGELINA L. TRUJILLO, HOWARD 

ZISSER, ALISON OKADA WOLLITZER, LOIS JOVANOVIC, Santa Barbara, 

CA 

2:30 p.m.–2:45 p.m. 

Sleep Disturbances in Pregnancy and the Relationship to Glucose 

Tolerance (GT) and Gestational Diabetes (GDM) 

SIRIMON REUTRAKUL, NAUSHEEN ZAIDI, HELEN H. KAY, MAHMOUD 

ISMAIL, DAVID A. EHRMANN, EVE VAN CAUTER, Chicago, IL 

2:45 p.m.–3:00 p.m. 

Serum Fatty Acid Composition and Inflammatory Activity in Women 

with Gestational Diabetes, Mild Gestational Hyperglycemia and Normal 

Pregnancies 

XINHUA CHEN, THERESA SCHOLL, MARIA LESKIW, T. PETER STEIN, 

Stratford, NJ 

3:00 p.m.–3:15 p.m. 

Beta-Cell Function Declines within the 1 st Year Postpartum in Women 

with Glucose Intolerance in Pregnancy 

RAVI RETNAKARAN, YING QI, MATHEW SERMER, PHILIP W. CONNELLY, 

ANTHONY J. HANLEY, BERNARD ZINMAN, Toronto, ON, Canada 

3:15 p.m.–3:30 p.m. 

Cardiac Function and Lipid Metabolism in Women with Prior Gestational 


YVONNE WINHOFER, MARTIN KRSSAK, CHRISTIAN ANDERWALD, 

GERD REITER, LATIFE BOZKURT, GIOVANNI PACINI, ANTON LUGER, 

MICHAEL KREBS, ALEXANDRA KAUTZKY-WILLER, Vienna, Austria, 

Padua, Italy 

3:30 p.m.–3:45 p.m. 

Quantitative Proteomic Profile in Skeletal Muscle from Women with 

Gestational Diabetes Reveals Potential for Reduced Mitochondrial 

Function 

KRISTEN E. BOYLE, HYONSON HWANG, JAMES E. DEVENTE, BENJAMIN 

BOWEN, TERI L. HERNANDEZ, LINDA BARBOUR, ZHENGPING YI, LAW- 

RENCE J. MANDARINO, JACOB E. FRIEDMAN, Aurora, CO, Tempe, AZ, 

Greenville, NC 

3:45 p.m.–4:00 p.m. 

Physical Activity Is Associated with Insulin Sensitivity and Beta-Cell 

Compensation for Insulin Resistance in Hispanic Women 

ANNY H. XIANG, XINWEN LIU, ENRIQUE TRIGO, SIRI L. KJOS, THOMAS 

A. BUCHANAN, Pasadena, CA, Los Angeles, CA, Torrance, CA 

FRIDAY—ORALS 

Continuing education credit will not be provided for oral presentations. 

13




2:00 p.m.–4:00 p.m. 

Session: Obesity and Type 2 Diabetes in Youth 

Room 312 

Co-Chairs: Sanjeev Mehta, MD and Andrew W. Norris, MD, PhD 

17-OR 

18-OR 

19-OR 

20-OR 

21-OR 

22-OR 

23-OR 

24-OR 

2:00 p.m.–2:15 p.m. 

Obesity Variants Associated with Longitudinal Change of BMI in Both 

Hispanic and Caucasian Children from the Children’s Health Study 

MOHAMED T. HASSANEIN, CHIH-CHIEH CHANG, JAMES BAURLEY, 

FRANK GILLILAND, W. JAMES GAUDERMAN, FREDRICK SCHUMACHER, 

KIROS BERHANE, Los Angeles, CA 

2:15 p.m.–2:30 p.m. 

Higher Psychosocial Stress Is Associated with Increased Cortisol 

Awakening Response (CAR) and Lower Insulin Sensitivity (SI) in Obese 

Latino Adolescents 

ERIC BOMBERG, DONNA SPRUIJT-METZ, SELENA NGUYEN-RODRIGUEZ, 

MICHAEL I. GORAN, MARC J. WEIGENSBERG, Los Angeles, CA 

2:30 p.m.–2:45 p.m. 

The rs738409 Variant in the PNPLA3 Gene Influences Hepatic Fat 

Accumulation in Obese Children and Adolescents 

NICOLA SANTORO, ROMY KURSAWE, DANIEL DYKAS, CLARENCE 

ZHANG, ALLEN BALE, HONGYU ZHAO, EBE D’ADAMO, ANNA CALI’, 

BRIDGET PIERPONT, SONIA CAPRIO, New Haven, CT 

2:45 p.m.–3:00 p.m. 

PCSK1 as an Obesity Gene—Clinical and Functional Characterization 

of Known and Newly Identified Variants 

ANTJE KÖRNER, DENNIS LÖFFLER, JOHN CREEMERS, ROY TAUSCHER, 

JÜRGEN KRATZSCH, JÜRGEN KLAMMT, WIELAND KIESS, PETER 

KOVACS, Leipzig, Germany, Leuven, Belgium 

3:00 p.m.–3:15 p.m. 

The Central Role of Fatty Liver in the Pathogenesis of Insulin Resistance 

in Obese Adolescents 

EBE D’ADAMO, ANNA CALI, RAM WEISS, NICOLA SANTORO, BRIDGET 

PIERPONT, SONIA CAPRIO, New Haven, CT, Jerusalem, Israel 

3:15 p.m.–3:30 p.m. 

Effects of Exercise without Calorie Restriction on Total and Abdominal 

Fat, and In Vivo Insulin Sensitivity in Obese Boys: A Randomized Controlled 

Trial 

SOJUNG LEE, YOONMYUNG KIM, NANCY GUERRA, ALLISON PRINCE, 

FIDA BACHA, SILVA ARSLANIAN, Pittsburgh, PA 

3:30 p.m.–3:45 p.m. 

Longitudinal Assessment of Beta-Cell Function in Adolescents Newly 

Diagnosed with T2DM Compared to Weight Matched Controls-Two Year 

Assessment 

DEBORAH A. ELDER, JESSICA G. WOO, DAVID A. D’ALESSIO, Cincinnati, OH 

3:45 p.m.–4:00 p.m. 

Metabolic Testing in Adolescents with Polycystic Ovary Syndrome 

CLARE A. FLANNERY, MAREEN THOMAS, ELVIRA J. DURAN, BETH W. 

RACKOW, TANIA S. BURGERT, New Haven, CT 

14 

Continuing education credit will not be provided for oral presentations.



4:15 p.m.–6:15 p.m. 

Session: Hypoglycemia 

Room 207 

Chair: Carmine G. Fanelli, MD, PhD 

25-OR 

26-OR 

27-OR 

28-OR 

29-OR 

30-OR 

31-OR 

32-OR 

4:15 p.m.–4:30 p.m. 

Lactate Increases GABA Levels in the Ventromedial Hypothalamus: 

A Mechanism for Impaired Glucose Counterregulation Caused by 

Antecedent Hypoglycemia and Diabetes 

OWEN CHAN, SACHIN A. PARANJAPE, WANLING ZHU, ADAM 

HORBLITT, DANIEL CZYZYK, BEI WANG, MARGRETTA SEASHORE, 

ROBERT S. SHERWIN, New Haven, CT 

4:30 p.m.–4:45 p.m. 

Hypoglycemia Allows the Counterregulatory Hormones To Override 

Insulin’s Action at the Liver 

NOELIA RIVERA-GONZALEZ, CHRISTOPHER RAMNANAN, ZHIBO AN, 

MELANIE SCOTT, JON HASTINGS, ERIC ALLEN, ALAN D. CHERRINGTON, 

Nashville, TN 

4:45 p.m.–5:00 p.m. 

Selective Thalamic Activation and Glucose Counterregulation in Humans 

ANA MARIA ARBELAEZ, TOM O. VIDEEN, WILLIAM J. POWERS, TAMARA 

G. HERSHEY, PHILIP E. CRYER, St. Louis, MO, Chapel Hill, NC 

5:00 p.m.–5:15 p.m. 

Brain Activation for Working Memory Is Altered in Type 1 Diabetes 

during Hypoglycemia 

NICOLAS BOLO, GAIL MUSEN, DONALD C. SIMONSON, KATIE 

WEINGER, PERRY F. RENSHAW, ALAN M. JACOBSON, Belmont, MA, 

Boston, MA, Salt Lake City, UT, Mineola, NY 

5:15 p.m.–5:30 p.m. 

Reduced Adulthood Cognitive Function in Type 1 Diabetic Subjects with 

Early Exposure to Severe Hypoglycaemia: A 16-Year Follow-Up Study 

BJØRN O. ÅSVOLD, KNUT A. HESTAD, TROND SAND, MARIT R. 

BJØRGAAS, Trondheim, Norway 

5:30 p.m.–5:45 p.m. 

Hypoglycemic Events May Be Associated with an Increased Risk of 

Acute Cardiovascular Events in Patients with Type 2 Diabetes 

STEPHEN S. JOHNSTON, CHRISTOPHER CONNER, MARK AAGREN, 

DAVID M. SMITH, JONATHAN BOUCHARD, Washington, DC, Seattle, 

WA, Princeton, NJ, Montvale, NJ 

5:45 p.m.–6:00 p.m. 

Impact of Hypoglycemia among Hospitalized Insulin-Treated Patients on 

Inpatient Mortality, Ischemic Events, and Neurologic Complications 

KIMBERLY G. BRODOVICZ, VINAY MEHTA, QIAOYI ZHANG, CHANGGENG 

ZHAO, JIELING CHEN, LARRY RADICAN, SAMUEL S. ENGEL, North 

Wales, PA, Whitehouse Station, NJ, Rahway, NJ 

6:00 p.m.–6:15 p.m. 

Mean Glucose during ICU Admission Is Related to Mortality by a 

U-Shaped Curve; Implications for Clinical Care 

SARAH E. SIEGELAAR, JEROEN HERMANIDES, HELEEN OUDEMANS- 

VAN STRAATEN, PETER H.J. VAN DER VOORT, ROBERT J. BOSMAN, 

DURK F. ZANDSTRA, J. HANS DEVRIES, Amsterdam, The Netherlands 

4:15 p.m.–6:15 p.m. 

Session: Insulin Therapy 

Room 311 


33-OR 

34-OR 

35-OR 

36-OR 

37-OR 

38-OR 

39-OR 

40-OR 

4:15 p.m.–4:30 p.m. 

RAndomized Study of Basal Bolus Insulin Therapy in the Inpatient 

Management of Patients with Type 2 Diabetes Undergoing General 

Surgery (RABBIT 2 Surgery) 

GUILLERMO E. UMPIERREZ, DAWN SMILEY, SOL JACOBS, LIMIN PENG, 

ANGEL TEMPONI, CHRISTOPHER NEWTON, DENISE UMPIERREZ, 

PATRICK MULLIGAN, DARIN OLSON, JANA MCLEOD, MONICA RIZZO, 

Atlanta, GA 

4:30 p.m.–4:45 p.m. 

Once-Daily Use of a New Generation Ultra-Long Acting Basal Insulin 

with a Bolus Boost in Insulin-Naïve Subjects with Type 2 Diabetes: 

Compari son with Insulin Glargine 

TIM HEISE, CEES TACK, BOB MICHEAL CUDDIHY, JAIME DAVIDSON, 

DIDIER GOUET, ANDREAS LIEBL, ENRIQUE ROMERO BOBILLO, HENRI- 

ETTE MERSEBACH, PATRIK DYKIEL, ROLFE JORDE, Neuss, Germany, 

Nijmegen, The Netherlands, Minneapolis, MN, Dallas, TX, La Rochelle, 

France, Bad Heilbrunn, Germany, Valladolid, Spain, Søborg, Denmark, 

Tromsø, Norway 

4:45 p.m.–5:00 p.m. 

Basal Insulin NPH, Glargine and Detemir in Type 2 Diabetes: 

Hepatospecificity, Effects on Glucose, Lipid Metabolism, and Pancreatic 

Islet Alpha- and Beta-Cell Rest: A PK-PD Study 

FRANCESCA PORCELLATI, PAOLO ROSSETTI, PAOLA LUCIDI, PAOLA 

CANDELORO, PATRIZIA CIOLI, STEFANIA MARZOTTI, ANNA MARINELLI 

ANDREOLI, GEREMIA B. BOLLI, CARMINE G. FANELLI, Perugia, Italy 

5:00 p.m.–5:15 p.m. 

An Open-Label Multicenter Trial of VIAject® vs. Regular Human Insulin 

in Patients with Type 2 Diabetes: Final Analyses 

HELENA W. RODBARD, FRANK FLACKE, PATRICK SIMMS, ALAN 

KRASNER, PHILIP PICHOTTA, ANDREAS PFÜTZNER, SOLOMON 

STEINER, Rockville, MD, Danbury, CT, Mainz, Germany 

5:15 p.m.–5:30 p.m. 

Continuation vs. Discontinuation of Insulin Secretagogues When 

Initiating Insulin in Type 2 Diabetes 

SANNE G. SWINNEN, MARIE-PAULE DAIN, DIDAC MAURICIO, J. HANS 

DEVRIES, JOOST B. HOEKSTRA, FRITS HOLLEMAN, Amsterdam, The 

Netherlands, Paris, France, Lleida, Spain 

5:30 p.m.–5:45 p.m. 

Initial Short-Term Intensive Insulin Therapy as a Strategy for Evaluating 

the Preservation of Beta-Cell Function with Oral Anti-Diabetic 

Medications: A Randomized Clinical Trial with Sitagliptin 

RAVI RETNAKARAN, YING QI, CHRISTINE OPSTEEN, EDNA VIVERO, 

BERNARD ZINMAN, Toronto, ON, Canada 

5:45 p.m.–6:00 p.m. 

Insulin Degludec Is a New Generation Ultra-Long Acting Basal Insulin 

with a Unique Mechanism of Protraction Based on Multi-Hexamer 

Formation 

IB JONASSEN, SVEND HAVELUND, ULLA RIBEL, THOMAS HOEG- 

JENSEN, DORTE BJERRE STEENSGAARD, THUE JOHANSEN, HANNE 

HAAHR, ERICA NISHIMURA, PETER KURTZHALS, Måløv, Denmark, 

Søborg, Denmark 

6:00 p.m.–6:15 p.m. 

Insulin Degludec, a New Generation Ultra-Long Acting Insulin, Used Once 

Daily or 3-Times Weekly in People with Type 2 Diabetes: Comparison to 

Insulin Glargine 

BERNARD ZINMAN, GREG FULCHER, PATURI V. RAO, NIHAL THOMAS, 

LARS ENDAHL, THUE JOHANSEN, ANDREW LEWIN, JULIO ROSen- 

STOCK, MICHEL PINGET, CHANTAL MATHIEU, Toronto, ON, Canada, 

Sydney, Australia, Hyderabad, India, Vellore, India, Søborg, Denmark, Los 

Angeles, CA, Dallas, TX, Strasbourg Cedex, France, Leuven, Belgium 



15


FRIDAY, June 25 


4:15 p.m.–6:15 p.m. 

Session: Signal Transduction 

Room 304 E 

Chair: Ann Louise Olson, PhD 

41-OR 

42-OR 

43-OR 

44-OR 

45-OR 

46-OR 

47-OR 

48-OR 

4:15 p.m.–4:30 p.m. 

Molecular Basis of Static GLUT4 Storage Compartment Formation in 

3T3-L1 Adipocytes Revealed by Quantum Dot-Based Quantitative Single 

Molecular Imaging 

HIROYASU HATAKEYAMA, MAKOTO KANZAKI, Sendai, Japan 

4:30 p.m.–4:45 p.m. 

The SNARE Protein SNAP23 and the SNARE Interacting Protein Munc18c 

in Human Skeletal Muscle Are Implicated in Insulin Sensitivity 

PONTUS BOSTRÖM, LINDA ANDERSSON, BIRGITTE F. VIND, LILIANA 

HÅVERSEN, YLVA WICKSTRÖM, ERIK LARSSON, PER-ANDERS 

JANSSON, MARIA K. SVENSSON, RICHARD BRÅNEMARK, CHARLOTTE 

LING, HENNING BECK-NIELSEN, JAN BORÉN, KURT HØJLUND, SVEN- 

OLOF OLOFSSON, Göteborg, Sweden, Odense, Denmark, Malmö, 

Sweden 

4:45 p.m.–5:00 p.m. 

Inhibition of Starvation-Induced Autophagy in Cardiomyocytes by Insulin 

Signaling Is Independent of Nutrient Availability 

QUAN-JIANG ZHANG, ADAM R. WENDE, AILI GUO, SANDRA SENA, J. 

DAVID SYMONS, E. DALE ABEL, Salt Lake City, UT 

5:00 p.m.–5:15 p.m. 

Decreased IRS2 Signaling Ameliorates Brain Pathologies and Extends 

Survival in a Mouse Model of Huntington Disease 

MARIANNA SADAGURSKI, ZHIYONG CHENG, ALDO ROZZO, 

XIAOCHENG DONG, MORRIS F. WHITE, Boston, MA 

5:15 p.m.–5:30 p.m. 

Heterozygous Loss of Pik3r1 Reduces Obesity-Induced Macrophage 

Infiltration and Inflammation in Adipose Tissue through a Mechanism 

That Is Independent of Pik3r1 Action in Hematopoietic-Derived Cells 

MICHAEL J. HOLLIDAY, SIMON SCHENK, SUSAN M. MAJKA, CARRIE E. 

MCCURDY, Aurora, CO, San Diego, CA 

5:30 p.m.–5:45 p.m. 

Protein Phosphatase 5, a Novel Member of the Insulin Signaling 

Cascade, Promotes Insulin-Induced Phosphorylation of a Highly Specific 

Subset of Activation Sites on ERK1 and Akt 

XIANGDONG WU, MINGZHEN LI, KEYANG CHEN, MING-LIN LIU, KEVIN 

JON WILLIAMS, Philadelphia, PA 

5:45 p.m.–6:00 p.m. 

Regulation of Nutrient Homeostasis by Forkhead FoxO Proteins in the 

Liver of Mice 

SHAODONG GUO, BOY GAN, RONALD A. DEPINHO, Temple, TX, Boston, 

MA 

6:00 p.m.–6:15 p.m. 

Novel Mechanism for AMPKα2 Regulation: Serine491 Phosphorylation 

Is Critical for Leptin Action in Hypothalamus 

YOSSI DAGON, ELIZABETH E. HUR, BARBARA B. KAHN, Boston, MA 

4:15 p.m.–6:15 p.m. 

Session: Obesity—Human 

Room 314 

Chair: Louis J. Aronne, MD 

49-OR 

51-OR 

52-OR 

53-OR 

54-OR 

55-OR 

56-OR 

50-OR 

4:15 p.m.–4:30 p.m. 

A Genome-Wide Association Analysis in over 177,000 Individuals Identifies 

15 Loci Contributing to Variation in Central Obesity and Fat-Distribution 

CECILIA M. LINDGREN, ON BEHALF OF THE GIANT CONSORTIUM, 

Oxford, United Kingdom 

4:30 p.m.–4:45 p.m. 

Identification a Novel Susceptibility Gene—NOS1AP for Obesity in the 

Old Order Amish 

MAO FU, CAROLE SZTALRYD, MING BELL, HONG WANG, XIAOLIAN 

SHI, QUINCE GIBSON, KEITH TANNER, JEFFERY O’CONNELL, BRAXTON 

D. MITCHELL, ALAN R. SHULDINER, Baltimore, MD 

4:45 p.m.–5:00 p.m. 

Molecular Mechanisms of NAFLD Associated Hepatic Insulin Resistance 

in Man 

NAOKI KUMASHIRO, DEREK M. ERION, DONGYAN ZHANG, MARIO 

KAHN, SARA A. BEDDOW, XIN CHU, CHRISTOPHER D. STILL, GLENN 

S. GERHARD, VARMAN T. SAMUEL, GERALD I. SHULMAN, New Haven, 

CT, Danville, PA 

5:00 p.m.–5:15 p.m. 

Association Studies and Functional Validation Studies Identified NFIB as 

a Potential Obesity Gene 

TINGWEI GUO, YAN DONG, ROBERT L. HANSON, MICHAEL TRAURIG, 

JIANYING HE, YUNHUA MULLER, KIM WIEDRICH, SAYUKO KOBES, 

WILLIAM C. KNOWLER, CLIFTON BOGARDUS, LESLIE J. BAIER, Phoenix, 

AZ 

5:15 p.m.–5:30 p.m. 

Glucose-Stimulated Insulin Secretion in Gastric Bypass Patients with 

Hypoglycemic Syndrome: No Evidence for Inappropriate Pancreatic 

β-Cell Function 

SUN H. KIM, FAHIM ABBASI, CINDY LAMENDOLA, GERALD REAVEN, 

TRACEY MCLAUGHLIN, Stanford, CA 

5:30 p.m.–5:45 p.m. 

Genome-Wide Association Meta-Analysis Including 123,000 Individuals 

Identifies 20 New Obesity Susceptibility Loci 

RUTH J.F. LOOS, ON BEHALF OF THE GIANT CONSORTIUM, Cambridge, 

United Kingdom 

5:45 p.m.–6:00 p.m. 

COR-Diabetes: Naltrexone SR/Bupropion SR Combination Therapy Led to 

Significant and Sustained Weight Loss and Improved HbA1c in Overweight/ 

Obese Subjects with Type 2 Diabetes 

PRISCILLA HOLLANDER, RAYMOND PLODKOWSKI, ALOK K. GUPTA, 

MARIA GUTTADAURIA, JANELLE ERICKSON, DENNIS KIM, EDUARDO 

DUNAYEVICH, Dallas, TX, Reno, NV, Baton Rouge, LA, New York, NY, 

Indianapolis, IN, La Jolla, CA 

6:00 p.m.–6:15 p.m. 

Impact of Age on the Relationships of Brown Adipose Tissue with 

Gender and Adiposity in Humans 

NORBERT STEFAN, MATTHIAS KLAUS WERNER, MATTHIAS 

REIMOLD, HANS-ULRICH HÄRING, CLAUS D. CLAUSSEN, CHRISTINA 

PFANNENBERG, Tübingen, Germany 

16 



SATURDAY, JUNE 26 


8:00 a.m.–10:00 a.m. 


Is Diabetes Really a Cardiovascular Disease Equivalent 


Room 311 

Chair: K.M. Venkat Narayan, MD 

8:00 a.m.–8:30 a.m. Yes 

Eberhard Standl, MD 

8:30 a.m.–9:00 a.m. No 

Iskandar R. Idris, DM 

Symposia 

Does Diabetes Affect the Approach to Diagnosis or Management of Cardiovascular Disease 


Chair: Theodore Mazzone, MD 

8:00 a.m.–8:30 a.m. Screening for Cardiovascular Disease in Asymptomatic Patients—Lessons from DIAD 

Silvio E. Inzucchi, MD 

8:30 a.m.–9:00 a.m. Revascularization vs. Medical Treatment for Coronary Disease in Diabetes—Lessons from BARI 2D 

Darren K. McGuire, MD 

9:00 a.m.–9:30 a.m. Biomarkers in Diabetes—Useful or Not 

Peter W.F. Wilson, MD 

9:30 a.m.–10:00 a.m. Should the Presence of Cardiovascular Disease Affect Glycemic Targets in Type 2 Diabetes Mellitus 

Peter D. Reaven, MD 

SATURDAY—PROGRAM 

Diabetes Prevention and Behavioral Interventions in Underserved Populations 

Room 221 

Chair: Julie Wagner, PhD 

8:00 a.m.–8:30 a.m. Adaptation of the DPP Lifestyle Intervention for the Arab-American Community in Detroit 

Linda A. Jaber, PharmD 

8:30 a.m.–9:00 a.m. Diabetes Prevention for Diverse Adults within the Primary Care Setting 

Robin Whittemore, PhD, APRN 

9:00 a.m.–9:30 a.m. Problem-Solving Training among Urban African-Americans with Type 2 Diabetes—Project DECIDE 

Felicia Hill-Briggs, PhD 

9:30 a.m.–10:00 a.m. The DIALBEST Study—Diabetes Interventions for an Urban Hispanic Population 

Rafael Perez-Escamilla, PhD 

Prescribing Exercise for Severely Obese Patients 

Room 209 

Chair: Thomas H. Inge, MD, PhD 

8:00 a.m.–8:40 a.m. Psychosocial Issues in Bariatric Surgery 

David B. Sarwer, PhD 

8:40 a.m.–9:20 a.m. Exercise Prescriptions for the Severely Obese Patient 

Charles W. Webb, DO 

9:20 a.m.–10:00 a.m. Benefits of Exercise after Bariatric Surgery 

Thomas H. Inge, MD, PhD 

17




8:00 a.m.–10:00 a.m. 

(continued) 

ADA Education Recognition Program—Assessing the Impact of Diabetes Education 

Room 207 

Chair: Paulina N. Duker, MPH, RN, BC-ADM, CDE 

8:00 a.m.–8:30 a.m. Outcomes Measurement—The Case for Quality Improvement in a Diabetes Education Program 

Gretchen Youssef, MS, RD, CDE 

8:30 a.m.–9:15 a.m. Process Improvement—University of Pittsburgh McKeesport Case 

Janice L. Koshinsky, MS, RN, CDE 

9:15 a.m.–9:45 a.m. Tools for Outcomes Management 

Paulina N. Duker, MPH, RN, BC-ADM, CDE 

9:45 a.m.–10:00 a.m. Questions and Answers 

Combination Therapies for Type 2 Diabetes From the Get-Go—Are We There Yet 

Room 224 

Chair: Vivian A. Fonseca, MD 

8:00 a.m.–8:40 a.m. Metformin +/- SU or TZD 

Bernard Zinman, MD 

8:40 a.m.–9:20 a.m. Incretin-Related Agents 

Robert M. Cuddihy, MD 

9:20 a.m.–10:00 a.m. Insulin 

Hannele Yki-Jarvinen, MD 

A1C Targets in Pediatric Diabetes—Ideal vs. Real 

Room 308 

Chair: Janet H. Silverstein, MD 

8:00 a.m.–8:30 a.m. Pediatric A1C Levels—Where We Are and Where We Want to Be 

Georgeanna J. Klingensmith, MD 

8:30 a.m.–9:00 a.m. Barriers to Achieving Targets and Risks of Hypoglycemia 

Timothy W. Jones, MD 

9:00 a.m.–9:30 a.m. Barriers to Achieving Targets and Risks of Hyperglycemia 

Fergus J. Cameron, MD 

9:30 a.m.–10:00 a.m. Should We Assess Measures of Glycemia Other Than A1C in Pediatric Diabetes 

William L. Clarke, MD 

Joint ADA/The Lancet Symposium 


Co-Chairs: Lin Guo, MPhil and M. Sue Kirkman, MD 

8:00 a.m.–8:20 a.m. Diabetes, Fasting Glucose, and Risk of Vascular Disease—A Collaborative Meta-Analysis of 96 

Prospective Studies 

Nadeem Sarwar, MBBS, MPhil 

8:20 a.m.–8:40 a.m. Prandial Inhaled Insulin Plus Basal Insulin Glargine vs. Pre-Mixed Biaspart Insulin for Type 2 Diabetes— 

A Multicentre Randomised Trial 

Daniel L. Lorber, MD 

8:40 a.m.–9:00 a.m. Efficacy and Safety of Exenatide Once Weekly vs. Sitagliptin or Pioglitazone as an Adjunct to Metformin 

for Treatment of Type 2 Diabetes (DURATION-2)—A Randomised Trial 

Richard M. Bergenstal, MD 

9:00 a.m.–9:20 a.m. Once-Weekly Exenatide Compared with Insulin Glargine Titrated to Target in Patients with Type 2 Diabetes 

(DURATION-3)—An Open-Label Randomised Trial 

Michaela Diamant, MD, PhD 

9:20 a.m.–9:40 a.m. Effect of Dapagliflozin in Patients with Type 2 Diabetes Who have Inadequate Glycaemic Control with 

Metformin—A Randomised, Double-Blind, Placebo-Controlled Trial 

Clifford J. Bailey, MD, PhD 

9:40 a.m.–10:00 a.m. Vitamins C and E for Prevention of Pre-Eclampsia in Women with Type 1 Diabetes (DAPIT)— 

A Randomised Placebo-Controlled Trial 

David R. McCance, MD 

18



8:00 a.m.–10:00 a.m. 

(continued) 

Novel Insights into Insulin Resistance and Metabolic Syndrome 

Room 304 E 

Chair: Alan R. Saltiel, PhD 

8:00 am.–8:30 a.m. Mechanism of Fructose-Induced Lipogenesis 

Varman T. Samuel, MD, PhD 

8:30 a.m.–9:00 a.m. Membrane and Cytoskeletal Aspects of Insulin Resistance 

Jeffrey S. Elmendorf, PhD 

9:00 a.m.–9:30 a.m. The Role of Dietary Branched-Chain Amino Acids in the Induction of Insulin Resistance 

Christopher B. Newgard, PhD 

9:30 a.m.–10:00 a.m. Pigment Epithelium-Derived Factor and Insulin Resistance 

Matthew J. Watt, PhD 

Adipose Tissue and Inflammation 

Room 414 

Chair: Eleftheria Maratos-Flier, MD 

8:00 a.m.–8:20 a.m. Biology of Resistin Revisited 

Rexford S. Ahima, MD, PhD 

8:20 a.m.–8:40 a.m. PGC-1—Sirtuins and Inflammation 

Pere Puigserver, PhD 

8:40 a.m.–9:00 a.m. Inflammation and Gene Expression in Adipose Tissue with Insulin Resistance 

Philip A. Kern, MD 

9:00 a.m.–9:20 a.m. Ketogenic Diets and FGF21 

Eleftheria Maratos-Flier, MD 

9:20 a.m.–9:40 a.m. Inflammatory Effects of High Fat Diets 

Anthony W. Ferrante, Jr., MD, PhD 



Beta Cell Intracellular Signaling-1—mTor to S6Kinase 

Room 304 A 

Chair: Rohit N. Kulkarni, MD, PhD 

8:00 a.m.–8:30 a.m. Beta Cell Intracellular Signaling-1—mTor to S6Kinase 

Ernesto Bernal-Mizrachi, MD 

8:30 a.m.–9:00 a.m. mTor and S6Kinase in the Beta Cell 

Sara C. Kozma, PhD 

9:00 a.m.–9:30 a.m. TSC2, mTorC, and Beta Cell Function 

Yoshiaki Kido, MD 

9:30 a.m.–10:00 a.m. Lkb1 Signaling in the Beta Cell 

Robert A. Screaton, PhD 


Incretin Comparisons........................................................................................................................................................... 57-OR to 64-OR 



Chair: Ian Blumer, MD 

19



10:15 a.m.–11:15 a.m. 

President, Health Care & Education Address 

Room 224 

Unique Challenges in Diabetes Care 

Christine T. Tobin, RN, MBA, CDE 

and 


Outstanding Educator in Diabetes Award Lecture 

Room 224 

From the Land of Oz—Brains, Heart, Courage, and Power 

Supported by an educational grant from Eli Lilly and Company 

Belinda P. Childs, ARNP, MN, CDE, BC-ADM 

11:30 a.m.–1:30 p.m. 

General Poster Session/Guided Audio Poster Tours 

Hall C 

12:00 p.m.–1:15 p.m. 

Interest Group Discussions 

Interest Group Discussion on Behavioral Medicine and Psychology 

Room 209 

Patient-Reported Outcomes in Pharmaceutical Clinical Trials—The Behavioral Scientist’s Role 

Richard R. Rubin, PhD, CDE 

Mark F. Peyrot, PhD 

William H. Polonsky, PhD 

Interest Group Discussion on Education 

Room 207 

Diabetes Education—Inspiring Ideas from Around the World 

Jane Jeffrie Seley, GNP, MPH, MSN, CDE, BC-ADM 

Interest Group Discussion on Clinical Endocrinology, Health Care Delivery, and Public Health 

Room 307 

Practical Use of Continuous Glucose Monitoring for Patients and Providers 

Steven V. Edelman, MD and Irl B. Hirsch, MD 

20



1:45 p.m.–3:45 p.m. 


Glycemic Outcomes and Acute Complications—MDI or the Pump—Which Is Best 


Co-Chairs: Steven V. Edelman, MD and Mary T. Korytkowski, MD 

1:45 p.m.–2:15 p.m. MDI 


2:15 p.m.–2:45 p.m. Pumps 

Thomas C. Blevins, MD 

Symposia 

Pregnancy and Diabetes Research—A 20-Year Tribute to Norbert Freinkel 

(Includes Norbert Freinkel Lecture) 

Room 311 

Co-Chairs: Assiamira Ferrara, MD, PhD and Boyd E. Metzger, MD 

1:45 p.m.–2:00 p.m. Freinkel’s Legacy—Understanding the Impact of Maternal Hyperglycemia on the Fetus 

Boyd E. Metzger, MD 

2:00 p.m.–2:45 p.m. Norbert Freinkel Award Lecture—From Insulin to Inflammation—Evolving Paths to Fetal Programming 

Sylvie Hauguel-de Mouzon, PhD 

2:45 p.m.–3:15 p.m. Fuel Mediated Teratogenesis—Revisiting the Concept 

Andreas Plagemann, MD 

3:15 p.m.–3:45 p.m. Congenital Anomalies—Lessons for the Future 

Ulf J. Eriksson, MD, PhD 


Cardiovascular Disease in Diabetes 


Chair: Ira J. Goldberg, MD 

1:45 p.m.–2:15 p.m. Correcting Cardiac Lipotoxicity 

Ira J. Goldberg, MD 

2:15 p.m.–2:45 p.m. Mouse Models of Cardiac Insulin Resistance 

Jason K. Kim, PhD 

2:45 p.m.–3:15 p.m. Mouse Models of Diabetic Atherosclerosis—What Have We Learned 

Ann Marie Schmidt, MD 

3:15 p.m.–3:45 p.m. Coronary Atheromata in Diabetes—Are They Different 

Renu Virmani, MD 

Advancing the Field—The Role of Inflammation in Depression and Diabetes 

(Includes Behavioral Medicine and Psychology Interest Group Award and Lectureship for Distinguished Contributions) 


Chair: Sherita H. Golden, MD 

1:45 p.m.–2:25 p.m. Behavioral Medicine and Psychology Interest Group Award and Lectureship for Distinguished 

Contributions—Reflections on 30 Years of Behavioral Medicine in Diabetes 

Supported by an unrestricted educational grant from Novo Nordisk, Inc. 

Richard R. Rubin, PhD, CDE 

2:25 p.m.–3:05 p.m. Inflammation and Type 2 Diabetes 

Birgit Gustafson, PhD 

3:05 p.m.–3:45 p.m. The Future of Depression Treatment and Implications for Diabetes 

Lisa M. Thornton, PhD 

21



1:45 p.m.–3:45 p.m. 

(continued) 


Clinical Impact of the New Genetic Discoveries in Diabetes 

Room 315 

Chair: Jose C. Florez, MD, PhD 

1:45 p.m.–2:15 p.m. Genetic Prediction of Type 2 Diabetes 

A. Cecile J.W. Janssens, PhD 

2:15 p.m.–2:45 p.m. Pharmacogenomic Studies of Diabetes 

Ewan R. Pearson, PhD 

2:45 p.m.–3:15 p.m. The Genetics of HbA1C 

Nicole Soranzo, PhD 

3:15 p.m.–3:45 p.m. What Do Genetics Tell Us about the Presentation, Course, and Complications of Type 1 Diabetes 

George S. Eisenbarth, MD, PhD 

Mitochondrial Metabolism and Substrate Selection 

Room 304 E 

Chair: Gerald I. Shulman, MD, PhD 

1:45 p.m.–2:15 p.m. Fatty Acid Metabolism in Insulin Resistant Men 

Fredrik Karpe, MD, PhD 

2:15 p.m.–2:45 p.m. Mitochondrial Dynamics in Heart Tissue 

Charles L. Hoppel, MD 

2:45 p.m.–3:15 p.m. Redox Regulation of Krebs Cycle Function 

Luke I. Szweda, PhD 

3:15 p.m.–3:45 p.m. Carnitine Dysregulation and Metabolic Inflexibility in Rodent Models of Obesity and Diabetes 

Deborah M. Muoio, PhD 

Joint ADA/EASD Symposium—Glucagon-Like Peptide-1—From Secretion to Function 


Room 414 

Co-Chairs: Patricia L. Brubaker, PhD and Ulf Smith, MD 

1:45 p.m.–2:15 p.m. GLP-1 Secretion—A New Approach to Incretin Therapy 

Frank Reimann, MD 

2:15 p.m.–2:45 p.m. TCF7L2 and GLP-1—Is There a Connection 

Kathrin Maedler, PhD 

2:45 p.m.–3:15 p.m. KCNQ1 and WFS1—Novel Determinants of GLP-1 Effects in Type 2 Diabetes 

Andreas Fritsche, MD 

3:15 p.m.–3:45 p.m. Two for the Money—Glucagon/GLP-1 Hybrids 

Matthias H. Tschoep, MD 


Pediatric Diabetes—Clinical Aspects of Beta Cell Function.................................................................... Abstracts 65-OR to 72-OR 

Room 312 

Co-Chairs: Lawrence M. Dolan, MD and Georgeanna J. Klingensmith, MD 

Pharmacotherapies for the Treatment of Type 2 Diabetes—From the Old to the New.......................... Abstracts 73-OR to 80-OR 

Room 224 

Chair: William T. Cefalu, MD 

Integrated Physiology—Liver........................................................................................................................... Abstracts 81-OR to 88-OR 

Room 314 

Co-Chairs: Rita Basu, MD and Terry P. Combs, PhD 

Islet Development and Signal Transduction.................................................................................................. Abstracts 89-OR to 96-OR 

Room 304 A 

Co-Chairs: Catherine Lee May, PhD and Lori Sussel, PhD 

22



4:00 p.m.–6:00 p.m. 


Should New Diabetes Drugs Submitted to the FDA Have a Higher Bar for Cardiovascular Safety Than Other Drugs 


Chair: John B. Buse, MD, PhD 

4:00 p.m.–4:30 p.m. Yes 

Steven E. Nissen, MD 

4:30 p.m.–5:00 p.m. No 

David G. Orloff, MD 

Symposia 

Diabetes in the New Realm of Comparative Effectiveness Research (CER) 

Room 224 

Chair: TBD 

4:00 p.m.–4:30 p.m. The Role of CER in Evidence-Based Diabetes Care and Prevention 

David H. Hickam, MD 

4:30 p.m.–5:00 p.m. Priority Areas for CER in Diabetes 

Robert E. Ratner, MD 

5:00 p.m.–5:30 p.m. Emerging Research from the DECIDE Network 

Jodi B. Segal, MD 

5:30 p.m.–6:00 p.m. Communicating Comparative Features of Different Diabetes Therapies to Patients 

Nilay D. Shah, PhD 


NIDDK Symposium—Novel Pathways to Treatment of Type 2 Diabetes and Obesity 


Chair: Griffin P. Rodgers, MD 

4:00 p.m.–4:30 p.m. Persistence of Brown Fat in Human Adults and the Therapeutic Potential of this Discovery 

C. Ronald Kahn, MD 

4:30 p.m.–5:00 p.m. Novel Pathways for Adipose Regulation—Implications for New Therapies 

Bruce M. Spiegelman, PhD 

5:00 p.m.–5:30 p.m. Uncovering New Therapeutic Approaches for Type 2 Diabetes Through Bariatric Surgery Research 

Allison B. Goldfine, MD 

5:30 p.m.–6:00 p.m. Pharmacogenetic Findings from DPP 

Jose C. Florez, MD, PhD 

Central Modulators of Obesity 

Room 311 

Chair: George Argyropoulos, PhD 

4:00 p.m.–4:30 p.m. Central Dopamine Plasticity in Genetic and Dietary Obesity 

Emmanuel N. Pothos, PhD 

4:30 p.m.–5:00 p.m. Role of Brain Glucose Sensing in Energy Balance 

Charles V. Mobbs, PhD 

5:00 p.m.–5:30 p.m. Metabolic Actions of Brain SIRT1 

Roberto Coppari, PhD 

5:30 p.m.–6:00 p.m. Leptin Action in the Control of Appetite 

Gina M. Leinninger, PhD 

23



4:00 p.m.–6:00 p.m. 

(continued) 


Beta Cell Intracellular Signaling-2—PI3Kinase and PKCs, and IKKs 

Room 304 A 

Chair: Michael L. McDaniel, PhD 

4:00 p.m.–4:30 p.m. Rapamycin and Beta Cell Death 

Gil Leibowitz, MD 

4:30 p.m.–5:00 p.m. PI3K and Foxo1 Interactions in the Beta Cell 

Domenico Accilli, MD 

5:00 p.m.–5:30 p.m. PKC-Delta as a Mediator of Free Fatty Acid Induced Beta Cell Dysfunction 

Susanne Ullrich, PhD 

5:30 p.m.–6:00 p.m. PKC-Zeta 

Adolfo Garcia-Ocana, PhD 


Diabetic Dyslipidemia...................................................................................................................................... Abstracts 97-OR to 104-OR 

Room 209 

Chair: John E. Hokanson, PhD 

Novel Approaches to Patient and Provider Education............................................................................ Abstracts 105-OR to 112-OR 

Room 207 

Chair: Robin B. Nwankwo, MPH, RD, CDE 

Exercise and Diabetes................................................................................................................................... Abstracts 113-OR to 120-OR 

Room 208 

Chair: Patrice Brassard, PhD 

Continuous Glucose Monitoring.................................................................................................................. Abstracts 121-OR to 128-OR 

Room 414 

Co-Chairs: Steven V. Edelman, MD and Anne Peters, MD 

Genetic Risks and Gene Specific Studies.................................................................................................. Abstracts 129-OR to 136-OR 

Room 315 

Chair: Michele M. Sale, PhD 

Monitoring and Clinical Impact of Islet Transplantation........................................................................ Abstracts 137-OR to 144-OR 

Room 221 

Chair: Camillo Ricordi, MD 

Mitochondria and Energy Homeostasis...................................................................................................... Abstracts 145-OR to 152-OR 

Room 304 E 

Chair: Shingo Kajimura, PhD 

24


SATURDAY, June 26 

8:00 a.m.–10:00 a.m. 

Session: Incretin Comparisons 



Chair: Ian Blumer, MD 

57-OR 

58-OR 

59-OR 

60-OR 

61-OR 

62-OR 

63-OR 

64-OR 

8:00 a.m.–8:15 a.m. 

Liraglutide Reduces A1c to a Greater Extent Than Sitagliptin Regardless 

of Baseline A1c Levels 

MELANIE DAVIES, RICHARD PRATLEY, EDUARD MONTANYA, ANNE 

THOMSEN, ALI FALAHATI, GIORGIO SESTI, Leicester, United Kingdom, 

Burlington, VT, Barcelona, Spain, Copenhagen, Denmark, Catanzaro, 

Italy 

8:15 a.m.–8:30 a.m. 

Once Weekly Taspoglutide, a Human GLP-1 Analog, Is Superior to 

Sitagliptin in Improving Glycemic Control and Weight Loss in Patients 

with Type 2 Diabetes (T2D): Results from the T-emerge 4 Trial 

RICHARD BERGENSTAL, ADRIANA FORTI, JEAN-LOUIS CHIASSON, 

MIKE WOLOSCHAK, MARK BOLDRIN, LAWRENCE A. LEITER, RAFFAELLA 

BALENA, Minneapolis, MN, Fortaleza, Brazil, Montreal, QC, Canada, 

Nutley, NJ, Toronto, ON, Canada, Basel, Switzerland 

WITHDRAWN 

8:30 a.m.–8:45 a.m. 

Taspoglutide, a Once-Weekly Human GLP-1 Analog, Provides Comparable 

Glycemic Control to Insulin Glargine, with Superior Weight Loss and 

Less Hypoglycemia in Type 2 Diabetes (T2D): A Phase 3, Open-Label Trial 

(T-emerge 5) 

MICHAEL NAUCK, EDWARD HORTON, MIRJANA ANDJELKOVIC, F. 

JAVIER AMPUDIA-BLASCO, MARK N. BOLDRIN, RAFFAELLA BALENA, 

Bad Lauterberg im Harz, Germany, Boston, MA, Basel, Switzerland, 

Valencia, Spain, Nutley, NJ 

8:45 a.m.–9:00 a.m. 

Safety and Tolerability of Exenatide Once Weekly Pooled Summary of 

1095 Patients from DURATION-1, 2, and 3 

SIMON BRUCE, JENNY HAN, CARL BROWN, DAWN NICEWARNER, JEFF 

FERGUSON, DANA LEE, LAURA BOIES, San Diego, CA, Indianapolis, IN 

9:00 a.m.–9:15 a.m. 

Superior Glycemic Control with Taspoglutide, a Once-Weekly Human 

GLP-1 Analog, Compared with Twice Daily Exenatide in Type 2 Diabetes 

(T2DM) Inadequately Controlled on Oral Agents: The T-emerge 2 Trial 

JULIO ROSENSTOCK, BOGDAN BALAS, BERNARD CHARBONNEL, 

GEREMIA B. BOLLI, MARK BOLDRIN, ROBERT RATNER, RAFFAELLA 

BALENA, Dallas, TX, Basel, Switzerland, Nantes, France, Perugia, Italy, 

Nutley, NJ, Hyattsville, MD 

9:15 a.m.–9:30 a.m. 

Beta-Cell Function and Glycemic Control Following One-Year Vildagliptin 

Treatment, and after 12-Week Washout, in Drug-Naive Patients with 

Type 2 Diabetes and Mild Hyperglycemia 

MATHIJS C. BUNCK, MARIEKE POELMA, DIANE L. GOEDE, LARISSA 

W. VAN GOLEN, RENATE E. VAN GENUGTEN, E. MARELISE EEKHOFF, 

ANJA SCHWEIZER, ROBERT J. HEINE, JAMES E. FOLEY, GIEL NIJPELS, 

MICHAELA DIAMANT, Amsterdam, The Netherlands, Basel, Switzerland, 

East Hanover, NJ 

9:30 a.m.–9:45 a.m. 

Saxagliptin Initial Combination with Metformin Provides Sustained 

Glycemic Control and Is Well Tolerated in Patients with Type 2 Diabetes: 

76-Week Results 

ANDREAS PFÜTZNER, ELIZABETH PAZ-PACHECO, NIKLAS BERGLIND, 

ELSIE ALLEN, BOB FREDERICH, ROLAND CHEN, Mainz, Germany, Pasig 

City, Philippines, Princeton, NJ 

SATURDAY—ORALS 


25



1:45 p.m.–3:45 p.m. 

Session: Pediatric Diabetes—Clinical Aspects of Beta Cell Function 

Room 312 

Co-Chairs: Lawrence M. Dolan, MD and Georgeanna J. Klingensmith, MD 

1:45 p.m.–3:45 p.m. 

Session: Pharmacotherapies for the Treatment of Type 2 Diabetes— 

From the Old to the New 

Room 224 

Chair: William T. Cefalu, MD 


65-OR 

66-OR 

67-OR 

68-OR 

69-OR 

1:45 p.m.–2:00 p.m. 

Urinary C-Peptide Creatinine Ratio Is a Novel Non Invasive Alternative to 

the Inpatient Mixed Meal Tolerance Test in Young Onset Type 1 Diabetes 

RACHEL E.J. BESSER, ANGUS G. JONES, TIMOTHY J. MCDONALD, 

BEVERLEY M. SHIELDS, GAYLE GITHENS-MAZER, KIRSTY WENSLEY, 

BRIDGET A. KNIGHT, ANDREW T. HATTERSLEY, Exeter, United Kingdom 

2:00 p.m.–2:15 p.m. 

One-Year Results from a Phase 1/2 Clinical Trial of BHT-3021, a DNA 

Plasmid Vaccine for Type 1 Diabetes (T1D) 

PETER GOTTLIEB, PETER G. COLMAN, NANETTE SOLVASON, KELLY 

OTTO, BART ROEP, LEONARD C. HARRISON, GEORGE EISENBARTH, 

WILLIAM ROBINSON, PAUL J. UTZ, LAWRENCE STEINMAN, HIDEKI 

GARREN, JOANNE QUAN, Aurora, CO, Parkville, Australia, San Mateo, 

CA, Leiden, The Netherlands, Stanford, CA 

2:15 p.m.–2:30 p.m. 

Enterovirus Infections Are Common in Children at Risk of Type 1 Diabetes 

and Associated with Transient and Persistent Autoimmunity 

AMMIRA AL-SHABEEB, RUTTY TALATI, JACKI CATTEAU, KRISTY 

SANDERSON, ZIN NIANG, WILLIAM RAWLINSON, NEVILLE J. 

HOWARD, MARIA E. CRAIG, Sydney, Australia 

2:30 p.m.–2:45 p.m. 

Changes in ICA512 and GAD65 Autoantibodies with Progression to Type 

1 Diabetes in the Diabetes Prevention Trial-Type 1 (DPT-1) 

JAY M. SOSENKO, JAY S. SKYLER, JERRY P. PALMER, JEFFREY P. 

KRISCHER, DAVID CUTHBERTSON, LIPING YU, DESMOND SCHATZ, 

TIHAMER ORBAN, GEORGE EISENBARTH, THE DPT-1 STUDY GROUP, 

Miami, FL, Seattle, WA, Tampa, FL, Denver, CO, Gainesville, FL, Boston, 

MA 

2:45 p.m.–3:00 p.m. 

Health Behaviors and Preservation of C-Peptide in Youth with Recently 

Diagnosed Type 1 Diabetes: SEARCH for Diabetes in Youth 

ELIZABETH MAYER-DAVIS, DANA DABELEA, RALPH D’AGOSTINO, JR., 

KATHY WOJCIK, LAWRENCE DOLAN, CATHERINE PIHOKER, Chapel Hill, 

NC, Denver, CO, Winston-Salem, NC, Cincinnati, OH, Seattle, WA 

73-OR 

74-OR 

75-OR 

WITHDRAWN 

1:45 p.m.–2:00 p.m. 

Thiazolidinedione Associated Fractures Are Not Limited to Distal 

Fractures and Occur in Men as Well as Women 

THE SCOTTISH DIABETES RES. NETWORK EPID. GRP., HELEN M. 

COLHOUN, Dundee, United Kingdom 

2:00 p.m.–2:15 p.m. 

ASP1941, a Novel, Selective SGLT2 Inhibitor, Was Effective and Safe 

in Japanese Healthy Volunteers and Patients with Type 2 Diabetes 

Mellitus 

ATSUNORI KASHIWAGI, ATSUSHI UTSUNO, KENICHI KAZUTA, SATOSHI 

YOSHIDA, SHIGERU KAGEYAMA, Shiga/Otsu, Japan, Tokyo/Itabashi, 

Japan, Tokyo/Minato, Japan 

2:15 p.m.–2:30 p.m. 

76-OR Canagliflozin, a Novel Inhibitor of Sodium Glucose Co-Transporter 2, 

Induces Dose-Dependent Urinary Glucose Excretion in Healthy Subjects 

SUE SHA, DAMAYANTHI DEVINENI, ATALANTA GHOSH, DAVID 

POLIDORI, SHUCHEAN CHIEN, DAVID WEXLER, KEVIN SHALAYDA, 

KEITH DEMAREST, PAUL L. ROTHENBERG, Raritan, NJ, La Jolla, CA 

77-OR 

78-OR 

2:30 p.m.–2:45 p.m. 

Canagliflozin, an Inhibitor of Sodium Glucose Co-Transporter 2 (SGLT2), 

Improves Glycemic Control and Lowers Body Weight in Subjects with 

Type 2 Diabetes (T2D) on Metformin 

JULIO ROSENSTOCK, DEBORAH ARBIT, KEITH USISKIN, GEORGE 

CAPUANO, WILLIAM CANOVATCHEL, Dallas, TX, Raritan, NJ 

2:45 p.m.–3:00 p.m. 

Dapagliflozin in Patients with Type 2 Diabetes Poorly Controlled on 

Insulin Therapy—Efficacy of a Novel Insulin-Independent Treatment 

JOHN P.H. WILDING, VINCENT WOO, NORMAN G. SOLER, ANDREA 

PAHOR, JENNIFER SUGG, SHAMIK PARIKH, Liverpool, United Kingdom, 

Winnipeg, MB, Canada, Springfield, IL, Wedel, Germany, Wilmington, 

DE 

70-OR 

71-OR 

72-OR 

3:00 p.m.–3:15 p.m. 

Adiposity Is Unrelated to Age at Onset or Antibody Positivity among 

Children with Type 1 Diabetes 

MARIBEL CEDILLO, INGRID M. LIBMAN, LEI ZHOU, DIEGO IZE-LUDLOW, 

VINCENT ARENA, DOROTHY J. BECKER, Pittsburgh, PA, Chicago, IL 

3:15 p.m.–3:30 p.m. 

Declining β-Cell Function Relative to Insulin Sensitivity with Increasing 

Fasting Glucose Levels in the Non Diabetic Range in Children 

HALA M. TFAYLI, SOJUNG LEE, SILVA ARSLANIAN, Pittsburgh, PA 

3:30 p.m.–3:45 p.m. 

Trends in Beta Cell Function among Children who Develop Impaired 

Fasting Glucose—An Eight-Year Longitudinal Study 

TERENCE J. WILKIN, ALISON N. JEFFERY, BRAD S. METCALF, LINDA D. 

VOSS, Plymouth, United Kingdom 

79-OR 

80-OR 

3:00 p.m.–3:15 p.m. 

First Proof of Pharmacology of a Novel Glucagon Receptor Antisense 

Drug in Humans 

ERIN S. MORGAN, TERESA A. BRANDT, MARLOES G.J. VAN DONGEN, 

BART F. GEERTS, JACOBUS BURGGRAAF, JOHANNES A. ROMIJN, 

ADAM F. COHEN, TANYA A. WATANABE, RICHARD S. GEARY, SANJAY 

BHANOT, Carlsbad, CA, Leiden, The Netherlands 

3:15 p.m.–3:30 p.m. 

A Study in Healthy Volunteers To Assess the Safety, Tolerability, 

Pharmacokinetics (PK) and Pharmacodynamics (PD) of Single and 

Multiple Doses of GSK1292263, a Novel GPR119 Agonist 

DEREK J. NUNEZ, ERIC W. LEWIS, SUZANNE SWAN, MARK A. BUSH, 

COURTNEY CANNON, SUSAN L. MCMULLEN, DAVID A. COLLINS, PAUL 

L. FELDMAN, Research Triangle Park, NC, Minneapolis, MN 

26 




1:45 p.m.–3:45 p.m. 

Session: Integrated Physiology—Liver 

Room 314 

Co-Chairs: Rita Basu, MD and Terry P. Combs, PhD 

81-OR 

82-OR 

83-OR 

84-OR 

85-OR 

86-OR 

87-OR 

88-OR 

1:45 p.m.–2:00 p.m. 

Evidence for a Key Role of Hepatic PEPCK-M in Glucose Homeostasis In 

Vivo 

ROMANA STARK, COLLEEN N. FERIOD, XIAOJIAN ZHAO, JIANYING 

DONG, MICHAEL RODEN, SANJAY BHANOT, GERALD I. SHULMAN, 

RICHARD G. KIBBEY, New Haven, CT, Düsseldorf, Germany, Carlsbad, 

CA 

WITHDRAWN 

2:00 p.m.–2:15 p.m. 

Evaluation of a PPARγ-Sparing Thiazolidinedione for Treatment of Insulin 

Resistance in Diet-Induced Obese Mice 

BRIAN N. FINCK, ZHOUJI CHEN, WILLIAM MCDONALD, JERRY COLCA, 

ROLF F. KLETZIEN, St. Louis, MO, Kalamazoo, MI 

2:15 p.m.–2:30 p.m. 

Significant Transaldolase Exchange Activity in Human Liver: Implications 

for Tracer Measurements of Gluconeogenesis 

CRISTINA BAROSA, RITA BASU, JOHN JONES, AHMED FARAG, 

BARBARA NORBY, BETTY DICKE, ANANDA BASU, ROBERT RIZZA, 

Coimbra, Portugal, Rochester, MN 

2:30 p.m.–2:45 p.m. 

A Novel Mechanism for AMPK To Regulate Hepatocyte Lipogenesis Via 

Directly Inhibiting SREBP and Attenuate Hepatic Steatosis in Insulin 

Resistance 

YU LI, SHANQIN XU, XIUYUN HOU, BINGBING JIANG, ZHIJUN LUO, 

ETIENNE LEFAI, MICHEL WIERZBICKI, TONY J. VERBEUREN, RICHARD 

A. COHEN, MENGWEI ZANG, Boston, MA, Lyon, France, Suresnes, 

France 

2:45 p.m.–3:00 p.m. 

Genetic Mutation of p66Shc Protein at Ser36 Prevents Oxidative Stress 

in Human Liver Cells 

SEBASTIO PERRINI, FRANCESCA DE STEFANO, ANNALISA NATA LICCHIO, 

FEDERICA TORTOSA, ALESSANDRO PESCHECHERA, ANGELO CIGNA - 

RELLI, ROMINA FICARELLA, MARIANGELA MELCHIORRE, FABRIZIO 

LOSURDO, LUIGI LAVIOLA, FRANCESCO GIORGINO, Bari, Italy 

3:00 p.m.–3:15 p.m. 

Maternal High Fat Diet Primes Juvenile Offspring for Increased Hepatic 

Inflammation and Insulin Resistance in the Non-Human Primate 

STEPHANIE R. THORN, KEVIN L. GROVE, JACOB E. FRIEDMAN, Aurora, 

CO, Portland, OR 

3:15 p.m.–3:30 p.m. 

Abnormal Glucose Metabolism Is Common in NASH Patients and 

Associated with More Severe Hepatic/Adipose Tissue Insulin Resistance 

and Hepatocyte Necroinflammation 

CAROLINA ORTIZ-LOPEZ, BEVERLY ORSAK, CELIA DARLAND, JOAN 

FINCH, ROMINA M. LOMONACO, KENNETH CUSI, San Antonio, TX 

1:45 p.m.–3:45 p.m. 

Session: Islet Development and Signal Transduction 

Room 304 A 

Co-Chairs: Catherine Lee May, PhD and Lori Sussel, PhD 

89-OR 

90-OR 

91-OR 

92-OR 

93-OR 

94-OR 

95-OR 

96-OR 

1:45 p.m.–2:00 p.m. 

DNMT1 Is Required for Cell Survival through Terminal Differentiation 

during Pancreas Development 

SENTA K. GEORGIA, GUOPING FAN, ANIL BHUSHAN, Los Angeles, CA 

2:00 p.m.–2:15 p.m. 

Neurogenin 3 Inhibits Proliferation of Islet Progenitor Cells through 

Induction of Cdkn1a 

TAKESHI MIYATSUKA, YASUHIRO KOSAKA, MICHAEL S. GERMAN, San 

Francisco, CA 

2:15 p.m.–2:30 p.m. 

Ductal Heterogeneity Suggests a Subpopulation Serves as Postnatal 

Pancreatic Progenitors 

LIMOR OUZIEL-YAHALOM, WAN-CHUN LI, SHARON STRAUSSMAN, 

LILI GUO, ARUN SHARMA, GORDON C. WEIR, SUSAN BONNER-WEIR, 

Boston, MA 

2:30 p.m.–2:45 p.m. 

Foxa2 and HNF6 Down-Regulate MafA Gene Expression through 

Conserved Foxa2 Binding Cis-Element 

KAORU YAMAMAMOTO, TAKA-AKI MATSUOKA, SATOSHI KAWA SHIMA, 

RYUICHI KASAMI, KAZUTOMI YOSHIUCHI, IICHIRO SHIMO MURA, 

MUNEHIDE MATSUHISA, HIDEAKI KANETO, Osaka, Japan, Yama daoka, 

Japan, Suita, Japan 

2:45 p.m.–3:00 p.m. 

Establishing an In Vitro Model of Pancreatic Beta Cell Differentiation 

with Human Embryonic Stem Cells 

XIAOFANG XU, VICTORIA BROWNING, JON ODORICO, Madison, WI 

3:00 p.m.–3:15 p.m. 

Phosphodiesterase 8B (PDE8B) Inhibition Stimulates Glucose-Stimulated 

Insulin Secretion in Islets: A Novel Target for Diabetes Therapy 

KAREN L. HOUSEKNECHT, MICHELE L. MILLHAM, MARIA WILSON, JEFF 

JOHNSON, THOMAS A. GUSTAFSON, MIKE DENINNO, DOM BREES, 

KIM ANDREWS, MARIA VANVOLKENBURG, Portland, ME, Groton, CT, 

Hayward, CA 

3:15 p.m.–3:30 p.m. 

Angiotensin II, a Novel Mediator of Islet Inflammation in Type 1 Diabetes 

HWYDA A. ARAFAT, GALINA CHIPITSYNA, QIAOKE GONG, Philadelphia, 

PA 

3:30 p.m.–3:45 p.m. 

Regulation of Glucagon-Like Peptide Receptor-1 by SUMO 

SINDHU RAJAN, JACQUELINE TORRES, DAVID A. JACOBSON, LOUIS H. 

PHILIPSON, Chicago, IL 



27




4:00 p.m.–6:00 p.m. 

Session: Diabetic Dyslipidemia 

Room 209 

Chair: John E. Hokanson, PhD 

97-OR 

98-OR 

99-OR 

4:00 p.m.–4:15 p.m. 

ApoA-I Mimetic Peptides Prevent Atherosclerosis Development in a 

Mouse Model of Diabetes 

CECILIA MORGANTINI, VICTOR GRIJALVA, MOHAMAD NAVAB, ALAN 

M. FOGELMAN, SRINIVASA T. REDDY, Pisa, Italy, Los Angeles, CA 

4:15 p.m.–4:30 p.m. 

High Density Lipoprotein Cholesterol (HDLc): Is Too Much of a Good 

Thing Harmful 

TINA COSTACOU, RHOBERT W. EVANS, TREVOR JOHN ORCHARD, 

Pitts burgh, PA 

4:30 p.m.–4:45 p.m. 

ApoCIII May Contribute to Paradoxically Normal Triglyceride Levels in 

Insulin-Resistant Black Women 

ANNE E. SUMNER, JEREMY D. FURTADO, AMBER COURVILLE, MADIA 

RICKS, BERNARD V. MILLER, ANITA V. TAMBAY, UGOCHI J. UKEGBU, 

VANDANA SACHDEV, FRANK M. SACKS, Bethesda, MD, Boston, MA 

4:45 p.m.–5:00 p.m. 

100-OR The Chronomics of Diabetic Dyslipidemia and Hypercholesterolemia: 

Evidence from Non Human Primates 

BARBARA C. HANSEN, JENNIFER D. NEWCOMB, RANIA SHAMEKH, 

Tampa, FL 

5:00 p.m.–5:15 p.m. 

101-OR Specific Role of Liver Fat Content and Decreased Adiponectin Levels on 

Hypertriglyceridemia and Low HDL-Cholesterol, in Type 2 Diabetes 

BRUNO VERGÈS, BORIS GUIU, JEAN-PIERRE CERCUEIL, ISABELLE 

ROBIN, PERRINE BUFFIER, BENJAMIN BOUILLET, MARIE-CLAUDE 

BRINDISI, ALIX POUSSIER, JEAN-MICHEL PETIT, Dijon, France 

5:15 p.m.–5:30 p.m. 

102-OR Glucagon Regulation of Hepatic and Intestinal Lipoprotein Metabolism 

in Humans 

CHANGTING XIAO, MIRJANA PAVLIC, LINDA SZETO, GARY F. LEWIS, 

Toronto, ON, Canada 

5:30 p.m.–5:45 p.m. 

103-OR Absence of Adipose Differentiation Related Protein Upregulates Hepatic 

VLDL Secretion, Relieves Hepatosteatosis and Improves Whole Body 

Insulin Resistance in Leptin-Deficient Mice 

BENNY CHANG, LAN LI, PRADIP SAHA, LAWRENCE CHAN, Houston, 

TX 

5:45 p.m.–6:00 p.m. 

104-OR Trends in Modifiable Cardiovascular Risk Factors among the US Diabetic 

Population, 1999–2006 

ANDREAS KUZNIK, JACK MARDEKIAN, New York, NY 

4:00 p.m.–6:00 p.m. 

Session: Novel Approaches to Patient and Provider Education 

Room 207 

Chair: Robin B. Nwankwo, MPH, RD, CDE 

4:00 p.m.–4:15 p.m. 

105-OR A Novel Approach to Diabetes Prevention: Evaluation of the Group 

Lifestyle Balance Program Delivered with Remote Support Via DVD 

M. KAYE KRAMER, ANDREA M. KRISKA, ELIZABETH M. VENDITTI, 

LINDA N. SEMLER, RACHEL G. MILLER, LINDA M. SIMINERIO, TREVOR 

J. ORCHARD, Pittsburgh, PA 

4:15 p.m.–4:30 p.m. 

106-OR Development of an Interactive Web-Based Diabetes Self-Management 

and Social Networking Tool 

HEATHER STUCKEY, SCOTT MINCEMOYER, GOKNUR AKILLI, BRIAN 

SMITH, ROBERT GABBAY, Hershey, PA, University Park, PA 

4:30 p.m.–4:45 p.m. 

107-OR Comparison of Diabetes Education Group Education as Administered 

through Telemedicine vs as Administered in Person 

ROBERTO IZQUIERDO, JOANNE KEARNS, DEBORAH BOWERMAN, 

MICHAEL WADE, DENNIS NORFLEET, RUTH S. WEINSTOCK, Syracuse, 

NY, Oswego, NY 

4:45 p.m.–5:00 p.m. 

108-OR An Office Based Physician Education Program To Enhance the Earlier 

Initiation of Insulin: An Evaluation of an Academic Detailing Intervention 

in the US 

SCOTT ENDSLEY, SANDRA LEAL, JEANNIE CHOI, ARTHUR N. MARTINEZ, 

Phoenix, AZ, Tucson, AZ, Bridgewater, NJ 

5:00 p.m.–5:15 p.m. 

109-OR The Church-Based Diabetes Prevention and Translation-2 Study 

(CBDPT-2) 

JOHN M. BOLTRI, MONIQUE DAVIS-SMITH, PAUL SEALE, JUDITH 

FIFIELD, JOY D. GOENS, IKE S. OKOSUN, Macon, GA, Farmington, CT, 

Atlanta, GA 

5:15 p.m.–5:30 p.m. 

110-OR Feasibility of Diabetes Prevention in Arab Americans 

NICOLE R. PINELLI, WILLIAM H. HERMAN, MORTON B. BROWN, LINDA 

A. JABER, Detroit, MI, Ann Arbor, MI 

5:30 p.m.–5:45 p.m. 

111-OR Self-Monitoring of Blood Glucose Is Associated with Problem-Solving 

Skills in Hyperglycemia and Hypoglycemia 

JING WANG, JANICE C. ZGIBOR, JUDITH T. MATTHEWS, DENISE 

CHARRON-PROCHOWNIK, RONALD E. LAPORTE, SUSAN M. SEREIKA, 

LINDA M. SIMINERIO, Pittsburgh, PA 

5:45 p.m.–6:00 p.m. 

112-OR Efficacy of Self Monitoring of Blood Glucose Plus Intensive Education in 

Patients with Type 2 Diabetes Not Treated with Insulin 

MONICA FRANCIOSI, GIUSEPPE LUCISANO, ALESSANDRO CANTA- 

RELLO, AGOSTINO CONSOLI, LIA CUCCO, ROSANGELA GHIDELLI, GIO- 

VANNI SARTORE, LUIGI SCIANGULA, ANTONIO NICOLUCCI, S. Maria 

Imbaro (CH), Italy, Padova, Italy, Pescara, Italy, Mariano Comense (CO), 

Italy 

28 




4:00 p.m.–6:00 p.m. 

Session: Exercise and Diabetes 

Room 208 

Chair: Patrice Brassard, PhD 

4:00 p.m.–4:15 p.m. 

113-OR Exercise Training Reduces Kidney Angiotensin II Levels and Attenuates 

Renal Dysfunction in Animal Diabetic Nephropathy 

TATIANA S. CUNHA, FERNANDA AP RONCHI, MAISA M. SAKATA, 

DANIELLE Y. ARITA, JULIANA A. COLUCCI, JULIANA D. PEREZ, KÁTIA 

DE ANGELIS, FERNANDA K. MARCONDES, MARIA CLÁUDIA IRIGOYEN, 

DULCE E. CASARINI, São Paulo, Brazil, Piracicaba, Brazil 

4:15 p.m.–4:30 p.m. 

114-OR Weight Loss Induced by Low-Fat Diet and Exercise Reduces Inflammation 

and Improves Insulin Action in Obese Mice 

DAE YOUNG JUNG, HWI JIN KO, YONGJIN LEE, EBEN LICHTMAN, 

ELIZABETH LAWTON, YOSHIHIRO AZUMA, KRISTINE YU, JASON K. 

KIM, Worcester, MA 

4:30 p.m.–4:45 p.m. 

115-OR A Single Bout of Exercise Reverses Muscle Insulin Resistance and 

Reduces Postprandial Hepatic De Novo Lipogenesis and Net Hepatic 

Triglyceride Synthesis in Young Lean Insulin Resistant Individuals 

RASMUS RABOL, KITT FALK PETERSEN, SYLVIE DUFOUR, CLARE 

FLANNERY, GERALD I. SHULMAN, New Haven, CT 

4:45 p.m.–5:00 p.m. 

116-OR Myo1c Regulates Glucose Uptake in Mouse Skeletal Muscle 

TARO TOYODA, DING AN, CAROL A. WITCZAK, HO-JIN KOH, MICHAEL 

F. HIRSHMAN, NOBUHARU FUJII, LAURIE J. GOODYEAR, Boston, MA, 

Tokyo, Japan 

5:00 p.m.–5:15 p.m. 

117-OR Intrahepatic Fat Changed with Abdominal Subcutaneous Fat, but 

Intramyocellular Fat Did Not during Diet or Exercise Intervention in Type 

2 Diabetes 

KYUNG AH HAN, HYUN-JIN KIM, KANG SEO PAK, KYUNG WAN MIN, 

HONG KYU LEE, Seoul, Republic of Korea, Daejeon, Republic of Korea, 

Taejon, Republic of Korea 

5:15 p.m.–5:30 p.m. 

118-OR Effects of Different Exercise Modalities on Metabolic Control and 

Cellular Insulin Signaling in Patients with Type 2 Diabetes 

MARIA LUIZA MENDONCA JORGE, VANESSA NEVES OLIVEIRA, PAULO 

TANNUS JORGE, FOUED SALMEN ESPINDOLA, ELMIRO SANTOS 

RESENDE, NATHALIA MARIA RESENDE, LARA FERREIRA PARAISO, 

ANTONIO CALIXTO, ANA CAROLINA JUNQUEIRA VASQUES, JOSE 

BARRETO CARVALHEIRA, EDUARDO ROCHETE ROPELLE, BRUNO 

GELONEZE, Uberlandia, Brazil, Campinas, Brazil 

5:30 p.m.–5:45 p.m. 

119-OR Lessened Decline in Physical Activity and Impairment of Older Adults 

with Diabetes with Telemedicine and Pedometer Use: Results from the 

IDEATel Study 

RUTH S. WEINSTOCK, GARY BROOKS, WALTER PALMAS, PHILIP C. 

MORIN, JOSEPH P. EIMICKE, STEPHANIE SILVER, JEANNE A. TERESI, 

ROBERTO IZQUIERDO, ROBIN GOLAND, STEVEN SHEA, Syracuse, NY, 

New York, NY, Bronx, NY 

5:45 p.m.–6:00 p.m. 

120-OR Pedometer-Determined Physical Activity Is Linked to Lower Systemic 

Inflammation and Arterial Stiffness in Type 2 Diabetes 

PÄR E:SON JENNERSJÖ, JOHNNY LUDVIGSSON, ELSA M. DAHLÉN, 

TOSTE LÄNNE, FREDRIK H. NYSTROM, JAN ERNERUDH, CARL J. ÖSTGREN, 

Linköping, Sweden 

4:00 p.m.–6:00 p.m. 

Session: Continuous Glucose Monitoring 

Room 414 

Co-Chairs: Steven V. Edelman, MD and Anne Peters, MD 

4:00 p.m.–4:15 p.m. 

121-OR Comparative Analysis of the Efficacy and Safety of Continuous Glucose 

Monitoring and Self-Monitoring Blood Glucose in Type 1 Diabetes 

Mellitus 

BARAKA D. FLOYD, PRAKASH CHANDRA, STEPHANIE P. HALL, 

CHRISTOPHER O. PHILLIPS, ERNEST ALEMA-MENSAH, GREGORY 

STRAY HORN, ELIZABETH OFILI, GUILLERMO UMPIERREZ, Atlanta, GA 

4:15 p.m.–4:30 p.m. 

122-OR Predictors of Glucagon Success vs. Failure in Preventing Hypoglycemia 

during Closed-Loop Treatment of Type 1 Diabetes 

JESSICA R. CASTLE, JOSEPH EL YOUSSEF, JULIA M. ENGLE, RYAN G. 

MASSOUD, W. KENNETH WARD, Portland, OR 

4:30 p.m.–4:45 p.m. 

123-OR Frequent Hypoglycemia among Older Adults with A1c>8% Detected by 

Continuous Glucose Monitoring 

MEDHA N. MUNSHI, EMMY SUHL, ADRIANNE STERNTHAL, JUDY 

GIUSTI, ELIZABETH STAUM, YISHAN LEE, RICHARD MCCARTNEY, 

LAURA DESROCHERS, PATRICIA BONSIGNORE, ALISSA SEGAL, Boston, 

MA 

4:45 p.m.–5:00 p.m. 

124-OR Effect of Continuous Glucose Monitoring on Glycemic Control in Subjects 

with Type 1 Diabetes (T1D) Delivering Insulin Via Pump or Multiple Daily 

Injections (MDI): A Prospective Study 

SATISH K. GARG, LAUREN B. CREW, EMILY G. MOSER, MARY K. 

VOELMLE, CHRISTIE R. BEATSON, Aurora, CO 

5:00 p.m.–5:15 p.m. 

125-OR Accuracy of an Improved Fluorescent Intravascular Continuous Glucose 

Sensor 

HOWARD ZISSER, LOIS JOVANOVIC, WENDY BEVIER, UZMA KHAN, 

SOYA GAMSEY, MATTHEW ROMEY, PAUL STRASMA, THOMAS A. 

PEYSER, Santa Barbara, CA, Irvine, CA 

5:15 p.m.–5:30 p.m. 

126-OR Accuracy of a Novel Continuous Glucose Monitoring System (CGMS) 

Using Intravenous (iv) Microdialysis 

ERIC ZIJLSTRA, MICHAEL HARTLEP, MARK O’CONNELL, TIM HEISE, 

WOLFGANG KÜNNECKE, Neuss, Germany, Braunschweig, Germany, 

Coventry, United Kingdom 

5:30 p.m.–5:45 p.m. 

127-OR Intensive Care Unit (ICU) Glucose Monitoring Measured in Plasma using 

Mid-Infrared Spectroscopy 

TIM HEISE, LESZEK NOSEK, JENNIFER GABLE, GENE LIM, CHRIS 

CALENTINE, Neuss, Germany, Hayward, CA 

5:45 p.m.–6:00 p.m. 

128-OR A1c and Mean Glucose: The Juvenile Diabetes Research Foundation 

Continuous Glucose Monitoring Randomized Trial 

DARRELL WILSON, DONGYUAN XING, Stanford, CA, Tampa, FL 



29



4:00 p.m.–6:00 p.m. 

Session: Genetic Risks and Gene Specific Studies 

Room 315 

Chair: Michele M. Sale, PhD 


135-OR 

129-OR 

130-OR 

4:00 p.m.–4:15 p.m. 

A Comprehensive Assessment of 40 Candidate Genes in the Diabetes 

Prevention Program (DPP) 

JOSE C. FLOREZ, KATHLEEN A. JABLONSKI, JARRED B. MCATEER, 

PAUL I.W. DE BAKKER, PAUL W. FRANKS, TONI I. POLLIN, ROBERT L. 

HANSON, RICHA SAXENA, SARAH E. FOWLER, ALAN R. SHULDINER, 

WILLIAM C. KNOWLER, DAVID M. ALTSHULER, DIABETES PREVENTION 

PROGRAM RESEARCH GROUP, Boston, MA, Rockville, MD, Umea, 

Sweden, Baltimore, MD, Phoenix, AZ 

4:15 p.m.–4:30 p.m. 

Stepwise or Linear Change in Penetrance of HLA Genotypes over the 

past 40 Years in Diabetes Onset 

TAYLOR K. ARMSTRONG, SUNANDA R. BABU, GEORGE S. EISENBARTH, 

ANDREA K. STECK, Aurora, CO 

4:30 p.m.–4:45 p.m. 

Suppressor of Superoxide Production—Locus Dominantly Prevents T1D 

as Well as Insulitis and Maps to Ankrd50 

MEREDITH S. CAMPBELL, TERRI C. THAYER, CHAO LIU, VADIM PLINER, 

CLAYTON E. MATHEWS, Gainesville, FL 

5:30 p.m.–5:45 p.m. 

134-OR Founder Effect of the Glucokinase (GCK) Gene Mutation among Polish 

Patients with Monogenic Diabetes 

MACIEJ BOROWIEC, KAROLINA ANTOSIK, GRAZYNA DEJA, PRZEMYS- 

LAWA JAROSZ CHOBOT, MALGORZATA MYSLIWIEC, AGNIESZKA 

ZMYSLOW SKA, MACIEJ MALECKI, WOJCIECH MLYN ARSKI, Lodz, 

Poland, Lodz, Katowice, Poland, Gdansk, Poland, Cracow, Poland 

5:45 p.m.–6:00 p.m. 

136-OR Replication Study for the Association of 23 Susceptibility Loci for Type 2 

Diabetes in the Japanese 

TOSHIHIKO OHSHIGE, SHINTARO OMORI, YASUSHI TANAKA, ATSUNORI 

KASHIWAGI, KOHEI KAKU, HIROSHI HIROSE, RYUZO KAWAMORI, YU- 

SUKE NAKAMURA, SHIRO MAEDA, Kawasaki, Japan, Otsu, Japan, 

Kura shiki, Japan, Tokyo, Japan, Yokohama, Japan 

131-OR 

4:45 p.m.–5:00 p.m. 

Whole-Genome CNV-Analysis in Patients with Monogenic Diabetes 

Identifies a Novel, Complex Structural Variant in the PRSS1-Locus as the 

Cause of Young-Onset Diabetes and Chronic Pancreatitis 

STEFAN JOHANSSON, KISHAN KUMAR CHUDASAMA, SHARONA 

AZRIEL, LOUISE GREVLE, MARIA-ANGELES NAVAS, ANDERS MOLVEN, 

PAL RASMUS NJOLSTAD, Bergen, Norway, Madrid, Spain 

132-OR 

5:00 p.m.–5:15 p.m. 

Family-Based Identification of a Rare Adiponectin Gene Variant in 

Hispanic American (HA) Families from the IRAS Family Study 

SANDY AN, NICHOLETTE D. PALMER, WILLIAM M. BROWN, STEVEN 

M. HAFFNER, JILL M. NORRIS, JEROME I. ROTTER, XIUQING GUO, IDA 

CHEN, LYNNE E. WAGENKNECHT, DONALD W. BOWDEN, Winston- 

Salem, NC, San Antonio, TX, Denver, CO, Los Angeles, CA 

133-OR 

5:15 p.m.–5:30 p.m. 

Identification of Novel Genetic Loci Associated with Birth Weight 

Confirms Genetic Links between Fetal Growth and Type 2 Diabetes 

RACHEL M. FREATHY, DENNIS O. MOOK-KANAMORI, ULLA SOVIO, 

INGA PROKOPENKO, NICHOLAS J. TIMPSON, DIANE J. BERRY, NICOLE 

M. WARRINGTON, ELISABETH WIDEN, JOUKE JAN HOTTENGA, 

JONATHAN P. BRADFIELD, CHIH-MEI CHEN, MIRNA KIRIN, ANDREW 

T. HATTERSLEY, MARIKA KAAKINEN, GERARD H. KOPPELMAN, 

MATTHEW W. GILLMAN, GEORGE V. DEDOUSSIS, KAREN L. MOHLKE, 

JAMES F. WILSON, JOACHIM HEINRICH, JOHAN G. ERIKSSON, 

STRUAN F.A. GRANT, LYLE J. PALMER, TIMOTHY M. FRAYLING, DORRET 

I. BOOMSMA, GEORGE DAVEY SMITH, CHRIS POWER, VINCENT W.V. 

JADDOE, MARJO-RIITTA JARVELIN, MARK I. MCCARTHY, EARLY 

GROWTH GENETICS (EGG) CONSORTIUM, Exeter, United Kingdom, 

Rotterdam, The Netherlands, London, United Kingdom, Oxford, United 

Kingdom, Bristol, United Kingdom, Perth, Australia, Helsinki, Finland, 

Amsterdam, The Netherlands, Philadelphia, PA, Munich, Germany, 

Edinburgh, United Kingdom, Oulu, Finland, Groningen, The Netherlands, 

Boston, MA, Harokopio, Greece, Chapel Hill, NC 

30 




4:00 p.m.–6:00 p.m. 

Session: Monitoring and Clinical Impact of Islet Transplantation 

Room 221 


4:00 p.m.–4:15 p.m. 

137-OR Comparison of Islet Cell Transplantation with Intensive Medical Therapy 

on the Rate of Decline in Glomerular Filtration Rate in Patients with Type 

1 Diabetes 

DAVID M. THOMPSON, ZILIANG AO, BREAY PATY, MARK MELOCHE, 

PAUL KEOWN, JEAN SHAPIRO, STEPHEN HO, DAN WORSLEY, 

GRAYDON MENEILLY, MOHAMMED AL MEHTHEL, KHALID ALGHOFALI, 

MICHELLE FUNG, JOMA KONDI, SHARON KOZAK, SUET TONG, MARY 

TRINH, BLAKE FENSOM, ROBERT KOZAK, CLAIRE HARRIS, GARTH 

WARNOCK, Vancouver, BC, Canada 

4:15 p.m.–4:30 p.m. 

138-OR Persistent Benefits of Clinical Islet Transplantation (CIT) Even with 

Resumption of Exogenous Insulin 

ANGELA KOH, SHARLEEN IMES, PARASTOO DINYARI, ANDREW 

MALCOLM, AM JAMES SHAPIRO, PETER SENIOR, Edmonton, AB, 

Canada 

4:30 p.m.–4:45 p.m. 

139-OR Long-Term Glycemic Control in Patients with Long-Standing (>20 Years) 

Type 1 Diabetes Mellitus: Combined Islet Transplantation vs Intensive 

Insulin Treatment 

REBECCA LOCHER, PHILIPP A. GERBER, RICHARD A. ZUELLIG, THOMAS 

PFAMMATTER, RUDOLF WÜTHRICH, GIATGEN A. SPINAS, ROGER 

LEHMANN, Zurich, Switzerland 

4:45 p.m.–5:00 p.m. 

140-OR Insulin Molecule Cleavage and Delayed Human Islet Function after 

Transplantation Due to Proteases Released from Co-Transplanted 

Pancreatic Acinar Cells 

A.N. BALAMURUGAN, GOPALAKRISHNAN LOGANATHAN, LEI TIAN, 

JIE GAO, ZHIGUANG GUO, MARK SANDERS, RAJINDER K. DAWRA, 

ASHOK K. SALUJA, DAVID E.R. SUTHERLAND, BERNHARD J. HERING, 

Minneapolis, MN, St. Paul, MN 

5:00 p.m.–5:15 p.m. 

141-OR Exenatide Pre-Treatment Improved Islet Graft Function Compared to 

Treatment Post-Transplant Only 

JILL L. BUSS, AMER RAJAB, ELIZABETH DIAKOFF, JIE WANG, KRISTEN 

MILLER, KWAME OSEI, Columbus, OH 

5:15 p.m.–5:30 p.m. 

142-OR Highly Dynamic Cytotoxic T-Lymphocytes and Pancreatic Islet Allograft 

Rejection 

MIDHAT H. ABDULREDA, GAETANO FALEO, R. DAMARIS MOLANO, 

JUDITH MOLINA, YAOHONG TAN, OSCAR A. RON ECHEVERRIA, ELSIE 

ZAHR, RAYNER RODRIGUEZ-DIAZ, PATRICK K. EDLUND, INGO LEIBIGER, 

ALISON BAYER, VICTOR L. PEREZ, CAMILLO RICORDI, PER-OLOF 

BERGGREN, ANTONELLO PILEGGI, ALEJANDRO CAICEDO, Miami, FL, 

Stockholm, Sweden 

5:30 p.m.–5:45 p.m. 

143-OR Development of GAD65-Specific T Cell Immunity Is Associated with 

Chronic Graft Rejection in Islet Transplantation 

DAISUKE CHUJO, HIROFUMI NOGUCHI, EMILE FOUCAT, BASHOO 

NAZIRUDDIN, MARLON F. LEVY, JACQUES BANCHEREAU, HIDEKI 

UENO, SHINICHI MATSUMOTO, Dallas, TX, Fort Worth, TX 

5:45 p.m.–6:00 p.m. 

144-OR W325 in ZnT-8 Allele Is Protective Against Cyclosporin A-Induced 

Impairment of Beta-Cell Insulin Secretion Capacity 

EUN SEOK KANG, INSOOK KIM, YEONG SHIN YIM, YU SEUN KIM, 

CHUL WOO AHN, BONG SOO CHA, CHUL HOON KIM, HYUN CHUL LEE, 

Boston, MA, Seoul, Republic of Korea 

4:00 p.m.–6:00 p.m. 

Session: Mitochondria and Energy Homeostasis 

Room 304 E 

Chair: Shingo Kajimura, PhD 

4:00 p.m.–4:15 p.m. 

145-OR Insulin Signaling Increases Mitochondrial Metabolism by Promoting 

Mitochondrial Fusion 

VALENTINA PARRA, DEBORAH L. JONES, HUGO VERDEJO, ROBERTO 

BRAVO, CRISTOBAL MORALES, VERONICA EISNER, ANTONIO 

ZORZANO, E. DALE ABEL, SERGIO LAVANDERO, Santiago, Chile, Salt 

Lake City, UT, Barcelona, Spain 

4:15 p.m.–4:30 p.m. 

146-OR Genetically Determined Insulin Resistance Is Characterized by Down- 

Regulation of Mitochondrial Oxidative Metabolism in Human Skeletal 

Muscle 

KURT HØJLUND, JONAS M. KRISTENSEN, VIBE SKOV, JØRGEN 

F. WOJTA SZEWSKI, HENNING BECK-NIELSEN, Odense, Denmark, 

Copenhagen, Denmark 

4:30 p.m.–4:45 p.m. 

147-OR Skeletal Muscle Mitochondrial Content in Insulin Resistance: Differ ences 

in Intermyofibrillar and Subsarcolemmal Subpopulations and Relation ship 

to Fuel Oxidation 

FREDERICO G.S. TOLEDO, PETER P. CHOMENTOWSKI, BRET H. GOOD- 

PASTER, PAUL M. COEN, ZOFIA RADIKOVA, Pittsburgh, PA 

4:45 p.m.–5:00 p.m. 

148-OR Effect of Increased Plasma Fatty Acid Concentrations on Mitochondrial 

Pyruvate Dehydrogenase Flux/Tricaboxylic Acid Cycle Flux in Muscle, 

Liver and Heart of Awake Rats 

TIAGO ALVES, RICHARD KIBBEY, DOUGLAS BEFROY, RUI A. CARVALHO, 

KITT FALK PETERSEN, GERALD I. SHULMAN, New Haven, CT, Coimbra, 

Portugal 

5:00 p.m.–5:15 p.m. 

149-OR Overexpression of hOGG1 in Mitochondria Prevents from Palmitate 

Induced Mitochondrial Dysfunction and Inhibition of Insulin Signaling in 

Rat Skeletal Muscle Cells 

LARYSA YUZEFOVYCH, GLENN WILSON, LYUDMILA RACHEK, Mobile, 

AL 

5:15 p.m.–5:30 p.m. 

150-OR Sirt3, a Novel Regulator of Mitochondrial Function and Insulin Signaling 

in Diabetes and Insulin Resistant States 

ENXUAN JING, BRICE EMANUELLI, JEREMIE BOUCHER, ASISH SAHA, 

NEIL RUDERMAN, C. RONALD KAHN, Boston, MA 

5:30 p.m.–5:45 p.m. 

151-OR Activation of Mitochondrial Akt1 Is a Novel Cue for Regulation of Human 

Embryonic Stem Cell Transcriptional Programming 

CHING-CHIEH SU, JOHN YANG, BETTY YEH, KEVIN LIN, PETER 

DONOVAN, PING H. WANG, Irvine, CA 

5:45 p.m.–6:00 p.m. 

152-OR Effect of Brown Adipogenic Factor BMP 7 on Systemic Energy Metabolism 

in Diet-Induced Obesity 

TIM J. SCHULZ, LINDSAY E. MCDOUGALL, TIAN LIAN HUANG, KEVIN 

LEE, KRISTY L. TOWNSEND, HONGBIN ZHANG, DENIS SCHRIER, DEAN 

FALB, YU-HUA TSENG, Boston, MA, Hopkinton, MA 



31


SaturDAY, June 26 

All Abstracts selected for Poster Presentation will be displayed continuously Saturday, Sunday, and Monday. 

Presenters will be available at their posters for questions and discussion with attendees during a scheduled Poster Session. 

Late Breaking Abstracts will be presented during the Poster Session in their respective categories. 

SaturDAY—POSTERS 

Hall C 

10:00 a.m.–6:00 p.m. All Posters on Display 

11:30 a.m.–1:30 p.m. 

General Poster Session 

Complications, Macrovascular—Atherosclerotic CVD and Human Diabetes 

Complications, Macrovascular—Cellular Mechanisms of Atherogenesis in Diabetes 

Complications—Ocular 

Exercise—Animal 

Exercise—Human 

Foot Care—Lower Extremities 

Insulin Action—Metabolism 

Insulin Action—Signal Transduction 

Integrated Physiology—Insulin Secretion In Vivo 

Integrated Physiology—Liver 

Integrated Physiology—Macronutrient Metabolism and Food Intake 

Integrated Physiology—Muscle 

Integrated Physiology—Other Hormones 

Islet Biology—Beta Cell—Development 

Islet Biology—Beta Cell—Postnatal Growth 

Islet Biology—Beta Cell—Stimulus-Secretion Coupling & Metabolism 

Pediatrics—Obesity 

Pediatrics—Type 1 Diabetes 

Pediatrics—Type 2 Diabetes 

Signal Transduction (Not Insulin Action) 

& Guided Audio Poster Tours & 

11:30 a.m.–12:30 p.m. 

1) Getting off the Roller Coaster—Continuous Glucose 

Sensing (486-P–495-P) 

2) SGLT-2 Inhibitors (562-P–571-P) 

3) New Therapies I (602-P–610-P) 

4) Hypoglycemia I (753-P–762-P) 

5) Biomarkers of Diabetic Nephropathy (909-P–915-P) 

6) Mostly Pharmacoepidemiology (1088-P–1096-P) 

7) Type 2 Diabetes, HbA1C, and Insulin Resistance 

Epidemiology (1127-P–1136-P) 

8) Quality and Access Issues in Diabetes (1298-P–1306-P) 

9) Glucose Transport Mechanisms (1363-P–1368-P) 

10) Adipocyte Physiology I (1443-P–1448-P) 

11) Islet Biology—Apoptosis I (1668-P–1677-P) 

12) Islet Biology—Signal Transduction (1746-P–1754-P) 

13) Obesity—Human I (1849-P–1858-P) 

14) Pre-Gestational Diabetes and Gestational Diabetes Mellitus— 

Treatment and Health Consequences (1932-P–1941-P) 

15) New Therapies for Islet Transplantation (484-PP–485-PP; 

2032-P–2039-P) 

12:30 p.m.–1:30 p.m. 

1) Back to the Future—Glucose Measuring, Monitoring, and 

Predicting (496-P–505-P) 

2) DPP-4 Inhibitors (572-P–581-P) 

3) New Therapies II (611-P–618-P) 

4) Hypoglycemia II (401-PP; 763-P–770-P) 

5) Epidemiology of Diabetic Nephropathy— 

Potential Therapeutic Targets (916-P–924-P) 

6) Animal Models of Neuropathy—Enhancing Our 

Understanding (975-P–981-P) 

7) Epidemiology of Childhood Type 1 Diabetes (1097-P–1106-P) 

8) Monogenic, Neonatal, and Type 1 Diabetes 

Genetics (1223-P–1232-P) 

9) Predictors and Treatment of Type 1 Diabetes (435-PP–437-PP; 

1320-P–1326-P) 

10) Adipocyte Physiology II (1449-P–1454-P) 

11) Islet Biology—Apoptosis II (1678-P–1687-P) 

12) Clinical Nutrition (1755-P–1764-P) 

13) Obesity—Human II (1859-P–1868-P) 

14) Predictors, Prevention Diagnosis, and Outcomes of Pregnancy- 

Related Hyperglycemia (1942-P–1951-P) 

15) Quality of Life and Self-Care Behaviors (1972-P–1981-P) 

32


SUNDAY, JUNE 27 

WEAR RED TO STOP DIABETES SM 


8:00 a.m.–10:00 a.m. 

Symposia 

Lipids—Key Issues in the Management of Dyslipidemia 


Chair: Om Ganda, MD 

8:00 a.m.–8:30 a.m. Debate—The LDL-C Goal in Patients with Diabetes Should Be



8:00 a.m.–10:00 a.m. 

(continued) 

Controversies Relating Cancer with Diabetes, Obesity, and Insulin 


Co-Chairs: David M. Harlan, MD and Irl B. Hirsch, MD 

8:00 a.m.–8:30 a.m. Epidemiology of Diabetes and Cancer 

Jeffrey A. Johnson, PhD 

8:30 a.m.–9:00 a.m. The Links between Diabetes and Cancer 

Derek LeRoith, MD, PhD 

9:00 a.m.–9:30 a.m. Insulin Glargine and Cancer—Facts and Fallacies 

John M. Lachin, ScD 

9:30 a.m.–10:00 a.m. Lessons from the Diabetologia Story 

Jay S. Skyler, MD 

SUNDAY—PROGRAM 

A 21st Century Look at Genetic Causes of Diabetes and Its Complications in Youth 


Room 312 

Chair: Linda A. DiMeglio, MD 

8:00 a.m.–8:30 a.m. Newly Identified Causes of Monogenic Diabetes in Youth—Should a Genetic Counselor Be a Member of 

the Pediatric Diabetes Team 

Pal R. Njolstad, MD, PhD 

8:30 a.m.–9:00 a.m. A New Look at Celiac Disease—Should We Be Doing Genetic Testing 

Joseph A. Murray, MD 

9:00 a.m.–9:30 a.m. Genetic Protection or Genetic Predisposition for Long Term Complications of Type 1 Diabetes 

Andrzej S. Krolewski, MD, PhD 

9:30 a.m.–10:00 a.m. Protean Effects of Neonatal Diabetes—An Update of Treatments and Outcomes 

Michel Polak, MD, PhD 

Society for Clinical Trials Symposium—Issues in the Design, Conduct, and Analysis of 

Large Randomized Clinical Trials in Diabetes 

Room 414 

Chair: Robert P. Byington, PhD 

8:00 a.m.–8:40 a.m. Issues to be Considered in the Design of Large Randomized Trials 

Robert P. Byington, PhD 

8:40 a.m.–9:20 a.m. Safety Issues in the Conduct of Large Diabetes Clinical Trials 

Denise E. Bonds, MD 

9:20 a.m.–10:00 a.m. Principles of Data Analysis and Their Application to Clinical Trials in Diabetes 

Domenic J. Reda, PhD 

The Role of Sex Hormones in the Epidemiology of Type 2 Diabetes and Cardiometabolic Risk 

Room 315 

Chair: Simin Liu, MD, ScD 

8:00 a.m.–8:30 a.m. Hormone Replacement Therapy 

Elizabeth L. Barrett-Connor, MD 

8:30 a.m.–9:00 a.m. Endogenous Testosterone 

Yiqing Song, MD, ScD 

9:00 a.m.–9:30 a.m. Endogenous Estrogen 

Jane A. Cauley, DrPh 

9:30 a.m.–10:00 a.m. Environmental Endocrine Disrupters 

Ana M. Soto, MD 

34



8:00 a.m.–10:00 a.m. 

(continued) 

Selective Hepatic Insulin Resistance 

Room 304 E 

Chair: Sudha Biddinger, MD, PhD 

8:00 a.m.–8:30 a.m. Selective Insulin Resistance in Humans 

David B. Savage, MD 

8:30 a.m.–9:00 a.m. ER-Stress Regulation of SREBP and Hepatic Steatosis 

Fabienne Foufelle, PhD 

9:00 a.m.–9:30 a.m. XBP1 and Hepatic Steatosis 

Ann Hwee Lee, PhD 

9:30 a.m.–10:00 a.m. ER Stress, PI3K System, and Insulin Resistance in the Liver 

Umut Ozcan, MD 

Inflammation in Glucose Homeostasis 

Room 311 

Co-Chairs: Mary Ann Banerji, MD and Richard N. Bergman, PhD 

8:00 a.m.–8:30 a.m. Islet Inflammation in Obesity and Type 2 Diabetes 

Jan A. Ehses, PhD 

8:30 a.m.–9:00 a.m. Diabetes and Obesity—Targeting the Gut and the Brain 

Tony K.T. Lam, PhD 

9:00 a.m.–9:30 a.m. Inflammation and Energy Utilization 

Alan R. Saltiel, PhD 

9:30 a.m.–10:00 a.m. Free Fatty Acids and Insulin Resistance 

Richard N. Bergman, PhD 


The Effects of Obesity, Excessive Gestational Weight Gain, 

and Hyperglycemia on Pregnancy Metabolism and the Fetus...............................................................Abstracts 153-OR to 160-OR 

Room 307 

Co-Chairs: Jacob E. Friedman, PhD and Elisabeth R. Mathiesen, MD, DMSC 

Improving Islet Transplantation...................................................................................................................Abstracts 161-OR to 168-OR 

Room 221 

Chair: Paolo Fiorina, MD, PhD 


Obesity—Animal.............................................................................................................................................Abstracts 169-OR to 176-OR 

Room 314 

Chair: Aamir R. Zuberi, PhD 

Life and Death in the Islet I...........................................................................................................................Abstracts 177-OR to 184-OR 

Room 304 A 

Co-Chairs: Senta K. Georgia, PhD and Anath Shalev, MD 

10:15 a.m.–12:15 p.m. 

President, Medicine & Science Address 

Hall D 

Patient-Centered Team Diabetes Care in an Era of Health Care Reform—Lessons from Three Leaders in the Field 


and 

Banting Medal for Outstanding Scientific Achievement Award Lecture 

Hall D 

The Liver as a Prime Target for Individualized Therapy in Diabetes 

Robert A. Rizza, MD 

35



12:00 p.m.–2:00 p.m. 

General Poster Session/Guided Audio Poster Tours 

Hall C 

12:30 p.m.–1:45 p.m. 


Interest Group Discussion on Diabetes in Youth 

Room 308 

In-Patient vs. Out-Patient Management of New-Onset Pediatric Diabetes—Approaches to Treatment and Reimbursement 

Henry Rodriguez, MD and Karen R. Rubin, MD 

Interest Group Discussion on Foot Care 

Room 209 

The State of the Diabetic Foot in 2010 

Lee C. Rogers, DPM 

Interest Group Discussion on Pregnancy and Reproductive Health 

Room 307 

Using A1C to Screen and Diagnose Diabetes During and After Pregnancy—Advantages and Disadvantages 

Catherine Kim, MD and Lynn P. Lowe, PhD 


Kelly West Lecture 

2:00 p.m.–2:45 p.m. 


The Role of Diet, Lifestyle, and Gene-Environment Interactions in the Global Epidemic of Type 2 Diabetes 

Supported by an educational grant from Merck 

Frank B. Hu, MD, PhD 

2:00 p.m.–4:00 p.m. 

Symposia 

Complications of Diabetes—What Is Unique about the Retina 

Room 224 

Chair: Timothy J. Lyons, MD 

2:00 p.m.–2:30 p.m. Angiogenesis in the Microvascular Complications of Diabetes 

Elia J. Duh, MD 

2:30 p.m.–3:00 p.m. The Retinal Pigment Epithelium in Health and Diabetes 

David R. Hinton, MD 

3:00 p.m.–3:30 p.m. Induced Pluripotential Stem Cells—Roles in Treating Retinopathy and Nephropathy 

Konrad Hochedlinger, PhD 

3:30 p.m.–4:00 p.m. Inflammation and the Microvascular Complications of Diabetes 

Antonia M. Joussen, MD, PhD 

New Technologies for Diabetes Education 

Room 208 

Chair: Neesha Ramchandani, APRN, PNP, CDE 

2:00 p.m.–2:30 p.m. Mobile and Web Diabetes Management Coaching 

Guillaume Charpentier, MD 

2:30 p.m.–3:00 p.m. Imagining the Future of Diabetes Self Care 

Kate Rutter, BA 

3:00 p.m.–3:30 p.m. Diabetes Education Using Cell Phone Mobi Films 

Kshitij Shankhdhar, MBBS, Dip. Diab 

3:30 p.m.–4:00 p.m. TeenCope—Using the Internet to Engage Teens 

Margaret Grey, DrPH, RN, FAAN 

36



2:00 p.m.–4:00 p.m. 

(continued) 

Joint ADA/JDRF Symposium—The Artificial Pancreas—A Goal within Reach 

Room 311 

Co-Chairs: Richard M. Bergenstal, MD and Richard A. Insel, MD 

2:00 p.m.–2:20 p.m. Are We Closer to Closing the Loop 

Aaron Kowalski, PhD 

2:20 p.m.–2:40 p.m. Landmark Continuous Glucose Management Trials—Findings and Implications for Care 

William V. Tamborlane, MD 

2:40 p.m.–3:00 p.m. Barriers to Continuous Glucose Management Use 

Marilyn D. Ritholz, PhD 

3:00 p.m.–3:20 p.m. Progress—Results of Overnight Closed-Loop Studies 

Roman Hovorka, PhD 

3:20 p.m.–4:00 p.m. Questions and Answers 

Managing Insulin Therapy in the Obese, Extremely Insulin Resistant Patient 

Supported by an unrestricted educational grant from Amylin Pharmaceuticals, Inc. 


Co-Chairs: Anuj Bhargava, MD and Charles F. Shaefer, MD 

2:00 p.m.–2:30 p.m. High Dose Insulin Therapy—When, Why, and How to Use U-500 Insulin 

Wendy S. Lane, MD 

2:30 p.m.–3:00 p.m. Adding Oral Agents to Insulin 

Candis M. Morello, PharmD, CDE, FCSHP 

3:00 p.m.–3:30 p.m. Use of GLP-1 Agonists and Pramlintide with Insulin 

Matthew C. Riddle, MD 

3:30 p.m.–4:00 p.m. Bariatric Surgery 

Santiago Horgan, MD 

Pregnancy Diet and Supplements—Needs and Concerns 

Room 308 

Chair: Elizabeth Mayer-Davis, MSPH, PhD, RD 

2:00 p.m.–2:30 p.m. Folate and B12 

Chittaranjan S. Yajnik, MD 

2:30 p.m.–3:00 p.m. Iron and Vitamin D 

Michelle A. Williams, ScD 

3:00 p.m.–3:30 p.m. Epigenetics of Nutritionally Regulated Genes—Effects on the Fetus 

David E. Williams, PhD 

3:30 p.m.–4:00 p.m. Docosahexaenoic Acid and Update on the Nutrition Intervention to Prevent Diabetes Trial 

H. Peter Chase, MD 


Bile Acids as Metabolic Regulators 

Room 314 

Chair: Moshe Levi, PhD 

2:00 p.m.–2:40 p.m. The Fibroblast Growth Factor Connection 

Steven A. Kliewer, PhD 

2:40 p.m.–3:20 p.m. TGR5—Connecting Nutrition to Metabolism 

Kristina Schoonjans, PhD 

3:20 p.m.–4:00 p.m. Role of FXR in Glucose Homeostasis 

David D. Moore, PhD 

37



2:00 p.m.–4:00 p.m. 

(continued) 

Beta Cell Intracellular Signaling-3—A Potpourri 

Room 304 A 

Chair: Philippe A. Halban, PhD 

2:00 p.m.–2:30 p.m. Insights into Glucokinase Regulation from Naturally Occurring Glucokinase Mutations 

Anna L. Gloyn, DPhil 

2:30 p.m.–3:00 p.m. Cell Adhesion-Dependent Signaling Driving Growth and Differentiation in the Developing Pancreas 

Vincenzo Cirulli, MD, PhD 

3:00 p.m.–3:30 p.m. Serotonin as a Mediator of Beta Cell Replication in Pregnancy 

Michael S. German, MD 

3:30 p.m.–4:00 p.m. Extranuclear Estrogen Receptors and Beta Cells 

Franck Mauvais-Jarvis, MD, PhD 


Foot Complications.........................................................................................................................................Abstracts 185-OR to 190-OR 

Room 414 

Chair: Lawrence A. Lavery, DPM 


With Roger Pecoraro Lecture by David G. Armstrong, DPM, PhD 

Healing Wounds and Preventing Amputations—A Marriage of Team, Technology, and Tenacity 

Supported by an unrestricted educational grant from Curative Health Services, ConvaTec, Ortho-McNeil Pharmaceuticals, 

and Sechrist Clinical Services 

Nutrition............................................................................................................................................................Abstracts 191-OR to 198-OR 

Room 207 

Chair: Molly Gee, MEd, RD, LD 

Targeting and Tailoring—Keys to Maximizing Health and 

Economic Outcomes in Diabetes Care and Prevention...........................................................................Abstracts 199-OR to 204-OR 

Room 307 

Chair: TBD 

With State of the Art Lecture by Ann L. Albright, PhD, RD 

Achieving Individual and Population Improvements in Diabetes Care and Prevention 

Genome-Wide Genetics.................................................................................................................................Abstracts 205-OR to 212-OR 

Room 315 

Chair: Struan Grant, PhD 

Prediction and Natural History of Type 1 Diabetes..................................................................................Abstracts 213-OR to 220-OR 

Room 221 

Chair: Jonathan D. Katz, PhD 

Mechanisms of In Vivo Insulin Action........................................................................................................Abstracts 221-OR to 228-OR 

Room 304 E 

Chair: Paul W. Hruz, MD, PhD 

Insulin Secretion—In Vivo............................................................................................................................Abstracts 229-OR to 236-OR 

Room 312 

Co-Chairs: Meredith A. Hawkins, MD and Kenneth S. Polonsky, MD 

38



4:15 p.m.–6:15 p.m. 

Vascular, Infection, Pressure—The VIPs of Healing Diabetic Wounds 

Room 308 

Chair: Lawrence B. Harkless, DPM 

4:15 p.m.–4:45 p.m. Old and New Tools to Identify and Manage Atherosclerotic Gridlock 

George Andros, MD 

4:45 p.m.–5:15 p.m. Etiology of Diabetic Foot Ulcers 

Lawrence A. Lavery, DPM 

5:15 p.m.–5:45 p.m. What’s Bugging this Diabetic Foot Ulcer and How Can I Manage it 

Benjamin A. Lipsky, MD 

5:45 p.m.–6:15 p.m. Pressure on the Diabetic Foot Take a Load Off 

Nicholas J. Bevilacqua, DPM 

Practical Issues in Diabetes and Exercise 

Room 224 

Chair: Catrine Tudor-Locke, PhD, FACSM 

4:15 p.m.–4:45 p.m. Motivating People to Exercise 

Shane N. Sweet, MA 

4:45 p.m.–5:15 p.m. Monitoring Glycemic Responses During and After Exercise 

Thierry Gaudet-Savard, MSc 

5:15 p.m.–5:45 p.m. Using Pedometers to Quantify Your Exercise Prescription 

Catrine Tudor-Locke, PhD, FACSM 

5:45 p.m.–6:15 p.m. Making Physical Activity Fun with Interactive Video Gaming 

Ralph Maddison, PhD 

Tactics and Controversies in the Management of Hyperglycemia in the Hospital 


Chair: Guillermo E. Umpierrez, MD 

4:15 p.m.–4:45 p.m. How Do the Outcome Trials Inform Hospital Glycemic Targets 

Mary T. Korytkowski, MD 

4:45 p.m.–5:15 p.m. Hypoglycemia Risk in the Hospital 

Mikhail Kosiborod, MD 

5:15 p.m.–5:45 p.m. Insulin Tactics for the ICU/CCU 

Mercedes Falciglia, MD 

5:45 p.m.–6:15 p.m. Challenges in Implementing Insulin Regimens in the General Ward 

Stephen C. Clement, MD 


Newer Insulins—As They Approach Availability What Should We Know about Them 


Chair: Steven V. Edelman, MD 

4:15 p.m.–4:55 p.m. Warp Speed Insulins 

Michael A. Weiss, MD, PhD 

4:55 p.m.–5:35 p.m. Slow Release Insulins 

Satish K. Garg, MD 

5:35 p.m.–6:15 p.m. Alternate Delivery Methods (Inhaled, Buccal, Intraperitoneal) 

William T. Cefalu, MD 

39



4:15 p.m.–6:15 p.m. 

(continued) 

HEALTHY Study—Middle School-Based Intervention to Reduce Diabetes Risk 


Chair: John B. Buse, MD, PhD 

4:15 p.m.–4:25 p.m. Rationale and Design 

Kathryn Hirst, PhD 

4:25 p.m.–4:40 p.m. Primary Endpoints (Adiposity Related Endpoints, Glucose, and Insulin) 

Gary D. Foster, PhD 

4:40 p.m.–4:55 p.m. Secondary Endpoints (Lipid, Blood Pressure, Fitness, Food Frequency Questionnaire, Process Evaluation) 

Marsha D. Marcus, PhD 

4:55 p.m.–5:15 p.m. Panel Discussion 

Cynthia L. Ogden, PhD 

Griffin P. Rodgers, MD 

Philip S. Zeitler, MD, PhD 


Alternative Cellular Sources for Beta Cell Replacement Therapy—Today and Tomorrow 

Room 221 


4:15 p.m.–4:45 p.m. New Developments in Islet Transplantation 

Camillo Ricordi, MD 

4:45 p.m.–5:15 p.m. Embryonic Stem Cell Sources of Insulin Producing Tissue for Transplantation 

Hsun Teresa Ku, PhD 

5:15 p.m.–5:45 p.m. Pluripotent Stem Cells for Disease Modeling and Cell Replacement Therapy 

Rene Maehr, PhD 

5:45 p.m.–6:15 p.m. Xenogenic Islet Sources for Transplantation 

Colin J. Weber, MD 

Clues to Mechanisms of Insulin Resistance from Other Human Syndromes 

Room 304 E 

Chair: Phillip Gorden, MD 

4:15 p.m.–4:45 p.m. Diabetes Mellitus in HIV-1 Infection Treated with Combined Antiretroviral Therapy 

Paul W. Hruz, MD, PhD 

4:45 p.m.–5:15 p.m. Mechanisms of Insulin Resistance in PCOS 

Jean-Patrice Baillargeon, MD 

5:15 p.m.–5:45 p.m. Phenotype and Course of Hutchinson-Gilford Progeria Syndrome 

Marie D. Gerhard-Herman, MD 

5:45 p.m.–6:15 p.m. Lipodystrophy—New Mutations, New Insights 

Abhimanyu Garg, MD 

40



4:15 p.m.–6:15 p.m. 

(continued) 


Ocular................................................................................................................................................................Abstracts 237-OR to 244-OR 

Room 207 


Cellular Mechanisms of Cardiovascular Complications of Diabetes...................................................Abstracts 245-OR to 252-OR 

Room 209 

Co-Chairs: Sridevi Devaraj, PhD and Takashi Kadowaki, MD, PhD 

Behavioral Interventions in Diabetes.........................................................................................................Abstracts 253-OR to 260-OR 

Room 208 

Chair: Shelagh Mulvaney, PhD 

Deficiencies in Diabetes Care and Outcomes— 

Exploring Problem Areas and Emerging Solutions..................................................................................Abstracts 261-OR to 268-OR 

Room 414 

Chair: Joe V. Selby, MD 

Epidemiology of Type 1 and Type 2 Diabetes.............................................................................................Abstracts 269-OR to 276-OR 

Room 315 

Chair: Ingrid M. Libman-DeGordon, MD, PhD 

Incretin and Leptin Biology...........................................................................................................................Abstracts 277-OR to 284-OR 

Room 314 

Co-Chairs: Carolyn F. Deacon, PhD, DMSc and Michael A. Nauck, MD 

Beta Cell Stimulus-Secretion Coupling and Metabolism.......................................................................Abstracts 285-OR to 292-OR 

Room 304 A 

Chair: Susumu Seino, MD, PhD 


6:30 p.m.–7:45 p.m. 


Hall C 

41


SUNDAY, June 27 

8:00 a.m.–10:00 a.m. 

Session: The Effects of Obesity, Excessive Gestational Weight Gain, and 

Hyperglycemia on Pregnancy Metabolism and the Fetus 

Room 307 

Co-Chairs: Jacob E. Friedman, PhD and Elisabeth R. Mathiesen, MD, DMSC 

8:00 a.m.–10:00 a.m. 

Session: Improving Islet Transplantation 

Room 221 

Chair: Paolo Fiorina, MD, PhD 

153-OR 

154-OR 

155-OR 

8:00 a.m.–8:15 a.m. 

Maternal Obesity and Excess Weight Gain Exacerbate Effect of Mild 

Hyperglycemia on Infant Birth Weight 

MARY HELEN BLACK, DAVID A. SACKS, JEAN M. LAWRENCE, 

Pasadena, CA, Bellflower, CA 

8:15 a.m.–8:30 a.m. 

The Hyperglycemia & Adverse Pregnancy Outcome (HAPO) Study: 

Associations of Higher Levels of Maternal Glucose and BMI with 

Macrosomia: An Example of Diabesity 

BOYD E. METZGER, LYNN P. LOWE, ALAN R. DYER, DONALD R. 

COUSTAN, DAVID R. HADDEN, MOSHE HOD, JEREMY J.N. OATS, 

BENGT PERSSON, ELISABETH R. TRIMBLE, Chicago, IL, Providence, RI, 

Belfast, United Kingdom, Tel Aviv, Israel, Victoria, Australia, Stockholm, 

Sweden 

8:30 a.m.–8:45 a.m. 

Overnourished Obese Sheep in Pregnancy Alters Insulin Signaling 

Cascades and Cardiac Function in the Fetal Heart 

JINGYING WANG, CHAO TONG, STEPHEN P. FORD, PETER W. NATHANIELSZ, 

JI LI, Laramie, WY, San Antonio, TX, Buffalo, NY 

161-OR 

162-OR 

163-OR 

8:00 a.m.–8:15 a.m. 

Transplantation of Microencapsulated Neonatal Porcine Islets in 

Patients with Type 1 Diabetes: Safety and Efficacy 

ROBERT B. ELLIOTT, OLGA GARKAVENKO, PAUL TAN, NIKOLAI N. 

SKALETSKY, ANDREI GULIEV, BORIS DRAZNIN, Auckland, New Zealand, 

Moscow, Russia, Aurora, CO 

8:15 a.m.–8:30 a.m. 

Targeting IL21/IL21R Pathway as a Novel Strategy To Prolong Graft 

Survival in Allogenic Islet Transplantation 

ALESSANDRA PETRELLI, MICHELE M. CARVELLO, ANDREA VERGANI, 

SONJA KLEFFEL, SCOTT J. RODIG, DEBBIE YOUNG, MOHAMED 

SAYEGH, PAOLO FIORINA, Boston, MA, Milan, Italy, Cambridge, MA 

8:30 a.m.–8:45 a.m. 

Mesenchymal Stem Cells Requires Serpin Protease Inhibitor 6 (SPI6) To 

Evade Allogeneic Cytotoxic T-Lymphocytes 

NAJIB M. EL HADDAD, DEAN HEATHCOTE, JENG-SHIN LEE, ANDREA 

AUGELLO, TAKURIN AKIYOSHI, JAMIL AZZI, BECHARA MFARREJ, 

SUNMI YANG, ROBERT MOORE, MOHAMED SAYEGH, PHILIP ASHTON- 

RICKARDT, REZA ABDI, Boston, MA, London, United Kingdom 

SUNDAY—ORALS 

156-OR 

157-OR 

158-OR 

159-OR 

160-OR 

8:45 a.m.–9:00 a.m. 

Maternal-Fetal Competition for Glucose: Effects of Insulin and Dexamethasone 

ANDREW W. NORRIS, CHUNLIN WANG, JIANRONG YAO, SUSAN A. 

WALSH, ALEX SAWATZKE, SHANMING HU, JOHN J. SUNDERLAND, 

JEFFREY L. SEGAR, LAURA L.B. PONTO, Iowa City, IA 

9:00 a.m.–9:15 a.m. 

Recruitment of Innate Immune Pathways in Peripheral Mononuclear 

Cells and Placental Macrophages of Obese Women 

SUBHABRATA BASU, JEAN-CLAUDE CHALLIER, PATRICK LEAHY, 

JUDI MINIUM, PATRICK CATALANO, SYLVIE HAUGUEL-DE MOUZON, 

Cleveland, OH, Paris, France 

9:15 a.m.–9:30 a.m. 

Metabolic Inflammation Manifests in First Trimester of Pregnancy in 

Obese Women 

EUN-SUK OH, SUBHRABATA BASU, BONNIE CHEUNG, JUDI MINIUM, 

PATRICK CATALANO, SYLVIE HAUGUEL-DE MOUZON, Cleveland, OH 

9:30 a.m.–9:45 a.m. 

Oxidative Load and Antioxidant Enzyme Capacity in Gestational 


PANAGIOTIS G. HALVATSIOTIS, KONSTANTINOS PATSOURAS, MARIA 

VYTHOULKA, GEORGE SALAMALEKIS, MARIA TSILIKA, EMMANUEL 

SALAMALEKIS, THEOFANIS ECONOMOPOULOS, Athens, Greece 

9:45 a.m.–10:00 a.m. 

The Hyperglycemia & Adverse Pregnancy Outcome (HAPO) Study: Perinatal 

Outcome in Pregnancies with GDM and Fasting Plasma Glucose 

(FPG) ≤ 4.4 mmol/l 

BOYD E. METZGER, LYNN P. LOWE, ALAN R. DYER, ELISABETH R. 

TRIMBLE, BENGT PERSSON, JEREMY J.N. OATS, MOSHE HOD, DAVID R. 

HADDEN, DONALD R. COUSTAN, Chicago, IL, Belfast, United Kingdom, 

Stockholm, Sweden, Victoria, Australia, Tel Aviv, Israel, Providence, RI 

164-OR 

165-OR 

166-OR 

167-OR 

168-OR 

8:45 a.m.–9:00 a.m. 

Improving Islet Allograft Survival by Activating Two Negative Co- 

Signaling Pathways 

XIAOJIE WANG, JIANQIANG HAO, DANIEL L. METZGER, ALICE MUI, 

ZILIANG AO, C. BRUCE VERCHERE, LIEPING CHEN, DAWEI OU, GARTH 

L. WARNOCK, Vancouver, BC, Canada, Baltimore, MD 

9:00 a.m.–9:15 a.m. 

Anti-CD22/Calicheamycin Immunotoxin-Mediated B-Cell Depletion 

Prolongs Islet Allograft Survival in NOD Mice by Regulating Autoimmune 

Response 

MICHELE M. CARVELLO, ANDREA VERGANI, ALESSANDRA PETRELLI, 

MOLLIE JUREWICZ, FRANCESCA D’ADDIO, SCOTT RODIG, TOSHIRO 

WATANABE, KYRI DUNUSSI, SHAOPING DENG, JAMES F. MARKMANN, 

MOHAMED SAYEGH, PAOLO FIORINA, Boston, MA, Milano, Italy, 

Cambridge, MA 

9:15 a.m.–9:30 a.m. 

Cure of Diabetic NOD Mice by Isolated Sertoli Cell Xenografts Alone 

GIOVANNI LUCA, FRANCESCA FALLARINO, MARIO CALVITTI, ENNIO 

BECCHETTI, PAOLO PUCCETTI, RICCARDO CALAFIORE, Perugia, Italy 

9:30 a.m.–9:45 a.m. 

Allogeneic Bone Marrow Co-Cultured with Human Islets Significantly 

Improves Islet Survival and Function In Vivo 

JOHN Z.Q. LUO, FANG XIONG, ZHANGKE WANG, SAMER A. AL-HOMSI, 

TARA ROY, LUGUANG LUO, Providence, RI 

9:45 a.m.–10:00 a.m. 

Locally Delivered Immunosuppression into a Biohybrid Device Results in 

Long-Term Islet Allograft Survival 

NICOLA BOCCA, SIMONA MARZORATI, CAMILLO RICORDI, R. DAMARIS 

MOLANO, ANN-CHRISTINA BRADY, SUSANA VILLATE, JUDITH MOLINA, 

ELSIE ZAHR, CHRISTOPHER FRAKER, CHERIE STABLER, NORMA S. 

KENYON, LUCA INVERARDI, PETER BUCHWALD, ANTONELLO PILEGGI, 

Miami, FL 

42 




8:00 a.m.–10:00 a.m. 

Session: Obesity—Animal 

Room 314 

Chair: Aamir R. Zuberi, PhD 

8:00 a.m.–8:15 a.m. 

169-OR Overexpression of Fto Causes Increased Fat Mass through Increased 

Energy Intake and Reduced Energy Expenditure 

CHRIS D. CHURCH, FIONA MCMURRAY, LEE MOIR, LYDIA TEBOUL, 

JENS C. BRUNING, PATRICK M. NOLAN, FRANCES M. ASHCROFT, 

ROGER D. COX, Didcot, United Kingdom, Cologne, Germany, Oxford, 

United Kingdom 

8:15 a.m.–8:30 a.m. 

170-OR Deletion of the Mammalian INDY Homologue in Mice Promotes Energy 

Expenditure and Protects Against Diet and Age-Induced Adiposity and 

Insulin Resistance 

ANDREAS L. BIRKENFELD, HUI-YOUNG LEE, MICHAEL J. JURCZAK, 

FRANCOIS R. JORNAYVAZ, DAVID W. FREDERICK, TIAGO ALVES, 

MARIO KAHN, DONGYANG ZHANG, JENNIFER J. HSIAO, BLAS GUIGNI, 

CHRISTOPHER M. CARMEAN, DIRK WEISMANN, PABLO M. IRUSTA, 

RAFAEL DE CABO, STEPHEN L. HELFAND, VARMAN T. SAMUEL, 

GERALD I. SHULMAN, New Haven, CT, Washington, DC, Baltimore, MD, 

Providence, RI 

8:30 a.m.–8:45 a.m. 

171-OR A Hypothalamic Role for BMP Signaling in the Regulation of Appetite 

and Metabolism 

KRISTY L. TOWNSEND, RYO SUZUKI, EFI KOKKOTOU, ENXUAN JING, 

DANIEL O. ESPINOZA, TIM J. SCHULZ, KEVIN LEE, TIAN LIAN HUANG, 

LINDSAY MCDOUGALL, YU-HUA TSENG, Boston, MA 

8:45 a.m.–9:00 a.m. 

172-OR Inhibition of Adenylyl Cyclase Type 5, a Novel Target for Obesity and 

Diabetes Therapy 

DAVID W. HO, XIN ZHAO, WILLIAM STANLEY, SHUMIN GAO, LUKE F. 

FRITZKY, ERIC J. BURNETT, DOROTHY E. VATNER, LEONARY G. MEGGS, 

ASHWANI MALHOTRA, KOSAKU IWATSUBO, STEPHEN F. VATNER, 

Newark, NJ, Baltimore, MD 

9:00 a.m.–9:15 a.m. 

173-OR Mice Lacking Thioesterase Superfamily Member 1 (Them1)/StarD14 Are 

Protected Against Diet-Induced Obesity and Exhibit Improved Glucose 

Homeostasis 

YONGZHAO ZHANG, YINGXIA LI, MICHELE W. NIEPEL, DAVID E. COHEN, 

Boston, MA 

9:15 a.m.–9:30 a.m. 

174-OR Hypoxia Inducible Factor 1α Plays an Indispensible Role in Maintaining 

the Thermogenic Functions of Brown Adipose Tissue in Mice 

XINMIN ZHANG, KAREN S.L. LAM, SOOKJA K. CHUNG, AIMIN XU, 

Hong Kong, China 

9:30 a.m.–9:45 a.m. 

175-OR CCR5 Ablation Prevents Insulin Resistance Induced by High-Fat Feeding 

or Leptin Deficiency 

TSUGUHITO OTA, HIRONORI KITADE, KAZUKI SAWAMOTO, HIROSHI 

INOUE, TOSHINARI TAKAMURA, KEN-ICHI MIYAMOTO, NAOFUMI 

MUKAIDA, SHUICHI KANEKO, Kanazawa, Japan 

9:45 a.m.–10:00 a.m. 

176-OR Deficiency of ROCK1 in POMC Neurons Causes Obesity and Insulin 

Resistance 

HU HUANG, DEA HO LEE, JANICE M. ZABOLONTY, YOUNG-BUM KIM, 

Boston, MA 

8:00 a.m.–10:00 a.m. 

Session: Life and Death in the Islet I 

Room 304 A 

Co-Chairs: Senta K. Georgia, PhD and Anath Shalev, MD 

8:00 a.m.–8:15 a.m. 

177-OR Foxo1 Ablation Increases Endocrine Progenitor Cells in the Adult 

Pancreas 

CHUTIMA TALCHAI, DOMENICO ACCILI, New York, NY 

8:15 a.m.–8:30 a.m. 

178-OR Beta Cell Replication Is Sufficient To Account for Establishing beta Cell 

Mass 

SHUEN-ING TSCHEN, ANIL BHUSHAN, Los Angeles, CA 

8:30 a.m.–8:45 a.m. 

179-OR Regulated Induction of Human Beta Cell Replication: Tet-Inducible Overexpression 

of Cdk6 and Cyclin D1 

KAREN K. TAKANE, JEFFREY KLEINBERGER, FATIMAH SALIM, SEMARA 

THOMAS, NATHALIE FIASCHI-TAESCH, ANDREW F. STEWART, 

Pittsburgh, PA 

8:45 a.m.–9:00 a.m. 

180-OR A Single Copy of Pdx1 Gene Is Dispensable for Adaptive β-Cell Mass 

and Proliferation Following 60% Partial Pancreatectomy 

BASANTHI SATISH, AIDA HABIBOVIC, VIOLET ROSKENS, KRISTI HYZER, 

JAMES LAUSIER, TOM JETTON, MINA PESHAVARIA, Colchester, VT, 

Burlington, VT 

9:00 a.m.–9:15 a.m. 

181-OR BNip3L Mediates Mitochondrial Pancreatic beta Cell Death in Pdx1 

Insufficient States 

KEI FUJIMOTO, ERIC L. FORD, HUNG TRAN, BURTON M. WICE, SETH D. 

CROSBY, GERALD W. DORN II, KENNETH S. POLONSKY, St. Louis, MO 

9:15 a.m.–9:30 a.m. 

182-OR Protection by S-Nitrosoglutathione Reductase (GSNOR), a Negative 

Regulator of S-Nitrosylation, Against Apoptosis: Regulation of PDX-1 in 

Pancreatic β-Cells 

YOSHIAKI TAMURA, TOSHIHIRO TANIOKA, YUKO CHIBA, MAKIKO 

FUKAYA, TADAHIRO KITAMURA, HIDEKI ITO, JONATHAN S. STAMLER, 

MASAO KANEKI, Charlestown, MA, Maebashi, Japan, Tokyo, Japan, 

Cleveland, OH 

9:30 a.m.–9:45 a.m. 

183-OR Inhibiting the Mitochondrial Permeability Transition by Targeting 

Cyclophilin D Enhances beta Cell Survival and Prevents Diabetes in Pdx1 

Insufficiency 

KEI FUJIMOTO, YUN CHEN, KENNETH S. POLONSKY, GERALD W. DORN 

II, St. Louis, MO 

9:45 a.m.–10:00 a.m. 

184-OR Protection of Pancreatic β-Cells by Group VIA Phospholipase A 2 - 

Mediated Repair of Mitochondrial Membrane Peroxidation 

ZHENGSHAN ZHAO, CHUNYING ZHAO, ZHONGMIN A. MA, New York, 

NY 



43




2:00 p.m.–4:00 p.m. 

Session: Foot Complications 

Room 414 

Chair: Lawrence A. Lavery, DPM 

2:00 p.m.–2:30 p.m. 

Roger Pecoraro Lecture 

Healing Wounds and Preventing Amputations— 

A Marriage of Team, Technology, and Tenacity 

Supported by an unrestricted educational grant from Curative Health Services, 

ConvaTec, Ortho-McNeil Pharmaceuticals, and Sechrist Clinical Services 

David G. Armstrong, DPM, PhD 

2:30 p.m.–2:45 p.m. 

185-OR Incorporating Standing Time into Physical Activity Assessment of 

Patients at Risk of Diabetic Foot Ulceration 

BIJAN NAJAFI, RYAN T. CREWS, JAMES S. WROBEL, Chicago, IL 

2:45 p.m.–3:00 p.m. 

186-OR The Contribution of Bone Marrow-Derived Mesenchymal Stem Cells to 

Diabetic Wound Healing 

LAURA SHIN, DANIEL A. PETERSON, Chicago, IL 

3:00 p.m.–3:15 p.m. 

187-OR Risk Factors and 25-Year Cumulative Incidence of Lower Extremity 

Amputations in Type 1 Diabetes 

KARINE SAHAKYAN, BARBARA E.K. KLEIN, KRISTINE E. LEE, RONALD 

KLEIN, Madison, WI 

3:15 p.m.–3:30 p.m. 

188-OR Declining Trends in Hospitalizations for Non-Traumatic Lower Extremity 

Amputation in the Diabetic Population—United States, 1988-2006 

YANFENG LI, NILKA BURROWS, EDWARD GREGG, LINDA GEISS, 

Atlanta, GA 

3:30 p.m.–3:45 p.m. 

189-OR The Importance of Sustained Glycemic Control during Wound Healing 

EMILY A. COOK, JEREMY J. COOK, MARIBEL HENAO, BOZENA PAW- 

ELEK, ADAM S. LANDSMAN, ROBERT J. SNYDER, JASON R. HANFT, 

Boston, MA, Miami, FL, Tamarac, FL 

3:45 p.m.–4:00 p.m. 

190-OR Location, Location, Location: Specific Site of Biopsy within Superficial 

Wounds May Yield Different Organisms 

STEPHANIE C. WU, JAY CHRISTENSEN, KRISTY SHANAHAN, DAVID G. 

ARMSTRONG, Chicago, IL, Tucson, AZ 

2:00 p.m.–4:00 p.m. 

Session: Nutrition 

Room 207 

Chair: Molly Gee, MEd, RD, LD 

2:00 p.m.–2:15 p.m. 

191-OR Decrease in the Use of Hypoglycemic Agents, Long Term Weight Loss 

and Diabetes Control Achieved in Adults with Type 2 Diabetes Receiving 

Nutrition Therapy 

PATRICIA MOREIRA-CALI, SALVADOR GEZAN, Gainesville, FL 

2:15 p.m.–2:30 p.m. 

192-OR Association between Nutritional Recommendations for Cardiovascular 

Disease and a Lower Incidence of Cardiac Events in Patients with Type 2 


ANA LUIZA TEIXEIRA DOS SANTOS, TANARA WEISS, CAMILA 

KUMMEL DUARTE, GABRIELA AZAMBUJA CANTORI, MIRELA JOBIM 

DE AZEVEDO, JORGE LUIZ GROSS, THEMIS ZELMANOVITZ, Porto 

Alegre, Brazil, Poa, Brazil 

2:30 p.m.–2:45 p.m. 

193-OR One Year Administration of Dietary omega-3 Polyunsaturated Fatty 

Acids Decreases Oxidative Stress and Atherosclerosis Progression in 

Type 2 Diabetes Patients 

ANDREEA D. DRAGOMIR, GABRIELA RADULIAN, EMILIA RUSU, DAN 

M. CHETA, Bucharest, Romania 

194-OR 

195-OR 

WITHDRAWN 

Changed to Published Only per author’s request. 

See abstract 195-PO on page A678 in the Abstract Book. 

2:45 p.m.–3:00 p.m. 

196-OR A Low Glycemic Diet and Exercise Intervention Reduces Insulin Resistance 

and Suppresses Compensatory Hyperinsulinemia Via an Incretin 

Related Mechanism 

JOHN P. KIRWAN, THOMAS P. SOLOMON, JACOB M. HAUS, KAREN 

R. KELLY, MARC COOK, JULIANNE FILION, RICHARD M. WATANABE, 

SANGEETA R. KASHYAP, HOPE BARKOUKIS, Cleveland, OH, Los Angeles, 

CA 

3:00 p.m.–3:15 p.m. 

197-OR An Isocaloric Low-Fat Diet Decreases Liver Fat in Older Subjects 

KRISTINA M. UTZSCHNEIDER, MATTHEW D. ARBUCKLE, JAIME M. 

TIDWELL, SUZANNE CRAFT, Seattle, WA 

3:15 p.m.–3:30 p.m. 

198-OR Plasma 25-Hydroxyvitamin D Concentration and Risk of Type 2 Diabetes 

in Women 

ANASTASSIOS PITTAS, QI SUN, JOANN MANSON, BESS DAWSON- 

HUGHES, FRANK HU, Boston, MA 

44 




2:00 p.m.–4:00 p.m. 

Session: Targeting and Tailoring—Keys to Maximizing Health and Economic 

Outcomes in Diabetes Care and Prevention 

Room 307 

Chair: TBD 

2:00 p.m.–4:00 p.m. 

Session: Genome-Wide Genetics 

Room 315 

Chair: Struan Grant, PhD 

2:00 p.m.–2:30 p.m. 

State of the Art Lecture 

Achieving Individual and Population Improvements in 

Diabetes Care and Prevention 

Ann L. Albright, PhD, RD 

2:00 p.m.–2:15 p.m. 

210-OR A Systems Biology Approach Links Inflammation to Genetic Differences 

in Predisposition to Metabolic Diseases between Mouse Strains 

MARCELO A. MORI, MANWAY LIU, OLIVIER BEZY, KATRINE ALMIND, 

HAGIT SHAPIRO, SIMON KASIF, C. RONALD KAHN, Boston, MA 

199-OR 

200-OR 

201-OR 

202-OR 

203-OR 

204-OR 

2:30 p.m.–2:45 p.m. 

An Economic Analysis of Optimal A1c Cutpoints To Define Pre-DM 

XIAOHUI ZHUO, PING ZHANG, ELIZABETH SELVIN, RONALD ACKER- 

MANN, RUI LI, ED GREGG, Atlanta, GA, Baltimore, MD, Indianapolis, IN 

2:45 p.m.–3:00 p.m. 

Cost-Effectiveness of Implementing a Diabetes Primary Prevention 

Program in a Military Setting 

SHIHCHEN S. KUO, CINDY L. BRYCE, JANICE C. ZGIBOR, DONNA 

L. WOLF, MARK W. TRUE, HSIANG-YU CHEN, MARK S. ROBERTS, 

KENNETH J. SMITH, Pittsburgh, PA, San Antonio, TX 

3:00 p.m.–3:15 p.m. 

Cost-Effectiveness of Bariatric Surgery for Obese Persons with Diabetes 

THOMAS J. HOERGER, PING ZHANG, JOEL E. SEGEL, HENRY S. KAHN, 

LAWRENCE E. BARKER, STEVEN P. COUPER, Research Triangle Park, NC, 

Atlanta, GA, Ann Arbor, MI 

3:15 p.m.–3:30 p.m. 

Influence of Previous Medication Compliance on Future Compliance in 

Patients with Type 2 Diabetes 

FEMIDA GWADRY-SRIDHAR, R. SCOTT LESLIE, B. PATEL, GUSTAVUS 

ARANDA, LISA SANCHEZ-TRASK, London, ON, Canada, San Diego, CA, 

Deerfield, IL 

3:30 p.m.–3:45 p.m. 

Impact of Diabetes Mellitus on Work Cessation in the GAZEL Cohort 

Study 

ELEONORE HERQUELOT, ALICE GUEGUEN, SEBASTIEN BONENFANT, 

ROSEMARY DRAY-SPIRA, Villejuif, France 

3:45 p.m.–4:00 p.m. 

Towards Lower Macrovascular Risk in Diabetes Patients: A Simulation- 

Based Evaluation of Prioritization Strategies 

GEORG MEYER, GEDIMINAS ADOMAVICIUS, PAUL E. JOHNSON, 

PATRICK J. O’CONNOR, MOHAMED ELIDRISI, RYAN M. MCCABE, 

JOANN SPERL-HILLEN, WILLIAM A. RUSH, Minneapolis, MN 

2:15 p.m.–2:30 p.m. 

205-OR Mapping Genes near Type 2 Diabetes (T2D) Associated Loci as 

Expression Quantitative Trait Loci (eQTL) in Human Adipose and Muscle 

STEVEN C. ELBEIN, ERIC R. GAMAZON, PHILIP A. KERN, NEDA RASOULI, 

ANNA TIKHOMIROV, NANCY J. COX, Winston-Salem, NC, Chicago, IL, 

Lexington, KY, Denver, CO 

2:30 p.m.–2:45 p.m. 

206-OR Novel Loci Influencing Risk of Type 2 Diabetes and Their Relationship to 

Fasting Glycemic Traits Revealed by Large-Scale Genome-Wide Association 

Analyses 

INGA PROKOPENKO, BENJAMIN F. VOIGHT, Oxford, United Kingdom, 

Cambridge, MA 

2:45 p.m.–3:00 p.m. 

207-OR Genome Wide Copy Number Variation Study Reveals Loci Exclusively 

Impacted in Childhood Obesity Cases 

STRUAN F.A. GRANT, JOSEPH T. GLESSNER, JONATHAN P. BRADFIELD, 

KAI WANG, HAITAO ZHANG, FRANK D. MENTCH, JIANHUA ZHAO, 

CECILIA E. KIM, CUIPING HOU, SANDRA DELIARD, EDWARD C. 

FRACKELTON, ROSETTA M. CHIAVACCI, ROBERT I. BERKOWITZ, HAKON 

HAKONARSON, Philadelphia, PA 

3:00 p.m.–3:15 p.m. 

208-OR Influence of Novel Genetic Loci Associated with Elevated Fasting and 

Postprandial Glucose Levels on Islet Function in Man 

TARUNVEER S. AHLUWALIA, BO ISOMAA, TINAMAIJA TUOMI, LEIF 

GROOP, VALERIYA LYSSENKO, Malmö, Sweden, Helsinki, Finland 

3:15 p.m.–3:30 p.m. 

209-OR Disease-Associated Loci Are Highly Significantly Over-Represented 

among Genes Bound by TCF7L2 In Vivo 

JIANHUA ZHAO, JONATHAN SCHUG, MINGYAO LI, KLAUS H. 

KAESTNER, STRUAN F.A. GRANT, Philadelphia, PA 

3:30 p.m.–3:45 p.m. 

211-OR A Genome Wide Association Study for Diabetic Nephropathy Genes in 

African Americans 

CAITRIN W. MCDONOUGH, NICHOLETTE D. PALMER, MEREDITH A. 

BOSTROM, PAMELA J. HICKS, BONG H. ROH, MARIA R. WING, JESSICA 

N. COOKE, JESSICA M. HESTER, S. SANDY AN, MATTHEW E. TALBERT, 

LINGYI LU, MAGGIE C.Y. NG, JASMIN DIVERS, CARL D. LANGEFELD, 

BARRY I. FREEDMAN, DONALD W. BOWDEN, Winston-Salem, NC 


3:45 p.m.–4:00 p.m. 

212-OR Whole-Genome Identification and Functional Analysis of Type 1 

Diabetes-Associated Epigenetic Variation 

HURIYA BEYAN, VARDHMAN K. RAKYAN, THOMAS A. DOWN, SIARHEI 

MASLAU, MOHAMMED I. HAWA, BERNHARD O. BOEHM, STEPHAN 

BECK, RICHARD D. LESLIE, London, United Kingdom, Cambridge, United 

Kingdom, Ulm, Germany 


45




2:00 p.m.–4:00 p.m. 

Session: Prediction and Natural History of Type 1 Diabetes 

Room 221 

Chair: Jonathan D. Katz, PhD 

2:00 p.m.–2:15 p.m. 

213-OR Development of Autoantibodies in the TrialNet Natural History Study 

(NHS) 

KENDRA VEHIK, CRAIG A. BEAM, MICHAEL J. HALLER, JAY M. SO- 

SENKO, DESMOND A. SCHATZ, JEFFREY L. MAHON, JEFFREY P. KRISCH- 

ER, JAY S. SKYLER, TRIALNET STUDY GROUP, Tampa, FL, Gainesville, 

FL, Miami, FL, London, ON, Canada 

2:15 p.m.–2:30 p.m. 

214-OR Linear Population Progression to Diabetes Only If >= One Serum Sample 

Expresses 2 or 3 Confirmed Boichemical Autoantibodies 

KELLY JOHNSON, KATHY BARRIGA, DONGMEI MIAO, LIPING YU, JOHN 

HUTTON, GEORGE EISENBARTH, MARIAN REWERS, Aurora, CO 

2:30 p.m.–2:45 p.m. 

215-OR Measurement of Plasma Autoantibody to Zinc Transporter 8 Helps 

Identify Patients with Adult-Onset Latent Autoimmune Diabetes 

ZHIGUANG ZHOU, LINGLING PAN, GAN HUANG, YUFEI XIANG, LIN YANG, 

SHUOMING LUO, XIA LI, ZHENQI LIU, JOHN C. HUTTON, Changsha, 

China, Charlottesville, VA, Aurora, CO 

2:45 p.m.–3:00 p.m. 

216-OR Insulin Antibodies Associated with Technosphere® Insulin 

WEN YU, MARK T. MARINO, JAMES P. CASSIDY, ANDERS H. BOSS, 

SAMUEL FINEBERG, Valencia, CA, Crestline, AL 

3:00 p.m.–3:15 p.m. 

217-OR Epigenetic Dysfunction in Autoimmune Diabetes: Persistent Monocyte 

STAT5 Phosphorylation Promotes Epigenetic Dysregulation of GM-CSF- 

Induced PGS2/COX2 Expression in Type 1 Diabetes 

ZHAO HAN, ERIN GARRIGAN, MARK ATKINSON, CLIVE WASSERFALL, 

MICHAEL J. CLARE-SALZLER, MATTHEW AMICK, SALLY A. LITHERLAND, 

Gainesville, FL, Orlando, FL 

3:15 p.m.–3:30 p.m. 

218-OR Histopathology of Type 1 Diabetes in U.S Organ Donors 

MARTHA CAMPBELL-THOMPSON, PATRICK A. ROWE, CLIVE H. 

WASSERFALL, ROBERT PIETRAS, ANASTASIA A. ALBANESE-O’NEILL, 

ROBERTO GIANANI, DESMOND A. SCHATZ, MARK A. ATKINSON, 

Gainesville, FL, Denver, CO 

3:30 p.m.–3:45 p.m. 

219-OR Highly Constrained GLP-1 Analogues as Non-Invasive PET Imaging 

Probes for Pancreatic Beta-Cells 

JUNG-MO AHN, EUNICE N. MURAGE, MAI LIN, SU-TANG LO, XIANKAI 

SUN, Richardson, TX, Dallas, TX 

3:45 p.m.–4:00 p.m. 

220-OR Development of the Pancreatic Beta-Cell Surface-Specific Monoclonal 

Autoantibody, IC2, for Assessing Beta-Cell Mass In Vivo 

CARL-HENRIK BROGREN, WEIQIAO GAO, MD. GOLAM MIA, KARSTEN 

BUSCHARD, MICHAEL H. BACHMANN, CHRISTOPHER H. CONTAG, 

LAURENCE RENAUT, MARIE JULIE CARLES, NATHALIE SOUYRIS, PHILIPPE 

MONDON, Copenhagen, Denmark, Stanford, CA, Labege, France 

2:00 p.m.–4:00 p.m. 

Session: Mechanisms of In Vivo Insulin Action 

Room 304 E 

Chair: Paul W. Hruz, MD, PhD 

2:00 p.m.–2:15 p.m. 

221-OR Akt2 Governs Fuel Switching during the Fasted to Fed Transition 

BHAVAPRIYA VAITHEESVARAN, MORRIS BIRNBAUM, IRWIN J. 

KURLAND, Bronx, NY, Philadelphia, PA 

2:15 p.m.–2:30 p.m. 

222-OR Brain Specific Glucose Transporter 4 Knockout Mice Display Decreased 

Brain Glucose Uptake and Hepatic Insulin Resistance 

CANDACE RENO, ERWIN PUENTE, DORIT DAPHNA-IKEN, BARBARA 

KAHN, SIMON FISHER, St. Louis, MO, Boston, MA 

2:30 p.m.–2:45 p.m. 

223-OR Hypothalamic AMPK Regulates Glucose Production 

CLAIR S. YANG, CAROL K.L. LAM, MADHU CHARI, GRACE W.C. CHEUNG, 

ANDREA KOKOROVIC, SUN GAO, ISABELLE LECLERC, GUY A. RUTTER, 

TONY K.T. LAM, Toronto, ON, Canada, London, United Kingdom 

2:45 p.m.–3:00 p.m. 

224-OR Interleukin-10 Prevents Skeletal Muscle Inflammation and Insulin 

Resistance Induced by Acute Lipid Infusion 

HWI JIN KO, DAE YOUNG JUNG, YONGJIN LEE, HELENA ONG, 

YOSHIHIRO AZUMA, YUN H. NOH, JASON K. KIM, Worcester, MA, 

Seoul, Republic of Korea 

3:00 p.m.–3:15 p.m. 

225-OR Insulin-Stimulated ROCK1 Activity Is Impaired in Skeletal Muscle of 

Insulin Resistant Subjects 

KWANG-HOON CHUN, DAE HO LEE, YUNSHIN JUNG, THEODORE P. 

CIARALDI, YOUNG-BUM KIM, Boston, MA, La Jolla, CA 

3:15 p.m.–3:30 p.m. 

226-OR Adipose Tissue Gene Expression in Obese Insulin Resistance and Obese 

Insulin Sensitive Non Diabetic Subjects 

NEDA RASOULI, AIWEI YAO-BORENGASSER, PHILIP A. KERN, Aurora, 

CO, Little Rock, AR, Lexington, KY 

3:30 p.m.–3:45 p.m. 

228-OR Identification of Lipocalin-13 as an Endogenous Insulin Sensitizer 

KAE WON CHO, YINGJIANG ZHOU, HONG SHEN, LIANGYOU RUI, Ann 

Arbor, MI 

3:45 p.m.–4:00 p.m. 

227-OR Regulation of microRNA Processing in Adipose Tissue: Role in Aging, 

Caloric Restriction and Metabolic Regulation 

MARCELO A. MORI, PRASHANT RAGHAVAN, STEVEN J. RUSSELL, 

YAZMIN MACOTELA, JONATHON N. WINNAY, T. KEITH BLACKWELL, C. 

RONALD KAHN, Boston, MA 

46 




2:00 p.m.–4:00 p.m. 

Session: Insulin Secretion—In Vivo 

Room 312 

Co-Chairs: Meredith A. Hawkins, MD and Kenneth S. Polonsky, MD 

229-OR 

230-OR 

231-OR 

232-OR 

233-OR 

234-OR 

235-OR 

236-OR 

2:00 p.m.–2:15 p.m. 

Pre- and Post-Mortem Demonstration of Persistent β-Cell Function and 

Turnover after More Than 50 Years of Type 1 Diabetes 

HILLARY A. KEENAN, JENNIFER K. SUN, LEAH WHELAN, JOSHUA A. 

GELTMAN, LLOYD PAUL AIELLO, SUSAN BONNER-WEIR, GEORGE L. 

KING, Boston, MA 

2:15 p.m.–2:30 p.m. 

Exogenous Insulin Infusion Affects Insulin Secretion According to Insulin 

Sensitivity in Humans 

CHRISTIAN ANDERWALD, ANGELA GRASSI, ANDREA TURA, MICHAEL 

KREBS, JULIA SZENDROEDI, MICHAEL RODEN, MARTIN G. BISCHOF, 

ANTON LUGER, GIOVANNI PACINI, Vienna, Austria, Padova, Italy, 

Düsseldorf, Germany 

2:30 p.m.–2:45 p.m. 

β-Cell Specific Overexpression of 11β-Hydroxysteroid Dehydrogenase 

Type 1 Reverses High Fat Diet-Induced β-Cell Failure 

SOPHIE TURBAN, XIAOXIA LIU, LYNNE RAMAGE, JOHN J. MULLINS, 

JONATHAN R. SECKL, NICHOLAS M. MORTON, Edinburgh, United 

Kingdom 

2:45 p.m.–3:00 p.m. 

Interleukin-1 Receptor Antagonist Prevents Fat-Induced β-Cell Dysfunction 

in Diabetes-Prone BioBreeding Rats 

CHRISTINE TANG, JAN A. EHSES, MARC Y. DONATH, ADRIA GIACCA, 

Toronto, ON, Canada, Zurich, Switzerland 

3:00 p.m.–3:15 p.m. 

The Glucagon-Like Peptide Receptor Agonist Exenatide Protects Against 

Glucocorticoid-Induced Glucose Intolerance and Islet-Cell Dysfunction in 

Humans 

DANIEL H. VAN RAALTE, RENATE E. VAN GENUGTEN, MARGOT 

M.L. LINSSEN, MARGRIET D.M. OUWENS, MICHAELA DIAMANT, 

Amsterdam, The Netherlands, Leiden, The Netherlands, Düsseldorf, 

Germany 

WITHDRAWN 

3:15 p.m.–3:30 p.m. 

Impaired Insulin Secretion and Glucose Intolerance in Mice Lacking the 

Secreted Protein Ccdc80 

FREDERIC TREMBLAY, TIFFANY GARESKI, DAVID KUBASIAK, SARAH 

WILL, MYLENE PERREAULT, QINGCONG LIN, RUTH E. GIMENO, Cambridge, 

MA 

3:30 p.m.–3:45 p.m. 

Prediction of Diabetes in Relatives of People with Type 1 Diabetes: Role 

of Clinical Testing 

ELE FERRANNINI, ANDREA MARI, VALENTINA NOFRATE, JEFFREY P. 

KRISCHER, JAY M. SOSENKO, JAY S. SKYLER, DPT-1 STUDY GROUP, 

Pisa, Italy, Padova, Italy, Tampa, FL, Miami, FL 



47




4:15 p.m.–6:15 p.m. 

Session: Ocular 

Room 207 


4:15 p.m.–4:30 p.m. 

237-OR Gene Expression Profile in Endothelial Progenitor Cells (EPCs) Identify 

Novel Transcripts Upregulated in Diabetic Patients Protected from 

Development of Diabetic Retinopathy (DR) 

ASHAY D. BHATWADEKAR, YUANQING YAN, ELENA V. NIKONOVA, 

KEITH Q. TANIS, DAVID J. STONE, DAVID KENT, REINHOLD MEDINA, 

ALAN W. STITT, CATHY THUT, EVA M. FINNEY, MARIA B. GRANT, Gainesville, 

FL, West Point, PA, Kilkenny, Ireland, Belfast, United Kingdom 

4:30 p.m.–4:45 p.m. 

238-OR Inhibition of Plasminogen Activator Inhibitor-1 (PAI-1) Corrects Diabetic 

Endothelial Progenitor Cells (EPC) Dysfunction 

MARIA B. GRANT, SUGATA HAZRA, ASHAY D. BHATWADEKAR, 

STEPHEN BARTELMEZ, PAUL J. HIGGINS, MICHAEL E. BOULTON, Gainesville, 

FL, San Francisco, CA, Albany, NY 

4:45 p.m.–5:00 p.m. 

239-OR microRNA-200b Mediates Upregulation of VEGF in Diabetic Retinopathy 

KARA R. MCARTHUR, BIAO FENG, YUEXIU WU, SHALI CHEN, SUBRATA 

CHAKRABARTI, London, ON, Canada 

5:00 p.m.–5:15 p.m. 

240-OR miR146a Mediated Upregulation of Extracellular Matrix Protein in 

Diabetic Retinopathy 

BIAO FENG, SHALI CHEN, KARA MCARTHUR, YUEXIU WU, SUBRATA 

CHAKRABARTI, London, ON, Canada 

5:15 p.m.–5:30 p.m. 

241-OR Correlation of Vascular Complications with SHP-1 Expression in Patients 

with More Than 50 Years of Diabetes 

PEDRO GERALDES, JENNIFER K. SUN, HILLARY KEENAN, MOTONOBU 

MATSUMOTO, LLOYD P. AIELLO, GEORGE L. KING, Boston, MA 

5:30 p.m.–5:45 p.m. 

242-OR Protection from Diabetic Retinopathy (DR) Progression in Patients with 

50 or More Years of Type 1 Diabetes 

JENNIFER K. SUN, HILLARY A. KEENAN, CHERYL SHERROD, LEAH 

WHELAN, LLOYD PAUL AIELLO, GEORGE L. KING, Boston, MA 

5:45 p.m.–6:00 p.m. 

243-OR Genome-Wide Association Study of Risk for Diabetic Retinopathy in 

Type 1 Diabetes 

ANDREW D. PATERSON, DARYL WAGGOTT, ENQING SHEN, ANDREW P. 

BORIGHT, MOHSEN HOSSEINI, PATRICIA A. CLEARY, JOHN M. LACHIN, 

LEI SUN, SHELLEY BULL, DCCT/EDIC RESEARCH GROUP, Toronto, ON, 

Canada, Rockville, MD 

6:00 p.m.–6:15 p.m. 

244-OR Intravitreal Plasma Kallikrein Induces Retinal Thickening and Hemorrhage 


EDWARD P. FEENER, ALLEN C. CLERMONT, JIA LIU, TAKESHI KITA, 

BENBO GAO, Boston, MA 

4:15 p.m.–6:15 p.m. 

Session: Cellular Mechanisms of Cardiovascular Complications of Diabetes 

Room 209 

Co-Chairs: Sridevi Davaraj, PhD and Takashi Kadowaki, MD, PhD 

4:15 p.m.–4:30 p.m. 

245-OR Relationship between Glucose Variability, Glycaemic Control, Oxidative 

Stress and Peripheral Blood Mononuclear Cell NF-κB Activity in Patients 

with Type 1 and Insulin-Treated Type 2 Diabetes 

RONALD C. MA, CHUN KWOK WONG, CHI CHIU WANG, WING YEE SO, 

KIT MAN LOO, SALLY C. WONG, ANDREA O. LUK, ALICE P. KONG, CHUN 

CHUNG CHOW, PETER C. TONG, JULIANA C. CHAN, Hong Kong, China 

4:30 p.m.–4:45 p.m. 

246-OR The Role of CHOP Expressed in Vascular and Hematopoietic Cells in 

Vascular Remodeling 

KEIICHI KONDO, JUNHONG GAO, YASUSHI ISHIGAKI, YOSHITOMO 

OKA, HIDEKI KATAGIRI, Sendai, Japan 

4:45 p.m.–5:00 p.m. 

247-OR Impaired Ischemia-Induced Angiogenesis in Diabetic Mice Depends on 

Glycemic Variability 

DARIO PITOCCO, FRANCESCO ZACCARDI, FEDERICO BISCETTI, 

GIUSEPPE STRAFACE, PAOLA RIZZO, TITTANIA MUSELLA, GIOVANNI 

GHIRLANDA, Rome, Italy 

5:00 p.m.–5:15 p.m. 

248-OR Pathophysiological Roles of AdipoR2 in Endothelial Cells and AdipoR1 in 

Macrophages in the Prevention of Atherosclerosis 

MIKI O. IWABU, TOSHIMASA YAMAUCHI, MASATO IWABU, TETSUYA 

KUBOTA, NAOTO KUBOTA, KOHJIRO UEKI, TAKASHI KADOWAKI, Tokyo, 

Japan 

5:15 p.m.–5:30 p.m. 

249-OR Early Defects Occur in PI3-Kinase/Akt Signaling and Vascular Function in 

a Novel Porcine Model of Diet-Induced Obesity 

CECILIA C.L. WANG, JODY GUNTER, J. WAYNE LEITNER, LI LU, YA XU, 

CLIFFORD R. GREYSON, ROBERTO GIANANI, BORIS DRAZNIN, JANE 

E.B. REUSCH, GREGORY G. SCHWARTZ, Denver, CO, Aurora, CO 

5:30 p.m.–5:45 p.m. 

250-OR Epigenetic Alterations of Inflammatory Genes in Monocytes of Patients 

with Type 1 Diabetes 

JUNG-MI YUN, ISHWARLAL JIALAL, SRIDEVI DEVARAJ, Sacramento, 

CA 

5:45 p.m.–6:00 p.m. 

251-OR Diabetes-Like Paradoxical Expression of Vascular Endothelial Growth 

Factor (VEGF) and Angiogenesis in the Peripheral Tissue and Retina 

Reproduced in Endothelial Specific PKCβ 2 Overexpression Mice 

CHENZHONG LI, JUNKO HIRAOKA-YAMAMOTO, QIAN LI, ALLEN 

CLERMONT, LAURIE J. GOODYEAR, RONALD KAHN, GEORGE KING, 

Boston, MA 

6:00 p.m.–6:15 p.m. 

252-OR Timed Dopamine Agonist Treatment Ameliorates Both Vascular Nitrosative/Oxidative 

Stress Pathology and Aortic Stiffness in Arteriosclerotic, 

Hyper tensive SHR Rats 

MICHAEL EZROKHI, YELENA TRUBITSYNA, SHUQIN LUO, ANTHONY H. 

CINCOTTA, Tiverton, RI 

48 




4:15 p.m.–6:15 p.m. 

Session: Behavioral Interventions in Diabetes 

Room 208 

Chair: Shelagh Mulvaney, PhD 

4:15 p.m.–4:30 p.m. 

253-OR Impact of Diabetes Diagnosis on Health Related Quality of Life in the 

Diabetes Prevention Program-Outcomes Study (DPPOS) 

DAVID G. MARRERO, RICHARD R. RUBIN, RONALD T. ACKERMANN, 

QING PAN, ELIZABETH BARRETT-CONNOR, CAROL PERCY, MARIA G. 

MONTEZ, PING ZHANG, HERMES FLOREZ, THE DIABETES PREVENTION 

PROGRAM RESEARCH GROUP, Indianapolis, IN, Baltimore, MD, 

Rockville, MD, La Jolla, CA, Shiprock, NM, San Antonio, TX, Atlanta, 

GA, Miami, FL 

4:30 p.m.–4:45 p.m. 

254-OR TEAMcare: Evaluation of a Collaborative Treat-to-Target Intervention for 

Patients with Complex Chronic Disease and Depression 

ELIZABETH H. LIN, WAYNE KATON, MICHAEL VON KORFF, PAUL 

CIECHANOWSKI, BESSIE YOUNG, EVETTE LUDMAN, CAROLYN RUTTER, 

DO PETERSON, DAVID MCCULLOCH, Seattle, WA 

4:45 p.m.–5:00 p.m. 

255-OR Adherence to Diabetes Self Care for White, African American and 

Hispanic American Telemedicine Participants: IDEATel Project 

PAULA M. TRIEF, ROBERTO IZQUIERDO, JOSEPH P. EIMICKE, JEANNE 

A. TERESI, ROBIN GOLAND, WALTER PALMAS, STEVEN SHEA, RUTH S. 

WEINSTOCK, Syracuse, NY, Bronx, NY, New York, NY 

5:00 p.m.–5:15 p.m. 

256-OR Sustaining Short-Term Improvements over the Long-Term: Results from 

a 2-Year Diabetes Self-Management Support (DSMS) Intervention 

TRICIA S. TANG, MARTHA M. FUNNELL, SALMA NOORULLA, MORTON 

B. BROWN, Ann Arbor, MI 

5:15 p.m.–5:30 p.m. 

257-OR Impact of Diabetes Numeracy on Glycemic Control: A Longitudinal 

Study 

KERRI L. CAVANAUGH, KENNETH A. WALLSTON, TEBEB GEBRETSADIK, 

AYUMI SHINTANI, DIANNE DAVIS, REBECCA PRATT GREGORY, 

KATHLEEN WOLFF, ROBB MALONE, DARREN DEWALT, MICHAEL 

PIGNONE, TOM A. ELASY, RUSSELL L. ROTHMAN, Nashville, TN, Chapel 

Hill, NC 

5:30 p.m.–5:45 p.m. 

258-OR Subclinical Atherosclerosis Associates with Measures of Cerebral 

Functioning in Uncomplicated T1DM 

EELCO VAN DUINKERKEN, RICHARD G. IJZERMAN, MARTIN KLEIN, 

JEANNETTE BOEROP, ANNETTE C. MOLL, NIKI S.M. SCHOONENBOOM, 

FRANK J. SNOEK, CORNELIS J. STAM, MICHAELA DIAMANT, Amsterdam, 

The Netherlands 

5:45 p.m.–6:00 p.m. 

259-OR Baseline Symptoms of Depression Related to BMI in Youth Participating 

in the Treatment Options for Type 2 Diabetes in Adolescents and Youth 

(TODAY) Study 

BARBARA J. ANDERSON, LORRAINE KATZ, SHARON EDELSTEIN, 

NATALIE ABRAMSON, TERRI CASEY, PATRICIA KRINGAS, SYLVIA 

LAVIETES, SHERIDA TOLLEFSEN, PAULA TRIEF, PATRICE YASUDA, Houston, 

TX, Philadelphia, PA, Rockville, MD, Denver, CO, Cleveland, OH, New York, 

NY, New Haven, CT, St. Louis, MO, Syracuse, NY, Los Angeles, CA 

6:00 p.m.–6:15 p.m. 

260-OR High-Risk Youth with Diabetes Need Home-Based Behavioral Interventions 

DEBORAH A. ELLIS, SYLVIE NAAR-KING, CYNTHIA ARFKEN, PHILLIPPE 

CUNNINGHAM, KATHLEEN MOLTZ, APRIL CARCONE, Detroit, MI, 

Charles ton, SC 

4:15 p.m.–6:15 p.m. 

Session: Deficiencies in Diabetes Care and Outcomes—Exploring Problem 

Areas and Emerging Solutions 

Room 414 

Chair: Joe V. Selby, MD 

4:15 p.m.–4:30 p.m. 

261-OR Medical Expenditure Attributable to Diabetes Mellitus among Privately 

Insured Children and Adolescents 

SUNDAR S. SHRESTHA, PING ZHANG, GIUSEPPINA IMPERATORE, 

Atlanta, GA 

4:30 p.m.–4:45 p.m. 

262-OR Impact of Gender and Socioeconomic Status on Lower Extremity 

Amputation Rates in Individuals with Diabetes 

LEENA N. AMIN, GILLIAN L. BOOTH, ARLENE S. BIERMAN, LORRAINE L. 

LIPSCOME, BAIJU R. SHAH, Toronto, ON, Canada 

4:45 p.m.–5:00 p.m. 

263-OR Increased Medical Costs Associated with Progression of Diabetic 

Nephropathy 

GREGORY A. NICHOLS, SUMA VUPPUTURI, HELEN LAU, Portland, OR, 

Atlanta, GA, East Hanover, NJ 

5:00 p.m.–5:15 p.m. 

264-OR Time To Add-On Medication Use for Patients with Type 2 Diabetes 

Mellitus (T2DM) Who Failed Metformin Monotherapy 

YING QIU, ALEX Z. FU, LARRY RADICAN, Whitehouse Station, NJ, 

Cleveland, OH 

5:15 p.m.–5:30 p.m. 

265-OR The Economic Importance of Metabolic Memory in the Treatment of 

Type 2 Diabetes Mellitus (T2DM) 

MICHAEL WILLIS, CHRISTIAN ASSEBURG, CHERYL NESLUSAN, JIAN- 

MING HE, Lund, Sweden, Kuopio, Finland, Raritan, NJ 

5:30 p.m.–5:45 p.m. 

266-OR Cost Savings and Improved Clinical Outcomes of Early Insulin in Patients 

Treated with 2 vs 3 Oral Antidiabetic Agents 

AARON VINIK, QUANWU ZHANG, JOHN GERICH, Norfolk, VA, 

Bridgewater, NJ, Rochester, NY 

5:45 p.m.–6:00 p.m. 

267-OR Cost-Effectiveness of Implementing the Chronic Care Model for Diabetes 

Care in a Military Population 

SHIHCHEN S. KUO, CINDY L. BRYCE, JANICE C. ZGIBOR, DONNA L. 

WOLF, AGUSTIN MORENO, HSIANG-YU CHEN, MARK S. ROBERTS, 

KENNETH J. SMITH, Pittsburgh, PA, Brooks City-Base, TX 

6:00 p.m.–6:15 p.m. 

268-OR Cost Effectiveness of an EMR-Based Diabetes Clinical Decision Support 

System 

TODD P. GILMER, PATRICK J. O’CONNOR, JOANN M. SPERL-HILLEN, 

WILLIAM A. RUSH, PAUL E. JOHNSON, JERRY H. AMUNDSON, STEPHEN 

A. ASCHE, HEIDI L. EKSTROM, San Diego, CA, Minneapolis, MN 



49




4:15 p.m.–6:15 p.m. 

Session: Epidemiology of Type 1 and Type 2 Diabetes 

Room 315 

Chair: Ingrid M. Libman-DeGordon, MD, PhD 

4:15 p.m.–4:30 p.m. 

269-OR Self Reported Bronchitis or RS-Virus, Asthma and Development of 

Multiple Islet Autoantibodies in Children with the Type 1 Diabetes High- 

Risk Genotype: The MIDIA Study 

TROND RASMUSSEN, LARS CHRISTIAN STENE, KJERSTI SKJOLD 

RØNNINGEN, Oslo, Norway 

4:30 p.m.–4:45 p.m. 

270-OR Erythrocyte Membrane Omega-3 Fatty Acid Levels Are Not Associated 

with the Conversion to Type 1 Diabetes in Children with Islet Autoimmunity. 

The Diabetes Autoimmunity Study in the Young (DAISY) 

JILL M. NORRIS, XIANG YIN, MELISSA R. MILLER, MICHAEL CLARE- 

SALZLER, MARIAN REWERS, Aurora, CO, Gainesville, FL 

4:45 p.m.–5:00 p.m. 

271-OR Clinical Evolution of Beta-Cell Function in Youth with Diabetes: The 

SEARCH for Diabetes in Youth Study 

DANA DABELEA, ELIZABETH J. MAYER-DAVIS, JEANETTE S. ANDREWS, 

LAWRENCE DOLAN, CATHERINE PIHOKER, RICHARD F. HAMMAN, 

CARLA GREENBAUM, SANTICA MARCOVINA, WILFRED FUJIMOTO, 

BARBARA LINDER, GIUSEPPINA IMPERATORE, RALPH D’AGOSTINO, 

JR., Denver, CO, Chapel Hill, NC, Winston-Salem, NC, Cincinnati, OH, 

Seattle, WA, Honolulu, HI, Bethesda, MD, Atlanta, GA 

5:00 p.m.–5:15 p.m. 

272-OR Effect of Subsequent Pregnancies on the Risk of Developing Type 2 

Diabetes in Women with a History of Gestational Diabetes 

CHRISTINE OPSTEEN, BAIJU R. SHAH, PETER C. AUSTIN, RAVI 

RETNAKARAN, Toronto, ON, Canada 

5:15 p.m.–5:30 p.m. 

273-OR Pregnancy Complications and Subsequent Risk of Type 2 Diabetes 

TAMARRA M. JAMES-TODD, ANANTH KARUMANCHI, SUSAN M. 

MASON, FRANK HU, EILEEN L. HIBERT, MARY VADNAIS, JANET W. 

RICH-EDWARDS, Boston, MA 

5:30 p.m.–5:45 p.m. 

274-OR A Prospective Study of Computed Tomography Measured Thigh, Subcutaneous 

Abdominal, and Intra-Abdominal Fat Areas and Risk of Type 2 

Diabetes in Japanese Americans 

DEBORAH M. HOYER, EDWARD J. BOYKO, MARGUERITE J. MCNEELY, 

DONNA L. LEONETTI, STEVEN E. KAHN, WILFRED Y. FUJIMOTO, Seattle, 

WA 

5:45 p.m.–6:00 p.m. 

275-OR The Association between Hemoglobin A1c and Genetic Admixture in 

African American Adults 

NISA M. MARUTHUR, W.H. LINDA KAO, ELIZABETH SELVIN, Baltimore, 

MD 

6:00 p.m.–6:15 p.m. 

276-OR Implications of Using A1c Versus Fasting Plasma Glucose To Identify 

U.S. Adults at Higher Risk for Developing Diabetes 

CHERIE JAMES, EDWARD W. GREGG, KAI M. BULLARD, DEBORAH 

B. ROLKA, LINDA S. GEISS, DESMOND E. WILLIAMS, CATHERINE C. 

COWIE, ANN ALBRIGHT, Atlanta, GA, Bethesda, MD 

4:15 p.m.–6:15 p.m. 

Session: Incretin and Leptin Biology 

Room 314 

Co-Chairs: Carolyn F. Deacon, PhD, DMSc and Michael A. Nauck, MD 

4:15 p.m.–4:30 p.m. 

277-OR Intestinal L Cell Number Is Regulated by Glucagon-Like Peptide-1 

MARINE GRIGORYAN, MAMDOUH KEDEES, YELENA GUZ, GLADYS 

TEITELMAN, Brooklyn, NY 

4:30 p.m.–4:45 p.m. 

278-OR Metfomin Stimulates Glucagon-Like Peptide (GLP-1) Synthesis and 

Secretion Via Wnt Signaling 

MI-HYUN KIM, MYUNG-SHIK LEE, KWANG-WON KIM, KYU YEON HUR, 

JAE HYEON KIM, MOON-KYU LEE, Seoul, Republic of Korea 

4:45 p.m.–5:00 p.m. 

279-OR Tubby Is a Mediator of Leptin and Insulin Signaling/Action and Is 

Modulated by Ghrelin in Arcuate Nucleus 

PATRICIA O. PRADA, EDUARDO R. ROPELLE, ANDREA M. CARICILLI, 

DIOZE GUADAGNINI, JOSE B.C. CARVALHEIRA, MARIO J.A. SAAD, 

Campinas, Brazil 

5:00 p.m.–5:15 p.m. 

280-OR Enhanced Amylin-Mediated Weight Loss in Ovariectomized Rats Is 

Associated with Increased Metabolism and Does Not Require Intact 

Leptin Signaling 

CARRIE WITTMER, JAMES TREVASKIS, VICTORIA TUREK, PETER 

GRIFFIN, DAVID PARKES, JONATHAN ROTH, CATHLEEN CARTER, San 

Diego, CA 

5:15 p.m.–5:30 p.m. 

281-OR The Separate and Combined Impact of the Intestinal Hormones, GIP, 

GLP-1 and GLP-2, on Glucagon Secretion in Type 2 Diabetes 

ASGER LUND, TINA VILSBØLL, JONATAN ISSING BAGGER, JENS 

JUUL HOLST, FILIP KRAG KNOP, Herlev, Denmark, Hellerup, Denmark, 

Copenhagen, Denmark 

5:30 p.m.–5:45 p.m. 

282-OR The Role of R-Spondin1 in Pancreatic β-Cells In Vivo 

VICTOR S.C. WONG, AMY H. OH, ANN-AMANDINE CHASSOT, MARIE- 

CHRISTINE CHABOISSIER, PATRICIA L. BRUBAKER, Toronto, ON, Canada, 

Nice, France 

5:45 p.m.–6:00 p.m. 

283-OR Mechanism of Hepatic AMPK Activation by Leptin and Pathophysiological 

Significance of Hepatic AMPK in Lipoatrophic Diabetes 

LICHT MIYAMOTO, KEN EBIHARA, TORU KUSAKABE, DAISUKE AOTANI, 

SACHIKO YAMAMOTO-KATAOKA, TAKERU SAKAI, YUJI YAMAMOTO, 

TATSUYA HAYASHI, KIMINORI HOSODA, KAZUWA NAKAO, Kyoto, 

Japan 

6:00 p.m.–6:15 p.m. 

284-OR Incretins Prevent the Development of Atherosclerosis in Apolipoprotein 

E-Null Mice 

TOSHIHARU NAGASHIMA, TAKUYA WATANABE, KYOKO NOHTOMI, 

AKIRA MIYAZAKI, TSUTOMU HIRANO, Tokyo, Japan 

50 




4:15 p.m.–6:15 p.m. 

Session: Beta Cell Stimulus-Secretion Coupling and Metabolism 

Room 304 A 

Chair: Susumu Seino, MD, PhD 

285-OR 

286-OR 

287-OR 

288-OR 

289-OR 

290-OR 

291-OR 

292-OR 

4:15 p.m.–4:30 p.m. 

Wolfram Syndrome 1 Gene (wfs1) Product Localizes to Secretory Granule 

and Contributes to Maintenance of Granular Acidification in Pancreatic 

Beta Cells 

MASAYUKI HATANAKA, KATSUYA TANABE, YASUHARU OHTA, AKIE 

YANAI, MASARU AKIYAMA, MANABU KONDO, KOH SHINODA, 

YOSHITOMO OKA, YUKIO TANIZAWA, Yamaguchi, Japan, Sendai, 

Miyagi, Japan 

4:30 p.m.–4:45 p.m. 

Syntaxin-3 Regulates Exocytosis of Newcomer Insulin Granules during 

Biphasic Glucose-Stimulated Insulin Secretion in Pancreatic beta Cells 

ELLEN KOO, DAN ZHU, LI XIE, EDWIN KWAN, YU HE, SHUZO SUGITA, 

HERBERT Y. GAISANO, Toronto, ON, Canada 

4:45 p.m.–5:00 p.m. 

Severe Neonatal Hyperinsulinism in Heterozygous Patients Is Determined 

by High Relative Expression of the Mutant ABCC8 Transcript Compared 

to the Normal Transcript 

DAVID HAIM ZANGEN, CARMIT ZIV-AVNON, SHARONA TURNOVSKY- 

BABAEY, FEIFEI YAN, SHOWLING SHYNG, EFRAT LEIBA, BENJAMIN 

GLASER, RUTH SHEMER, Jerusalem, Israel, Portland, OR 

5:00 p.m.–5:15 p.m. 

ICA512 Regulates the Expression of Villin and TCF7L2 in Pancreatic 

Islets 

HASSAN MZIAUT, DESIREE SCHUMANN, TOBIAS HILDEBRANDT, ERIC 

SIMON, SILVIA BRAMBILLASCA, SUMEER DHAR, MYUNG-SHIK LEE, 

STEFAN KAUSCHKE, MICHAEL MARK, PETER EICKELMANN, MICHELE 

SOLIMENA, Dresden, Germany, Biberach, Germany, Seoul, Republic of 

Korea 

5:15 p.m.–5:30 p.m. 

VAMP8 Has Distinct Roles in Beta-Cell Insulin Exocytosis and Beta Cell 

Proliferation, Studies with VAMP8-Deletion Mice 

YI ZHANG, YUNFENG LIU, YOUHOU KANG, DIANA CHOI, PATRICK P.L. 

LAM, CHENG CHUN WANG, MINNA WOO, WANJIN HONG, HERBERT 

Y. GAISANO, Toronto, ON, Canada, Proteos, Singapore 

5:30 p.m.–5:45 p.m. 

Deficit in Mitochondrial Metabolism in β-Cells Leads to Reduced 

Glucose Stimulated Insulin Secretion (GSIS) 

SARAH WEKSLER-ZANGEN, GENYA AHARON-HANANEL, CARMIT 

MANTZUR, FIONA VERNEA, ANN SAADA, ITAMAR RAZ, Jerusalem, 

Israel 

5:45 p.m.–6:00 p.m. 

The Role of ZnT8 in Insulin Resistance and Type 2 Diabetes 

ALEXANDRE B. HARDY, NADEEJA WIJESEKARA, ALPANA BHATTA- 

CHARJEE, FABRICE CHIMIENTI, GUY A. RUTTER, MICHAEL B. WHEELER, 

Toronto, ON, Canada, Grenoble, France, London, United Kingdom 

6:00 p.m.–6:15 p.m. 

Expression of Bombesin Receptor Subtype-3 (BRS-3) in Islets from 

Different Species and Its Role in the Regulation of Insulin Secretion and 

Glucose Homeostasis 

YUN-PING ZHOU, YUE FENG, JIANYING XIAO, JUDITH GORSKI, JOSEPH 

METZGER, XIAO-MING GUAN, LINUS LIN, ANDREW HOWARD, NANCY 

THORNBERRY, BEI B. ZHANG, MARC REITMAN, Rahway, NJ 



51






Hall C 


12:00 p.m.–2:00 p.m. 


Clinical Therapeutics/New Technology—Glucose Monitoring and Sensing 

Clinical Therapeutics/New Technology—Insulin Delivery Systems 

Clinical Therapeutics/New Technology—Treatment of Insulin Resistance 

Complications—Nephropathy 

Diabetes Education 

Epidemiology 

Health Care Delivery—Economics 

Integrated Physiology—Adipocyte Biology 

Islet Biology—Apoptosis 

Islet Biology—Signal Transduction 

Nutrition—Clinical 


Psychosocial/Behavioral Medicine 

SUNDAY—Posters 

12:00 p.m.–1:00 p.m. 

1) GLP-1 Receptor Agonists and DPP-4 Inhibition (542-P–552-P) 

2) GLP-1 Receptor Agonists (582-P–591-P) 

3) Insulin Therapies (619-P–628-P) 

4) Cardiovascular Disease in Diabetes I (784-P–793-P) 

5) Mechanisms of Atherogenesis I (880-P–889-P) 

6) Discoveries in Human Peripheral Neuropathy 

and Treatments (963-P–969-P) 

7) Diabetic Dyslipidemia I (1060-P–1069-P) 

8) Exercise and Diabetes (1175-P–1185-P) 

9) Genetics of Type 2 Diabetes I (1236-P–1245-P) 

10) Insulin Secretion In Vivo (1509-P–1518-P) 

11) Muscle I (1599-P–1607-P) 

12) Beta Cell Development (1691-P–1700-P) 

13) Obesity—Animal I (1788-P–1797-P) 


1:00 p.m.–2:00 p.m. 

1) Insulin Therapies II (553-P–561-P) 

2) GLP-1 Receptors in Analogs (592-P–601-P) 

3) New Therapies III (629-P–635-P) 

4) Cardiovascular Disease in Diabetes II (794-P–803-P) 

5) Mechanisms of Atherogenesis II (890-P–898-P) 

6) Central Nervous System Markers and Complications 

of Diabetes (970-P–974-P) 

7) Diabetic Dyslipidemia II (1070-P–1077-P) 

8) Genetics of Type 2 Diabetes II (1246-P–1255-P, 1303-P) 

9) Insulin Resistance (1372-P–1377-P) 

10) Physiology of Liver Metabolism in Health 

and Disease (1551-P–1559-P) 

11) Muscle II (1608-P–1617-P) 

12) Post-Natal Beta Cell Growth (1703-P–1712-P) 

13) Obesity—Animal II (1798-P–1807-P) 

6:30 p.m.–7:45 p.m. 


Join us for the Presidents Poster Session and Reception. This prestigous session will 

feature a limited number of abstracts selected from each category. A total of 100 posters will be showcased. 

Presenters will be available during the session to discuss their research. Light refreshments and drinks will be served. 

52


MONDAY, JUNE 28 


8:00 a.m.–10:00 a.m. 

Symposia 

Update on Diabetic Peripheral Neuropathy 

Room 414 

Chair: Solomon Tesfaye, MD 

8:00 a.m.–8:30 a.m. Diabetic Neuropathy—Making the Diagnosis and Excluding Other Causes 

Vera Bril, MD 

8:30 a.m.–9:00 a.m. Understanding the Pathogenesis and Modifying Risk Factors of Diabetic Neuropathy 

Rayaz A. Malik, MD, PhD 

9:00 a.m.–9:30 a.m. Clinical Implications of Diabetic Neuropathy 

Dan Ziegler, MD 

9:30 a.m.–10:00 a.m. Diabetic Polyneuropathies—Mechanisms, Prevention, and Treatments—Lessons from the RDNS 

and Neurodiab Toronto Meeting 

Peter J. Dyck, MD 

NDEP Symposium—Translating New Research into a Public Health Campaign and Tools for Supporting Behavior Change 

Room 224 

Chair: Martha M. Funnell, MS, RN, CDE 

8:00 a.m.–8:30 a.m. Recent Research Findings on Long Term Benefits of Lifestyle Interventions and Behavior Change 

Judith E. Fradkin, MD 

8:30 a.m.–9:00 a.m. Building a Public Health Infrastructure for Behavior Change 

Ann L. Albright, PhD, RD 

9:00 a.m.–9:30 a.m. Using Behavior Change Tools in Clinical Practice 

Martha M. Funnell, MS, RN, CDE 

9:30 a.m.–10:00 a.m. Next Steps, Conclusions, and Questions and Answers 

Intensive Insulin Therapy at the Onset of Type 2 Diabetes—Can We Preserve Beta Cell Function and Reverse Diabetes 



Chair: Richard M. Bergenstal, MD 

8:00 a.m.–8:40 a.m. The Working Hypothesis 

Steven E. Kahn, MB, ChB 

8:40 a.m.–9:20 a.m. The Asian Experience 

Juliana C.N. Chan, MD 

9:20 a.m.–10:00 a.m. Early Insulinization in Type 2 Diabetes Mellitus—How Early Is Early 

Hertzel C. Gerstein, MD 

Drug Therapy during Pregnancy—Safety and Effectiveness 

Room 308 

Chair: Darcy B. Carr, MD 

8:00 a.m.–8:30 a.m. Glyburide and Metformin 

Mary F. Hebert, PharmD 

8:30 a.m.–9:00 a.m. Insulin Analogs and Human Insulin 

Gideon Koren, MD 

9:00 a.m.–9:30 a.m. Anti-Hypertensive Drugs 

Jason G. Umans, MD, PhD 

9:30 a.m.–10:00 a.m. Antidepressants 

Marlene P. Freeman, MD 

MONDAY—PROGRAM 

53



8:00 a.m.–10:00 a.m. 

(continued) 

From Genetic Association to Molecular Mechanism 

Room 315 

Chair: Leslie J. Baier, PhD 

8:00 a.m.–8:30 a.m. Functional Analysis of the PTPN22 Autoimmunity Gene 

Jane H. Buckner, MD 

8:30 a.m.–9:00 a.m. Deletion of the Mouse Slc30a8 Zinc Transporter and G6pc2 Glucose-6 Phosphatase Genes Have 

Opposite Effects on Insulin Secretion 

Richard M. O’Brien, PhD 

9:00 a.m.–9:30 a.m. Molecular Dissection of the ABCC8/KCNJ11 Gene 

Peter E. Light, PhD 

9:30 a.m.–10:00 a.m. Inactivation of the FTO Gene Protects Mice from Obesity 

Jens C. Brüning, MD 

Nanotechnology and Tissue Engineering for Beta Cell Replacement Therapy 

Room 221 

Chair: William L. Lowe, Jr., MD 

8:00 a.m.–8:40 a.m. Nanotechnology and Immunomodulation for Islet Transplantation 

Jeffrey A. Hubbell, PhD 

8:40 a.m.–9:20 a.m. Tissue Engineering and Local Immunomodulation 

Cherie Stabler, PhD 

9:20 a.m.–10:00 a.m. Scaffold Delivery Devices to Enhance Islet Graft Vascularization 

William L. Lowe, Jr., MD 


Cross-Talk in Insulin Signaling at the Cellular Level 

Room 304 E 

Chair: E. Steven Shoelson, MD, PhD 

8:00 a.m.–8:30 a.m. Role of JNK in Cross-Talk between Inflammatory Signaling and Insulin Signaling 

Gökhan S. Hotamisligil, MD, PhD 

8:30 a.m.–9:00 a.m. S6Kinase, Inflammatory Signaling, and Insulin Signaling 

Jianping Ye, MD 

9:00 a.m.–9:30 a.m. Cross-Talk between Angiotensin II and Insulin Signaling 

Mario J.A. Saad, MD, PhD 

9:30 a.m.–10:00 a.m. Dual Regulation of the mTor-S6Kinase Pathway by Adrenaline and Insulin in Adipocytes 

Sheila Collins, PhD 

Nutrient-Gut-Brain Modulators 

Room 311 

Chair: Lee M. Kaplan, MD, PhD 

8:00 a.m.–8:30 a.m. Gut-Hypothalamic Circuits in Appetite Control 

Tamas L. Horvath, DVM, PhD 

8:30 a.m.–9:00 a.m. Gut Microbe and Obesity 

Peter J. Turnbaugh, PhD 

9:00 a.m.–9:30 a.m. Intestinal Gluconeogenesis and Brain Control of Glucose Homeostasis 

Gilles Mithieux, PhD 

9:30 a.m.–10:00 a.m. Bariatric Surgery—Mechanisms for Amelioration of Diabetes and Obesity 

Lee M. Kaplan, MD, PhD 

54



8:00 a.m.–10:00 a.m. 

(continued) 

Does Autoimmunity Influence Beta Cell Regeneration 

Room 304 A 

Chair: David M. Harlan, MD 

8:00 a.m.–8:30 a.m. Activation of Beta Cell Regeneration by Inflammation—NPOD Dataset 

Roberto Gianini, MD 

8:30 a.m.–9:00 a.m. Activation of Beta Cell Regeneration by Inflammation 

Alberto Pugliese, MD 

9:00 a.m.–9:30 a.m. Inflammation and Beta Cell Regeneration 

Terry B. Strom, MD 

9:30 a.m.–10:00 a.m. T-Regs in Autoimmunity and Alloimmunity to Islet Transplantation 

Qizhi Tang, PhD 


Cardiovascular Complications of Diabetes...............................................................................................Abstracts 293-OR to 298-OR 


Co-Chairs: Maria F. Lopes-Virella, MD, PhD and Marian J. Rewers, MD, PhD 

With Edwin Bierman Lecture by Ira J. Goldberg, MD 

Diabetic Heart Diseases—Why 

Supported by an endowment established in 1999 by Merck 

Pediatric Diabetes—New Clinical Measurements, Approaches, and Outcomes.............................Abstracts 299-OR to 306-OR 

Room 307 

Co-Chairs: Larry A. Fox, MD and David M. Maahs, MD 

Integrated Physiology—Muscle..................................................................................................................Abstracts 307-OR to 314-OR 

Room 314 

Co-Chairs: Kitt Mia Falk Petersen, MD and Devjit Tripathy, MD, PhD 

10:15 a.m.–11:45 a.m. 

National Scientific & Health Care Achievement Awards Presentation 

Hall D 

and 

Outstanding Scientific Achievement Award Lecture 

Hall D 

Deconstructing Leptin—From Signals to Circuits 

Supported by an educational grant from Eli Lilly and Company 

Martin G. Myers, Jr., MD, PhD 


55



12:30 p.m.–1:45 p.m. 


Interest Group Discussion on Nutritional Science and Metabolism 

Room 209 

Diabetes Nutrition—A Global Perspective—Meal Planning Strategies from Around the World 

Alison Evert, MS, RD, CDE 

Interest Group Discussion on Epidemiology and Statistics 

Room 315 

Update on Epidemiologic Research to Explain the Higher Mortality in the Intensive Glycemic Control Arm of the ACCORD Trial 

John M. Lachin, ScD and Matthew C. Riddle, MD 

2:15 p.m.–4:15 p.m. 

Symposia 

Controversies in Blockade of the Renin-Angiotensin-Aldosterone System (RAAS) 

Room 224 

Chair: Nicholas Emanuele, MD 

2:15 p.m.–2:45 p.m. RAAS Blockers for Prevention of Diabetic Nephropathy 

Mark E. Cooper, PhD 

2:45 p.m.–3:15 p.m. RAAS Blockade and Progression of Established Chronic Kidney Disease 

Matthew R. Weir, MD 

3:15 p.m.–3:45 p.m. RAAS Inhibition in Patients with Cardiovascular Disease 

Michael A. Weber, MD 

3:45 p.m.–4:15 p.m. Use of RAAS Blockers in the Elderly Diabetic Patient 

Richard Glassock, MD 


Implications of the NAVIGATOR Trial for Prevention of Diabetes and Cardiovascular Disease in Subjects with 

Impaired Glucose Tolerance 


Chair: Hertzel C. Gerstein, MD 

2:15 p.m.–2:35 p.m. Background and Design of the NAVIGATOR Trial 

M. Angelyn Bethel, MD 

2:35 p.m.–2:55 p.m. Implications of NAVIGATOR Trial Results for Preventing Diabetes in Subjects with Impaired Glucose 

Tolerance 

Steve M. Haffner, MD 

2:55 p.m.–3:15 p.m. Implications of NAVIGATOR Trial Results for Preventing Cardiovascular Disease in Subjects with 

Impaired Glucose Tolerance 

Robert M. Califf, MD 

3:15 p.m.–4:15 p.m. Panel Discussion and Questions and Answers 


Lawrence A. Leiter, MD 

William C. Cushman, MD 

M. Angelyn Bethel, MD 

Steve M. Haffner, MD 

Robert M. Califf, MD 

56



2:15 p.m.–4:15 p.m. 

(continued) 

Integrating Complementary Practices into Diabetes Care—Herbs, Supplements, and Mindful Meditation 

Room 209 

Chair: Jane Jeffrie Seley, GNP, MPH, MSN, CDE, BC-ADM 

2:15 p.m.–2:45 p.m. Herbal Remedies for Diabetes—Show Me the Evidence 

Benjamin E. Kligler, MD 

2:45 p.m.–3:15 p.m. Counseling Your Patients about Herbal Remedies—Asking the Right Questions 

Laura Shane-McWhorter, PharmD, BCPS, FASCP, CDE, BC-ADM 

3:15 p.m.–3:45 p.m. Mindful Diabetes Management for Patients and Professionals 

Joseph B. Nelson, MA, LP, CST 

3:45 p.m.–4:15 p.m. Questions and Answers 

Updates on GLP-1 Agonists 



Chair: Steven V. Edelman, MD 

2:15 p.m.–2:45 p.m. Potential Cardiovascular Benefits 

Allison L. Cohen, MD 

2:45 p.m.–3:15 p.m. Long Acting GLP-1 Agonists on the Horizon 

Carol H. Wysham, MD 

3:15 p.m.–3:45 p.m. The Story on Pancreatitis and C-Cell Hyperplasia 

Kathleen M. Dungan, MD 

3:45 p.m.–4:15 p.m. GLP-1 Agonists and Transplants 

David M. Harlan, MD 

Pediatric Diabetes Trends—Epidemiology 2010 

Room 308 

Chair: Lori M. Laffel, MD 

2:15 p.m.–2:45 p.m. Escalating Incidence of Type 1 Diabetes in Youth—Why 

Anette-Gabriele Ziegler, MD 

2:45 p.m.–3:15 p.m. Are There Clusters of Increased Cases of Type 1 Diabetes 

Ralph B. D’Agostino, Jr., PhD 

3:15 p.m.–3:45 p.m. The Changing Natural History of Microvascular Complications in Childhood Onset Type 1 Diabetes 

Rebecca B. Lipton, PhD 

3:45 p.m.–4:15 p.m. Understanding the Numbers, Phenotype, and Trends of Type 2 Diabetes in Youth 

Joyce M. Lee, MD 

Joint ADA/AACC Symposium—Point of Care Devices for Glucose and HbA1C—Are They Up to the Task 

Room 311 

Chair: M. Sue Kirkman, MD 

2:15 p.m.–2:55 p.m. Glucose Meters—Need for Greater Accuracy (Lab Perspective) 

Mitchell G. Scott, PhD 

2:55 p.m.–3:35 p.m. Glucose Meters—Need for Greater Accuracy (Clinical Perspective) 

Richard Hellman, MD 

3:35 p.m.–4:15 p.m. Point of Care Testing for A1C—Is it Good Enough 

David B. Sacks, MBChB 


57



2:15 p.m.–4:15 p.m. 

(continued) 

Thyroid Hormone Signaling in Insulin Action and Metabolism 

Room 304 E 

Chair: Mary Elizabeth Patti, MD 

2:15 p.m.–2:45 p.m. Nuclear Corepressors, Thyroid Hormone Action, and Insulin Action in the Liver (NCOR) 

Anthony N. Hollenberg, MD 

2:45 p.m.–3:15 p.m. Role of Deiodinases in Insulin Action in Muscle and Adipose Tissue Physiology—Effects of Insulin 

Signaling, PPARG Induction of Deiodinases 

Antonio C. Bianco, MD, PhD 

3:15 p.m.–3:45 p.m. Thyroid Hormone-Linked Gene Expression in Human Fatty Liver 

Jussi A. Pihlajamäki, MD, PhD 

3:45 p.m.–4:15 p.m. Potential Therapeutic Role of TR Ligands in Clinical Medicine (Basic/Clinical Integration) 

John D. Baxter, MD 

Beta Cell Failure—The Key to Unlocking Type 2 Diabetes Mellitus 


Room 414 

Chair: Charles F. Burant, MD, PhD 

2:15 p.m.–2:45 p.m. Natural History and Novel Aspects of Beta Cell Dysfunction in Humans 

Gordon C. Weir, MD 

2:45 p.m.–3:15 p.m. Islet Remodeling and Alpha-Cell Proliferation in Baboons and Humans with Type 2 Diabetes Mellitus— 

Are We Closing the Circle 

Franco Folli, MD, PhD 

3:15 p.m.–3:45 p.m. Role of Lipotoxicity in Human Islet Dysfunction 

Roberto Lupi, PhD 

3:45 p.m.–4:15 p.m. TRB3 Mutations Cause Type 2 Diabetes Mellitus by Impairing Insulin Secretion 

Rohit N. Kulkarni, MD, PhD 



Update on BARI 2D—Treatment of Insulin Resistance............................................................................Abstracts 315-OR to 320-OR 

Room 307 

Co-Chairs: Thomas A. Buchanan, MD and Paul E. Knudson, MD 

With State of the Art Lecture by Saul M. Genuth, MD 

Treatment of Insulin Resistance—BARI 2D Insights 

Diabetes Outcomes and Related Conditions.............................................................................................Abstracts 321-OR to 328-OR 

Room 315 

Chair: Lynne E. Wagenknecht, DrPH 

Antigen-Specific and Non-Specific Mechanisms and Treatment of Diabetes...................................Abstracts 329-OR to 336-OR 

Room 221 

Chair: Li Wen, MD, PhD 

Life and Death in the Islet II.........................................................................................................................Abstracts 337-OR to 344-OR 

Room 304 A 

Chair: Ernesto Bernal-Mizrachi, MD 

58




Will DPP-4 Inhibitors Replace Sulfonylureas 



4:30 p.m.–5:00 p.m. Yes 

Michael A. Nauck, MD 

5:00 p.m.–5:30 p.m. No 

David R. Matthews, FRCP 

4:30 p.m.–6:30 p.m. 

Symposia 

From Children to Adults—Models of Transition Care in Youth with Diabetes 

Room 207 

Chair: Barbara J. Anderson, PhD 

4:30 p.m.–5:00 p.m. Identifying the Unique Needs of Transition Care for Young Adults with Type 1 Diabetes 

Howard A. Wolpert, MD 

5:00 p.m.–5:30 p.m. Adolescent Transition—Challenges and Resources for the Diabetes Educator 

Paula L. Jameson, ANRP, CDE 

5:30 p.m.–6:00 p.m. Moving On—Facts and Figures about the Transition to Adult Care 

Denis Daneman, MD 

6:00 p.m.–6:30 p.m. The Maestro Project—A Patient Navigator for the Transition of Care for Type 1 Youth 

Norma van Walleghem, MSc, RD, CDE 

Cardiovascular Disease and Diabetes—Nutrition Update 

Room 224 

Chair: Marion J. Franz, MS, RD, CDE 

4:30 p.m.–5:10 p.m. Dietary Fat and Cardiovascular Disease Risk—Past and Present 

Alice H. Lichtenstein, DSc 

5:10 p.m.–5:50 p.m. Omega-3 and Omega-6 Fatty Acids 

William S. Harris, PhD 

5:50 p.m.–6:30 p.m. Evidence for the Effectiveness of Nutrition Therapy Interventions for Cardiovascular Disease and Diabetes— 

The Mediterranean Diets 

Katherine Esposito, MD, PhD 

Novel Immune Mechanisms in Diabetes 

Room 221 

Chair: Alberto Pugliese, MD 

4:30 p.m.–5:00 p.m. Anti CD-3 Therapy in Type 2 Diabetes 

Hans-Michael Dosch, MD, PhD 

5:00 p.m.–5:30 p.m. Molecular Signatures of Inflammatory Responses in Type 1 Diabetes 

M. Virginia Pascual, MD 

5:30 p.m.–6:00 p.m. Molecular Signatures of Type 1 Diabetes Using Functional Genomics 

Martin J. Hessner, PhD 

6:00 p.m.–6:30 p.m. Innate Immune Control of the Gut Microbiota 

Alexander V. Chervonsky, MD, PhD 


59



4:30 p.m.–6:30 p.m. 

(continued) 

Epigenetics and Metabolic Disease 

Room 312 

Co-Chairs: Susan E. Ozanne, PhD and Anrdreas Plagemann, MD 

4:30 p.m.–5:00 p.m. Developmental Origins of Metabolic Disease 

Kevin L. Grove, PhD 

5:00 p.m.–5:30 p.m. Long Term Effects of Early Diet on Adult Health 

Susan E. Ozanne, PhD 

5:30 p.m.–6:00 p.m. Metabolic Memory—Hyperglycemia and Histone Methylation 

Assam El-Osta, PhD 

6:00 p.m.–6:30 p.m. Placental Programming—Epigenetics and Imprinting of the Trophoblast 

Miguel Constancia, PhD 

Mitochondria, Endoplasmic Reticulum (ER) and Oxidative Stress, and Beta Cell Survival 

Room 304 A 

Chair: Rupangi C. Vasavada, PhD 

4:30 p.m.–5:00 p.m. Over Accumulation of Misfolded Proinsulin in the ER—Stressing-Out without the Canonical 

ER Stress Response 

Douglas R. Cavener, PhD 

5:00 p.m.–5:30 p.m. Diabetes-Associated Transcription Factors Regulate Either Beta Cell Mitochondria or Endoplasmic 

Reticulum Function 

Claes B. Wollheim, MD 

5:30 p.m.–6:00 p.m. Where Are We with ER Stress 

Feroz R. Papa, MD, PhD 

6:00 p.m.–6:30 p.m. TXNIP and Beta Cell Survival 

Anath Shalev, MD 



Neuropathy....................................................................................................................................................... Abstracts 345-OR to 352-OR 

Room 208 

Chair: Arthur I. Vinik, MD 

Insulin Delivery Systems............................................................................................................................... Abstracts 353-OR to 360-OR 

Room 311 

Co-Chairs: Stuart A. Weinzimer, MD and Carol H. Wysham, MD 

Etiology of Type 2 Diabetes........................................................................................................................... Abstracts 361-OR to 368-OR 

Room 315 

Chair: Kristina M. Utzschneider, MD 

Molecular Mechanisms of Insulin Resistance/Action............................................................................ Abstracts 369-OR to 376-OR 

Room 304 E 

Chair: Umut Ozcan, MD 

Obesity—Human Pathophysiology and Treatment................................................................................... Abstracts 377-OR to 384-OR 

Room 314 

Chair: Christopher D. Still, DO 

60



8:00 a.m.–10:00 a.m. 

Session: Cardiovascular Complications of Diabetes 


Co-Chairs: Maria F. Lopes-Virella, MD, PhD and Marian J. Rewers, MD, PhD 

8:00 a.m.–8:15 a.m. 

293-OR Oxidized LDL and AGE—LDL Immune Complexes Strongly Predict the 

Development of Cardiovascular Disease in Type 1 Diabetes 

MARIA F. LOPES-VIRELLA, KELLY J. HUNT, NATHANIEL L. BAKER, JOHN 

LACHIN, G. VIRELLA, DCCT/EDIC RESEARCH GROUP, Charleston, SC, 

Washington, DC 

8:15 a.m.–8:30 a.m. 

294-OR Endothelial Dysfunction Is Associated with Arterial Stiffness in Hypertensive 

Patients with Type 2 Diabetes Mellitus but Not in Those without 


GIUSEPPE DANIELE, GIUSEPPE PENNO, ROSA MARIA BRUNO, ROBERTO 

MICCOLI, LAURA PUCCI, FRANCESCO STEA, ARMANDO MAGAGNA, 

STEF ANO TADDEI, LORENZO GHIADONI, STEFANO DEL PRATO, Pisa, 

Italy 

8:30 a.m.–8:45 a.m. 

295-OR Postprandial Glucose-Dependent Insulinotrophic Polypeptide Level 

Is Associated with Cardiovascular Function and the Prevalence of 

Cardiovascular Disease Independent of Glucose Level 

YASUNORI TAKATA, JUNICHI FUNADA, YUJI MATSUMOTO, GO 

HIASA, RYOICHI KAWAMURA, WATARU NISHIDA, HIROSHI ONUMA, 

HARUHIKO OSAWA, Toon, Japan, Saijyo, Japan 

8:45 a.m.–9:00 a.m. 

296-OR Liraglutide, a Once-Daily Human GLP-1 Analog, Lowers Systolic Blood 

Pressure (SBP) Independently of Concomitant Antihypertensive Treatment 

VIVIAN FONSECA, JORGE PLUTZKY, EDUARD MONTANYA, STEPHEN 

COLAGIURI, CHARLOTTE HANSEN, ALI FALAHATI, J. HANS DEVRIES, 

New Orleans, LA, Boston, MA, Barcelona, Spain, Sydney, Australia, 

Copenhagen, Denmark, Amsterdam, The Netherlands 

9:00 a.m.–9:15 a.m. 

297-OR Secreted Factors from Human Epicardial Fat Induce Insulin Resistance 

and Impair Cardiomyocyte Function 

SABRINA GREULICH, BUJAR MAXHERA, DANIELLA HERZFELD DE WIZA, 

HEIDI MUELLER, KONSTANTINOS SMIRIS, ARTUR LICHTENBERG, D. 

MARGRIET OUWENS, JUERGEN ECKEL, Düsseldorf, Germany 

9:15 a.m.–9:30 a.m. 

298-OR Coronary Artery Calcium Is Associated with Glycemic Variability Assessed 

by Continuous Glucose Monitoring in Men with Type 1 Diabetes 

JANET K. SNELL-BERGEON, ROSSANA ROMAN, SATISH GARG, DAVID 

M. MAAHS, IRENE E. SCHAUER, BRYAN C. BERGMAN, DAVID ROD- 

BARD, MARIAN REWERS, Aurora, CO, Potomac, MD 

9:30 a.m.–10:00 a.m. 

Edwin Bierman Lecture 

Diabetic Heart Diseases—Why 

Supported by an endowment established in 1999 by Merck 

Ira J. Goldberg, MD 

8:00 a.m.–10:00 a.m. 

Session: Pediatric Diabetes—New Clinical Measurements, Approaches, and 

Outcomes 

Room 307 

Co-Chairs: Larry A. Fox, MD and David M. Maahs, MD 

8:00 a.m.–8:15 a.m. 

299-OR Apparent Epidemic of Ketoacidosis in Children Diagnosed with Diabetes, 

Colorado, 2006-2009 

ARLETA REWERS, GEORGEANNA KLINGENSMITH, MARIAN REWERS, 

Aurora, CO 

8:15 a.m.–8:30 a.m. 

300-OR Cardiovascular (CV) Risk Factors Associated with Progression of Carotid 

Intima Media Thickness (cIMT) in Youth with Type 1 Diabetes (T1D) and 

Healthy Sibling Controls 

CHRISTINA M. SOUTHERN REH, CHUN-JU J. CHIEN, WENDY MACK, 

AVNI C. SHAH, BEATRIZ MEDINA, YANJIE LI, MINGZHU YAN, FRANCINE 

R. KAUFMAN, HOWARD N. HODIS, JAMIE R. WOOD, Los Angeles, CA 

8:30 a.m.–8:45 a.m. 

301-OR Validation of a Self-Report Measure To Assess Adherence in Youth with 

Type 1 Diabetes (T1D) 

SANJEEV N. MEHTA, LISA K. VOLKENING, TONJA R. NANSEL, MARGA- 

RET T. LAWLOR, LAURIE A. HIGGINS, LORI M.B. LAFFEL, Boston, MA, 

Bethesda, MD 

8:45 a.m.–9:00 a.m. 

302-OR Development/Initial Use of the Diabetes Support in School Scale 

DOREEN RADJENOVIC, LARRY A. FOX, MARTHA SENECA, Jacksonville, 

FL 

9:00 a.m.–9:15 a.m. 

303-OR Supplementary Fat Plus Protein (CFP) Counting for Insulin Bolus 

Calculation in Children with Pump Therapy Is Superior to Conventional 

Carbohydrate (CARB) Counting 

OLGA KORDONOURI, REINHARD HARTMANN, KERSTIN REMUS, 

SARAH BLÄSIG, EVELIN SADEGHIAN, CATHRIN GUNTERMANN, 

CHIARA SCARABELLO, NICOLIN DATZ, THORBEN KRACHT, THOMAS 

DANNE, Hannover, Germany 

9:15 a.m.–9:30 a.m. 

304-OR Factors Associated with Shared Decision-Making in Pediatric Type 1 

Diabetes: The SEARCH for Diabetes in Youth Study 

LAURA WILLIAMS, JESSICA VALENZUELA, MICHAEL SEID, RALPH 

D’AGOSTINO, JR., JEANETTE ANDREWS, BETH WAITZFELDER, JOYCE YI- 

FRAZIER, GIUSEPPINA IMPERATORE, BETH LOOTS, JEAN LAWRENCE, 

ELIZABETH MAYER-DAVIS, LAWRENCE DOLAN, Tampa, FL, Cincinnati, 

OH, Winston-Salem, NC, Honolulu, HI, Seattle, WA, Atlanta, GA, 

Pasadena, CA, Chapel Hill, NC 

9:30 a.m.–9:45 a.m. 

305-OR Newly Recommended “high-Risk” Hemoglobin A1C (A1C) Levels Are 

Associated with Decreased ß-Cell Function in Overweight Latino Youth 

CLAUDIA M. TOLEDO-CORRAL, LISA GUERRA-VARGAS, MICHAEL I. 

GORAN, MARC J. WEIGENSBERG, Los Angeles, CA 

9:45 a.m.–10:00 a.m. 

306-OR Performance of Nonfasting Tests in Relation to a Fasting 2 Hour Glucose 

Tolerance Test for Identifying Children with Prediabetes or Type 2 Diabetes 

JOYCE M. LEE, ACHAM GEBREMARIAM, JENNIFER LAROSE, EN-LING 

WU, JAMES GURNEY, Ann Arbor, MI 

MONDAY—ORALS 


61



8:00 a.m.–10:00 a.m. 

Session: Integrated Physiology—Muscle 

Room 314 

Co-Chairs: Kitt Mia Falk Peterson, MD and Devjit Tripathy, MD, PhD 


307-OR 

308-OR 

309-OR 

310-OR 

311-OR 

312-OR 

313-OR 

314-OR 

8:00 a.m.–8:15 a.m. 

Subjects with High and Low Muscle Mitochondrial Capacity Have Similar 

Fat Oxidation during Exercise. A Reappraisal of “Metabolic Flexibility” 

JOSE GALGANI, NEIL JOHANNSEN, SUDIP BAJPEYI, SHEILA COSTFORD, 

ALOK K. GUPTA, ERIC RAVUSSIN, Baton Rouge, LA 

8:15 a.m.–8:30 a.m. 

Mechanisms of Lipid- and Inflammation-Induced Insulin Resistance in 

Humans 

BETTINA NOWOTNY, DOROTHEA KROG, PETER J. NOWOTNY, CHRISTIAN 

HERDER, VOLKER BURKART, NANETTE C. SCHLOOT, JULIA SZENDROEDI, 

CHRISTIANE HABICH, DAN ZIEGLER, PETER SCHADE WALDT, MICHAEL 

RODEN, Düsseldorf, Germany 

8:30 a.m.–8:45 a.m. 

Effect of Aging and Exercise Training on NFkB Activity in Human Skeletal 

Muscle 

SANGEETA A. GHOSH, RAWEEWAN LERTWATTANARAK, KARTHIGAYAN 

SHANMUGASUNDARAM, JOAQUIN JOYA-GALEANA, MARJORIE 

MOLINA-CARRION, EUGENIO CERSOSIMO, RALPH A. DEFRONZO, 

SUMATHY MOHAN, NICOLAS MUSI, San Antonio, TX 

8:45 a.m.–9:00 a.m. 

Resveratrol Improves Insulin Action and Muscle Mitochondrial Function 

in Overweight Humans 

SYLVIA KEHLENBRINK, WEIJIE LI, SUDHA KOPPAKA, KEHAO ZHANG, 

NORICA TOMUTA, JILL CRANDALL, PREETI KISHORE, MEREDITH 

HAWKINS, Bronx, NY 

9:00 a.m.–9:15 a.m. 

Effect of Free Fatty Acid Reduction on Insulin and IκBa/NFκB Signaling 

in Obese and Type 2 Diabetic Subjects 

HANYU LIANG, PUNTIP TANTIWONG, APIRADEE SRIWIJITKAMOL, 

KARTHIGAYAN SHANMUGASUNDARAM, RALPH A. DEFRONZO, 

SUMATHY MOHAN, NICOLAS MUSI, San Antonio, TX 

9:15 a.m.–9:30 a.m. 

Salsalate Attenuates Free Fatty Acid-Induced Microvascular and 

Metabolic Insulin Resistance in Human Skeletal Muscle 

JIA LIU, LINDA A. JAHN, DALE E. FOWLER, EUGENE J. BARRETT, 

ZHENQI LIU, Charlottesville, VA 

9:30 a.m.–9:45 a.m. 

Leptin Receptors in Muscle Contribute to Energy Homeostasis 

KARYN J. CATALANO, NOBORU FURUKAWA, ODILE PERONI, 

BINGZHONG XUE, YOUNG-BUM KIM, ANNA LEE, KENJI ASAKURA, 

KAZUSHI ARAKI, ESRA ASILMAZ, JEFFREY M. FRIEDMAN, BARBARA 

B. KAHN, Boston, MA, New York, NY 

9:45 a.m.–10:00 a.m. 

Greater Mitochondrial Efficiency with Age Is Associated with Fat 

Accumulation and Insulin Resistance 

DARCY L. JOHANNSEN, STEVEN R. SMITH, ERIC RAVUSSIN, Baton 

Rouge, LA, Orlando, FL 

62 




2:15 p.m.–4:15 p.m. 

Session: Update on BARI 2D—Treatment of Insulin Resistance 

Room 307 

Co-Chairs: Thomas A. Buchanan, MD and Paul E. Knudson, MD 

2:15 p.m.–2:45 p.m. 

State of the Art Lecture 

Treatment of Insulin Resistance—BARI 2D Insights 

Saul M. Genuth, MD 

2:45 p.m.–3:00 p.m. 

315-OR INT131 Besylate, a Selective PPARγ Modulator (SPPARM), Improved 

Glycemic Control in Patients with Type 2 Diabetes without Causing the 

Edema Seen with Pioglitazone 

ALEX M. DEPAOLI, FREDRICK DUNN, PATRICK PAKELE, CHRISTOS 

MANTZ OROS, LINDA S. HIGGINS, Los Altos, CA, Dallas, TX, Boston, MA 

3:00 p.m.–3:15 p.m. 

316-OR ISIS 113715, a Novel PTP-1B Antisense Inhibitor, Improves Glycemic 

Control and Dyslipidemia and Increases Adiponectin Levels in T2DM 

Subjects Uncontrolled on Stable Sulfonylurea Therapy 

TERESA A. BRANDT, STANLEY T. CROOKE, ELIZABETH J. ACKERMANN, 

SHUTING XIA, ERIN S. MORGAN, QUE LIU, RICHARD S. GEARY, SANJAY 

BHANOT, Carlsbad, CA 

3:15 p.m.–3:30 p.m. 

317-OR Effect of Pioglitazone on Beta Cell Function in Impaired Glucose 

Tolerance: Results Form ACTNOW 

DEVJIT TRIPATHY, MARY ANN BANERJI, GEORGE A. BRAY, THOMAS A. 

BUCHANAN, STEPHEN CLEMENT, ROBERT R. HENRY, ABBAS KITABCHI, 

SUNDER MUDALIAR, NICOLAS MUSI, ROBERT RATNER, DAWN 

SCHWENKE, FRANKIE STENZ, RALPH A. DEFRONZO, San Antonio, TX 

3:30 p.m.–3:45 p.m. 

318-OR Evaluation of Insulin Sensitivity and Secretion in Type 2 Diabetic 

Patients (BMI



2:15 p.m.–4:15 p.m. 

Session: Antigen-Specific and Non-Specific Mechanisms and Treatment of 


Room 221 

Chair: Li Wen, MD, PhD 

2:15 p.m.–4:15 p.m. 

Session: Life and Death in the Islet II 

Room 304 A 

Chair: Ernesto Bernal-Mizrachi, MD 

329-OR 

2:15 p.m.–2:30 p.m. 

A Double-Blind Trial with Calcitriol in Recent Onset Type 1 Diabetes 

(IMDIAB XIII) 

CARLA BIZZARRI, DARIO PITOCCO, NICOLA NAPOLI, DARIA MAGGI, 

CONCETTA SURACI, ENRICO DI STASIO, GIUSEPPINA BERETTA ANGUIS- 

SO LA, PAOLO POZZILLI, IMDIAB GROUP, Rome, Italy 

337-OR 

2:15 p.m.–2:30 p.m. 

Fatty Acids Induce a Bi-Phasic Autophagic Response in INS-1 Cells 

Characterized by an Acute, Protective Stimulation Followed by a Detrimental 

Inhibition of Autophagic Flux 

GUY LAS, JAKOB WIKSTROM, GILAD TWIG, ORIAN SHIRIHAI, Boston, 

MA 

330-OR 

331-OR 

2:30 p.m.–2:45 p.m. 

Removal of Bovine Insulin from Cow’s Milk Formula Protects from the 

Early Initiation of Beta-Cell Autoimmunity 

OUTI VAARALA, MIKAEL KNIP, JORMA ILONEN, SUVI VIRTANEN, TERHI 

RUOHTULA, JOUNI PESOLA, TAINA HÄRKÖNEN, HARRI KALLIOI NEN, 

MATTI KOSKI, TUIJA POUSSA, JORMA KOMULAINEN, ANNA-LIISA 

JÄRVENPÄÄ, RAISA LOUNAMAA, HANS K. ÅKERBLOM, OLLI TOSSA- 

VAINEN, Helsinki, Finland, Turku, Finland, Kuopio, Finland, Tampere, 

Finland, Jyväskylä, Finland 

WITHDRAWN 

338-OR 

339-OR 

2:30 p.m.–2:45 p.m. 

PUMA/BBC3, a Pro-Apoptotic Gene, as a Novel Molecular Biomarker for 

TNF-α-Induced Human Islet Damage 

KEIKO OMORI, MASATO MITSUHASHI, KOHEI ISHIYAMA, JEFFREY 

RAWSON, IVAN TODOROV, FOUAD KANDEEL, YOKO MULLEN, Duarte, 

CA, Irvine, CA 

2:45 p.m.–3:00 p.m. 

Herp Is Required for ERAD-Mediated Degradation of Misfolded Insulin 

and Maintaining Pancreatic beta-Cell Survival 

MADURA SIVA, TAILA HARTLEY, ALLEN VOLCHUK, Toronto, ON, 

Canada 


332-OR 

333-OR 

334-OR 

335-OR 

336-OR 

2:45 p.m.–3:00 p.m. 

Inhibition of PI3Kγ Prevents and Reverses Autoimmune Diabetes 

JAMIL R. AZZI, NAGIB EL HADDAD, BECHARA MFARREJ, ROBERT 

MOORE, PETER T. JINDRA, WASSIM ELYAMAN, AYUMI TAKAKURA, 

SCOTT RODIG, SUNMI YANG, REZA ABDI, Boston, MA 

3:00 p.m.–3:15 p.m. 

Dietary Protection from Type 1 Diabetes Development Associated with 

Increased Foxp3 + Cells in the Gut Immune System of the LEW.1AR1- 

iddm/Ztm Rat 

JENNIFER A. CROOKSHANK, CHRISTOPHER PATRICK, GEN-SHENG 

WANG, FRASER W. SCOTT, Ottawa, ON, Canada 

3:15 p.m.–3:30 p.m. 

Type 1 Diabetes Induced by Thymus-Specific Deletion of Insulin 

YONG FAN, WILLIAM A. RUDERT, MARIA GRUPILLO, JING HE, 

CATARINA T. WONG, JOSEPH FLOUNLACKER, GIORGIA SISINO, 

MASSIMO TRUCCO, Pittsburgh, PA, Palermo, Italy 

3:30 p.m.–3:45 p.m. 

Identification of Small Molecules That Enhance Anti-Insulin Peptide T 

Cell Receptor Signaling and IL-10 Secretion 

AARON W. MICHELS, DAVID A. OSTROV, LI ZHANG, MAKA NAKAYAMA, 

MARK A. ATKINSON, GEORGE S. EISENBARTH, Aurora, CO, Gainseville, 

FL 

3:45 p.m.–4:00 p.m. 

A Combined Strategy of Thymoglobulin and CTLA4-Ig Cure Diabetes and 

Prevent Recurrence of Autoimmunity in NOD Mice 

ANDREA VERGANI, FRANCESCA D’ADDIO, ALESSANDRA PETRELLI, 

JOHN WILLIAMS, MOHAMED H. SAYEGH, PAOLO FIORINA, Boston, 

MA, Cambridge, MA 

340-OR 

341-OR 

342-OR 

343-OR 

344-OR 

3:00 p.m.–3:15 p.m. 

Accumulation of Polyubiquitinated Proteins and Deficiency in UCH-L1 

Are Characteristics of β-Cells in T2DM: Role of Human Islet Amyloid 

Polypeptide 

SAFIA COSTES, CHANG-JIANG HUANG, TATYANA GURLO, MARIE 

DAVAL, ALEKSEY V. MATVEYENKO, ALEXANDRA E. BUTLER, PETER C. 

BUTLER, Los Angeles, CA 

3:15 p.m.–3:30 p.m. 

GMRP1 Regulates Apoptosis or Proliferation of Islet β Cells Via AKT/ 

BAD Pathway 

XUANCHUN WANG, YU LIU, ZHIHONG YANG, ZHAOYUN ZHANG, 

FENGLING CHEN, RENMING HU, Shanghai, China 

3:30 p.m.–3:45 p.m. 

Glycogen Synthase Kinase-3β in Islet β-Cells Is Rate-Limiting for Cell 

Growth and Adaptation 

YANG LIU, KATSUYA TANABE, DELPHINE BARONNIER, LIN LI, SATISH 

PATEL, JAMES WOODGETT, CORENTIN CRAS-MÉNEUR, ALAN M. 

PERMUTT, St. Louis, MO, Toronto, ON, Canada, Ann Arbor, MI 

3:45 p.m.–4:00 p.m. 

Combined Genetic Loss of the Cell Cycle Inhibitors, p21cip1 and p27kip1, 

Reveals That Both Are Dispensable for Adult Beta Cell Proliferation, 

Mass and Function 

IRENE COZAR-CASTELLANO, JEFFREY KLEIMBERGER, EDWARD CHEROK, 

KAREN SELK, ANDREW F. STEWART, Cadiz, Spain, Pittsburgh, PA 

4:00 p.m.–4:15 p.m. 

Ablation of TSC2 Enhances Mitochondrial Function Via Activation of 

mTORC1 in β Cells 

MAKI KOYANAGI, YOSHIAKI KIDO, SHUN-ICHIRO ASAHARA, YUTAKA 

SHIGEYAMA, TOMOKAZU MATSUDA, YUKI SHIBUTANI, MEGUMI 

FUCHITA, TETSUO NODA, SUSUMU SEINO, MASATO KASUGA, Kobe, 

Japan, Tokyo, Japan 

64 




4:30 p.m.–6:30 p.m. 

Session: Neuropathy 

Room 208 

Chair: Arthur I. Vinik, MD 

4:30 p.m.–4:45 p.m. 

345-OR GLP-1 and Insulin Represent a Promising Treatment Modality for Diabetic 

Encephalopathy 

MASAHIRO OKOUCHI, NAOTSUKA OKAYAMA, RYOSUKE KIMURA, 

GOJI SHIGEKI, YASUHIRO TAMURA, KOHEI HATTORI, AKITOMO GOTO, 

YASUTAKA KAMIYA, TSUNEO OHNO, TAKASHI JOH, Inazawa, Japan, 

Nagoya, Japan 

4:45 p.m.–5:00 p.m. 

346-OR VEGF-A Transcription Factor (SB509) Enhances Epidermal Nerve Fiber 

and Blood Vessel Regeneration 

GIGI EBENEZER, ELY BENAIM, DALE ANDO, MICHAEL POLYDEFKIS, 

Baltimore, MD, Richmond, CA 

5:00 p.m.–5:15 p.m. 

347-OR Increased Expression of VEGF and Its Receptors in Diabetic Patients with 

Carpal Tunnel Syndrome Is Associated with Endoneurial Microangiopathy 

and Nerve Damage 

MOHAMMED S. AHMED, RAZWAN ALI, MOAZ MOJADDIDI, NIELS O.B. 

THOMSEN, LARS B. DAHLIN, MARIA JEZIORSKA, RAYAZ A. MALIK, 

Manchester, United Kingdom, Malmö, Sweden 

5:15 p.m.–5:30 p.m. 

348-OR Vascular Endothelial Growth Factor-A (VEGF-A) Zinc Finger Protein (ZFP) 

Activator (SB-509) Reverses Loss of Nerve Potentials in Severe Diabetic 

Peripheral Neuropathy (DPN). Interim Phase 2 Results (SB-509-0701-B 

Study) 

ELY BENAIM, SHELLEY WANG, SCOTT HAMILTON, KAYE SPRATT, 

MARTY GIEDLIN, DALE ANDO, SANGAMO DN STUDY GROUP, 

Richmond, CA 

5:30 p.m.–5:45 p.m. 

349-OR Therapeutic Possibility of Glucagon-Like Peptide-1 (GLP-1) Analog in 

Experimental Diabetic Neuropathy 

HEUNG YONG JIN, TAE SUN PARK, KYUNG AE LEE, JI HYUN PARK, 

HONG SUN BAEK, JeonJu, Republic of Korea 

5:45 p.m.–6:00 p.m. 

350-OR Role of Neuropeptides in Diabetic Heart Failure 

ASMA EJAZ, LEENA PRADHAN, FRANK W. LOGERFO, Boston, MA 

6:00 p.m.–6:15 p.m. 

351-OR Serum sICAM Levels in Patients with Mild to Moderate Diabetic Peripheral 

Neuropathy Can Help Identify Response to SB-509 Treatment 

RICHARD SUROSKY, ELY BENAIM, DALE ANDO, SHELLEY WANG, KAYE 

SPRATT, JASON HILL, JANET ESTEE, JEFF MILLER, ELO LEUNG, MARTIN 

GIEDLIN, Richmond, CA 

6:15 p.m.–6:30 p.m. 

352-OR Increased Expression of Alzheimer’s Disease Related Genes in Obesity 

ISLAM MOHAMED, HUSAM GHANIM, PARESH DANDONA, Buffalo, 

NY 

4:30 p.m.–6:30 p.m. 

Session: Insulin Delivery Systems 

Room 311 

Co-Chairs: Stuart A. Weinzimer, MD and Carol H. Wysham, MD 

4:30 p.m.–4:45 p.m. 

353-OR Human Hyaluronidase Coinjection Accelerates Insulin Pharmacokinetics 

and Glucodynamics of 3 Rapid Insulin Analogs 

LINDA MORROW, DOUGLAS MUCHMORE, MARCUS HOMPESCH, 

ELIZABETH LUDINGTON, DANIEL VAUGHN, Chula Vista, CA, San Diego, 

CA 

4:45 p.m.–5:00 p.m. 

354-OR Clinical Results of Automated Artificial Pancreatic β-Cell System with 

Unannounced Meal Using Multi-Parametric MPC and Insulin-on-Board 

EYAL DASSAU, HOWARD ZISSER, MATTHEW W. PERCIVAL, BENYAMIN 

GROSMAN, LOIS JOVANOVIC, FRANCIS J. DOYLE III, Santa Barbara, 

CA 

5:00 p.m.–5:15 p.m. 

355-OR Bi-Hormonal Closed-Loop Blood Glucose Control for Type 1 Diabetes 

STEVEN J. RUSSELL, FIRAS H. EL-KHATIB, DAVID M. NATHAN, ROBERT 

G. SUTHERLIN, EDWARD R. DAMIANO, Boston, MA 

5:15 p.m.–5:30 p.m. 

356-OR Glucagon at Clinically Relevant Concentrations Is Safe for Seven Days 

after Reconstitution: Results from Cytotoxicity Studies 

JOSEPH EL YOUSSEF, RYAN G. MASSOUD, JULIE M. ENGLE, JESSICA 

R. CASTLE, JULIE M. CARROLL, CHARLES T. ROBERTS, W. KENNETH 

WARD, Portland, OR 

5:30 p.m.–5:45 p.m. 

357-OR Reducing Postprandial Hypoglycemia Using Fuzzy Logic Controller with 

Insulin Dosing Governor 

ROBERT KIRCHER, YOUQING WANG, EYAL DASSAU, HOWARD ZISSER, 

LOIS JOVANOVIC, FRANCIS DOYLE, DON MATHESON, RICHARD MAUSETH, 

Seattle, WA, Santa Barbara, CA 

5:45 p.m.–6:00 p.m. 

358-OR Overnight Closed Loop (CL) Glucose Control Following Consumption of 

Alcohol in Adults with Type 1 Diabetes (T1D) 

KAVITA KUMARESWARAN, JULIE HARRIS, DANIELA ELLERI, JANET 

M. ALLEN, MARIANNA NODALE, JOANNA WESTON, MALGORZATA 

E. WILINSKA, DAVID B. DUNGER, STEPHANIE A. AMIEL, SIMON R. 

HELLER, MARK L. EVANS, ROMAN HOVORKA, Cambridge, United 

Kingdom, London, United Kingdom, Sheffield, United Kingdom 

6:00 p.m.–6:15 p.m. 

359-OR A1C and Hypoglycemia in Patients with Type 2 Diabetes Mellitus 

Incorporating Prandial Inhaled Technosphere Insulin into Their Usual 

Anti hyperglycemic Regimen vs Continuing Their Usual Antihyperglycemic 

Regimen 

PHILIP RASKIN, MARTIN D. PHILLIPS, ALICIA ROSSITER, ANDERS H. 

BOSS, PETER C. RICHARDSON, Dallas, TX, Valencia, CA 

6:15 p.m.–6:30 p.m. 

360-OR Comparative Trial between a Computer-Guided Intravenous Insulin 

Infusion Protocol vs. a Standard Insulin Infusion Algorithm vs. a Simple 

Calculated Insulin Infusion Protocol in the ICU 

ARCOT A. DWARAKANATHAN, ROBERT GALAGAN, GARY IWAMOTO, 

Chicago Heights, IL, Albuquerque, NM 



65




4:30 p.m.–6:30 p.m. 

Session: Etiology of Type 2 Diabetes 

Room 315 

Chair: Kristina M. Utzschneider, MD 

4:30 p.m.–4:45 p.m. 

361-OR Diabetes Risk with Biomarker-Calibrated Energy and Protein Intake in 

Postmenopausal Women 

LESLEY F. TINKER, GLORIA E. SARTO, BARBARA V. HOWARD, YING 

HUANG, MARIAN L. NEUHOUSER, KAREN L. MARGOLIS, YASMIN 

MOSSAVAR-RAHMANI, JEANNETTE BEASLEY, CHARLES B. EATON, 

LAWRENCE S. PHILLIPS, ROSS L. PRENTICE, Seattle, WA, Madison, 

WI, Washington, DC, New York, NY, Minneapolis, MN, Bronx, NY, 

Providence, RI, Atlanta, GA 

4:45 p.m.–5:00 p.m. 

362-OR Dietary Glycemic Index, Glycemic Load, Carbohydrate and Fiber and 

Incidence of Type 2 Diabetes in the EPIC-NL Study 

IVONNE SLUIJS, YVONNE T. VAN DER SCHOUW, DAPHNE L. VAN DER 

A, ANNEMIEKE M. SPIJKERMAN, DIEDERICK E. GROBBEE, JOLINE W. 

BEULENS, Utrecht, The Netherlands, Bilthoven, The Netherlands 

5:00 p.m.–5:15 p.m. 

363-OR Circulating sE-Selectin Predicts Type 2 Diabetes Independent of Other 

Biomarkers among High-Risk Persons in the Diabetes Prevention 

Program (DPP) 10-Year Follow-Up Study 

RONALD B. GOLDBERG, MARINELLA TEMPROSA, STEVEN M. HAFFNER, 

KIEREN J. MATHER, TREVOR J. ORCHARD, SANTICA M. MARCOVINA, 

DIABETES PREVENTION PROGRAM RESEARCH GROUP, Miami, FL, 

Rockville, MD, San Antonio, TX, Indianapolis, IN, Pittsburgh, PA, Seattle, 

WA 

5:15 p.m.–5:30 p.m. 

364-OR Retinol Binding Protein 4 and Incident Diabetes—The ARIC Study 

VIVIAN C. LUFT, MARK PEREIRA, JAMES S. PANKOW, CHRISTIE 

BALLANTYNE, DAVID COUPER, GERARDO HEISS, BRUCE B. DUNCAN, 

Porto Alegre, Brazil, Minneapolis, MN, Houston, TX, Chapel Hill, NC 

5:30 p.m.–5:45 p.m. 

365-OR Insulin Clearance and the Incidence of Type 2 Diabetes in Hispanics and 

African Americans: The IRAS Family Study 

ANTHONY J. HANLEY, STEVEN M. HAFFNER, LYNNE E. WAGENKNECHT, 

CARLOS LORENZO, JILL M. NORRIS, RICHARD BERGMAN, ANDREA 

ANDERSON, JEROME ROTTER, MARK O. GOODARZI, Toronto, ON, 

Canada, San Antonio, TX, Winston Salem, NC, Denver, CO, Los Angeles, 

CA 

5:45 p.m.–6:00 p.m. 

366-OR Late Phase Insulin Response during the Oral Glucose Tolerance Test 

Predicts Risk of Type 2 Diabetes 

TOMOSHIGE HAYASHI, EDWARD J. BOYKO, MARGUERITE J. MCNEELY, 

KYOKO KOGAWA SATO, DONNA L. LEONETTI, STEVEN E. KAHN, 

WILFRED Y. FUJIMOTO, Osaka, Japan, Seattle, WA 

6:00 p.m.–6:15 p.m. 

367-OR Disposition Index, Glucose Effectiveness, and Conversion to Type 2 

Diabetes: The Insulin Resistance Atherosclerosis Study (IRAS) 

CARLOS LORENZO, LYNNE E. WAGENKNECHT, MARIAN J. REWERS, 

ANDREW J. KARTER, BERGMAN N. BERGMAN, ANTHONY J. HANLEY, 

STEVEN M. HAFFNER, San Antonio, TX, Winston-Salem, NC, Aurora, 

CO, Oakland, CA, Los Angeles, CA, Toronto, ON, Canada 

6:15 p.m.–6:30 p.m. 

368-OR Adiponectin and the Incidence of Type 2 Diabetes in Hispanics (HA) and 

African Americans (AA): The IRAS Family Study 

ANTHONY J. HANLEY, LYNNE E. WAGENKNECHT, JILL M. NORRIS, 

RICHARD BERGMAN, ANDREA ANDERSON, Y.D. IDA CHEN, CARLOS 

LORENZO, STEVEN M. HAFFNER, Toronto, ON, Canada, Winston-Salem, 

NC, Denver, CO, Los Angeles, CA, San Antonio, TX 

4:30 p.m.–6:30 p.m. 

Session: Molecular Mechanisms of Insulin Resistance/Action 

Room 304 E 

Chair: Umut Ozcan, MD 

4:30 p.m.–4:45 p.m. 

369-OR Pigment Epithelium-Derived Factor (PEDF) Is One of the Most Abundant 

Proteins Secreted by Human Adipocytes and Induces Insulin Resistance 

and Inflammatory Signaling in Muscle and Fat Cells 

SUSANNE FAMULLA, DANIELA LAMERS, SONJA HARTWIG, ANDREA 

CRAMER, ANGELIKA HORRIGHS, WALTRAUD PASSLACK, STEFAN 

LEHR, HENRIKE SELL, JUERGEN ECKEL, Düsseldorf, Germany 

4:45 p.m.–5:00 p.m. 

370-OR Macrophage α1-AMP-Activated Protein Kinase (α1AMPK) Antagonizes 

Fatty Acid-Induced Inflammation through SIRT1 

ZHENGGANG YANG, BARBARA B. KAHN, HANG SHI, BINGZHONG XUE, 

Winston-Salem, NC, Boston, MA 

5:00 p.m.–5:15 p.m. 

371-OR Palmitate-Activated Macrophages Confer Insulin Resistance to Muscle 

Cells by a Mechanism Involving PKC theta 

GIRISH KEWALRAMANI, AMIRA KLIP, Toronto, ON, Canada 

5:15 p.m.–5:30 p.m. 

372-OR A Novel Interaction between the Regulatory Subunit of PI 3-Kinase and 

X-Box Binding Protein-1 Links Insulin Signaling and the Unfolded Protein 

Response 

JONATHON N. WINNAY, JEREMIE BOUCHER, MARCELO MORI, 

KOHJIRO UEKI, RONALD C. KAHN, Boston, MA, Tokyo, Japan 

5:30 p.m.–5:45 p.m. 

373-OR Roles of the ULK1-Atg13 Complex in Adipose Autophagy, Differentiation, 

and Metabolism 

SEUNG-HYUN RO, CHANG HWA JUNG, YOUNG-MI KIM, WENDY 

WRIGHT, DAVID A. BERNLOHR, DO-HYUNG KIM, Minneapolis, MN 

5:45 p.m.–6:00 p.m. 

374-OR CDK5 Inhibition Restores TNF-Alpha Induced Insulin Resistance in 3T3L1 

Adipocytes 

SHUICHI OKADA, JUNICHI OKADA, TSUGUMICHI SAITO, JUN 

NOHARA, HIROKI TAKAHASHI, KOSHI HASHIMOTO, MASANOBU 

YAMADA, HIROYUKI SHIMIZU, KIHACHI OHSHIMA, JEFFREY E. PESSIN, 

MASATOMO MORI, Maebashi, Japan, Yonago, Japan, Bronx, NY 

6:00 p.m.–6:15 p.m. 

375-OR Pleiotropic Action of ROCK1 in Insulin Signaling 

DEA HO LEE, JIANJIAN SHI, KWANG-HOON CHUN, YU YANG, JANICE 

M. ZABOLONTY, MORRIS F. WHITE, LEI WEI, YOUNG-BUM KIM, Jeju, 

Republic of Korea, Indianapolis, IN, Boston, MA, United States Virgin 

Islands 

6:15 p.m.–6:30 p.m. 

376-OR Signal Transduction Mechanisms by Which Adiponectin/AdipoR1 

Activate AMPK, SIRT1 and PGC-1alpha, Leading to Increased Mitochondrial 

Bioenergetics in Muscle Cells 

TOSHIMASA YAMAUCHI, MASATO IWABU, MIKI IWABU, KOHJIRO 

UEKI, TAKASHI KADOWAKI, Tokyo, Japan 

66 



MONDAY, June 28 

4:30 p.m.–6:30 p.m. 

Session: Obesity—Human Pathophysiology and Treatment 

Room 314 

Chair: Christopher D. Still, DO 

377-OR 

378-OR 

379-OR 

380-OR 

381-OR 

382-OR 

383-OR 

384-OR 

4:30 p.m.–4:45 p.m. 

Whole-Blood Transcriptomics Identifies Distinct Biological Pathways 

Associated with Obesity 

SUJOY GHOSH, ROBERT DENT, MARY-ELLEN HARPER, JOAN STUART, 

SHELBY GORMAN, RUTH MCPHERSON, Durham, NC, Ottawa, ON, 

Canada, Research Triangle Park, NC 

4:45 p.m.–5:00 p.m. 

Protein Tyrosine Phosphatase 1B (PTP1B) Abundance and Gene 

Expression in Skeletal Muscle Is Related to Clinical Parameters in Obese 

Subjects with Type 2 Diabetes 

APRIL STULL, ZHONG WANG, XIAN ZHANG, YONGMEI YU, JIANHUA 

QIN, WILLIAM T. CEFALU, Baton Rouge, LA 

5:00 p.m.–5:15 p.m. 

Physiopathological Mechanisms of the Diabetes Non-Reversion after 

RYGB 

FERNANDA F. HIRSCH, EVERTON CAZZO, JOSE PAREJA, ELINTOM 

CHAIM, SYLKA GELONEZE, BRUNO GELONEZE, Campinas, Brazil 

5:15 p.m.–5:30 p.m. 

Selective Denervation of the Omental Fat Depot in Dogs Supports the 

Chronic Sympathetic Stimulation on Visceral Lipolysis 

ANA VALERIA B. CASTRO, ORISON O. WOOLCOTT, ERLINDA L. 

KIRKMAN, HUIWEN LIU, DARKO STEFANOVSKI, CATHRYN M. KOLKA, 

L. NICOLE HARRISON, VIORICA IONUT, RICHARD N. BERGMAN, Los 

Angeles, CA 

5:30 p.m.–5:45 p.m. 

Prediction of Type 2 Diabetes with the Novel Metabolic Syndrome 

Consensus Definition: The Importance of Waist Circumference 

CHRISTOPH H. SAELY, ALEXANDER VONBANK, PHILIPP REIN, STEFAN 

BEER, TOBIAS GANSCH, SUSANNE GREBER, HEINZ DREXEL, Feldkirch, 

Austria, Triesen, Liechtenstein 

5:45 p.m.–6:00 p.m. 

A Low-Dose, Controlled-Release Formulation of Phentermine/Topira mate 

(PHEN/TPM) Demonstrates Significant Weight Loss, Clinical Improve ment 

in Overweight/Obese Patients with Type 2 Diabetes Mellitus (T2DM) or 

Prediabetes 

KISHORE GADDE, THOMAS NAJARIAN, WESLEY W. DAY, Durham, NC, 

Los Osos, CA, Mountain View, CA 

6:00 p.m.–6:15 p.m. 

Postprandial Alterations in the Processing of Visual Stimuli: An fMRI 

Study 

MARTIN HENI, RALF VEIT, CAROLINE KETTERER, MARTINA GUTHOFF, 

STEPHANIE KULLMANN, HUBERT PREISSL, HANS-ULRICH HARING, 

ANDREAS FRITSCHE, Tübingen, Germany 

6:15 p.m.–6:30 p.m. 

Effects of Oral and Intravenous Fat Load on Blood Pressure, Endothelial 

and Autonomic Function in Obese Subjects 

AIDAR R. GOSMANOV, DAWN SMILEY, NGOC-ANH LE, ROBALINO 

GONZALO, JOSELITA SIQUEIRA, RIYAZ PATEL, CHRISTOPHER NEWTON, 

BOBBY KHAN, ARSHED QUYYUMI, LIMIN PENG, GUILLERMO E. 

UMPIERREZ, Atlanta, GA 



67






Hall C 


12:00 p.m.–2:00 p.m. 


Clinical Therapeutics/New Technology—Pharmacologic Treatment of Diabetes or its Complications 

Complications—Hypoglycemia 

Complications—Neuropathy 

Diabetic Dyslipidemia 

Genetics—Type 1 Diabetes 

Genetics—Type 2 Diabetes 

Immunology 

Insulin Action—Glucose Transport 

Insulin Action—Insulin Resistance In Vitro 

Obesity—Animal 

Pregnancy 



MONDAY—POSTERS 

12:00 p.m.–1:00 p.m. 

1) Innovations in Novel Insulin Preparations (520-P–529-P) 

2) Cardiovascular Disease in Diabetes III (804-P–813-P) 

3) Retinopathy (1002-P–1011-P) 

4) Epidemiology of Diabetes Complications (1107-P–1116-P) 

5) Professional and Organizational Interventions to Improve 

Diabetes Care (1281-P–1290-P) 

6) Insulin Action—Metabolism (1382-P–1387-P) 

7) Liver—Molecular Mechanisms (1531-P–1541-P) 

8) Macronutrient Metabolism and Food Intake (1582-P–1591-P) 

9) Glucagon-Like Peptide-1 Biology (1625-P–1634-P) 

10) Beta Cell Stimulus-Secretion Coupling 

and Metabolism I (1717-P–1726-P) 

11) Obesity—Human Pathophysiology (1831-P–1840-P) 

12) Obesity—Human III (469-PP–472-PP; 1869-P–1870-P) 

13) Pediatrics—Type 1 Diabetes—Care and Outcomes (1905-P–1915-P) 

14) Diabetes and the Brain (1954-P–1961-P) 

15) Signal Transduction (Not Insulin Action) (2015-P–2020-P) 

1:00 p.m.–2:00 p.m. 

1) Insulin Delivery Systems and Analysis (530-P–539-P) 

2) Therapeutic Approaches to the Treatment of Insulin 

Resistance (735-P–741-P) 

3) Cardiovascular Disease in Diabetes IV (814-P–823-P) 

4) Genes Underlying Diabetic Nephropathy Pathogenesis and 

Mechanisms of Damage (925-P–933-P) 

5) Diabetes Education (1021-P–1030-P) 

6) Body Composition (1117-P–1126-P) 

7) Foot Complications of Diabetes (1199-P–1210-P) 

8) Therapeutic Decision Making in Diabetes—Importance of 

Choice and Timing (433-PP; 1291-P–1297-P) 

9) Insulin Action—Signal Transduction (1419-P–1424-P) 

10) Integrated Physiology—Liver (1542-P–1550-P) 

11) Biology of Other Hormones (1635-P–1644-P) 

12) Beta Cell Stimulus-Secretion Coupling 

and Metabolism II (1727-P–1736-P) 

13) Obesity—Human Treatment (1841-P–1848-P) 

14) Pediatrics—Correlates and Consequences 

of Obesity (1897-P–1904-P) 

15) Pediatrics—Type 2 Diabetes—Clinical Patterns 

in Youth (1921-P–1931-P) 

16) Psychosocial Issues in Pediatrics (1962-P–1971-P) 

2:00 p.m.–3:00 p.m. 

Poster Presenters Remove Materials from Board 

The ADA is not responsible for posters that remain after the removal time. 

All such posters will be discarded. 

68


TUESDAY, JUNE 29 


8:00 a.m.–10:00 a.m. 


Is the Patient with Well-Managed Type 1 Diabetes Still at Increased Risk for Cardiovascular Disease 


Room 224 

Co-Chairs: Satish K. Garg, MD and Henry N. Ginsberg, MD 

8:00 a.m.–8:30 a.m. Yes 

Robert H. Eckel, MD 

8:30 a.m.–9:00 a.m. No 

John D. Brunzell, MD 

Symposia 

The Potential of SGLT-2 Inhibitors for Diabetes Management 

Room 311 

Chair: Bernard Zinman, MD 

8:00 a.m.–8:40 a.m. The Biology of the Sodium-Glucose Co-Transporter LC5A Gene Family 

Robert R. Henry, MD 

8:40 a.m.–9:20 a.m. Renal Glucose Handling in Health and Diabetes 

John E. Gerich, MD 

9:20 a.m.–10:00 a.m. Clinical Trial Evidence for SGLT-2 Inhibition in Diabetes 

Lawrence Blonde, MD 

Late Breaking Clinical Studies 


Chair: David M. Kendall, MD 

Cardiovascular Risks of Hypoglycemia 

Room 209 

Chair: Gabriele Riccardi, MD 

8:00 a.m.–8:30 a.m. Hypoglycemia in Type 1 and Type 2 Diabetes Mellitus—The Size of the Problem 

Irving S. Gottesman, MD 

8:30 a.m.–9:00 a.m. Hypoglycemia, the Cardiovascular and Autonomic Nervous System—The Little We Know, the Lot We Ignore 

Francesca Porcellati, MD, PhD 

9:00 a.m.–9:30 a.m. Hypoglycemia-Activated Disease Mechanisms in High Risk Patients 

Angelo Avogaro, MD 

9:30 a.m.–10:00 a.m. How to Minimize Hypoglycemia in Intensive Treatment of Type 1 and Type 2 Diabetes Mellitus 

Antonio E. Pontiroli, MD 

TUESDAY—PROGRAM 

69




8:00 a.m.–10:00 a.m. 

(continued) 

The Art and Science of Gestational Diabetes Counseling 

Room 207 

Chair: Donna Jornsay, BSN, PNP, CDE 

8:00 a.m.–8:30 a.m. Evidence-Based Diabetes Education for Gestational Diabetes Mellitus 

TBD 

8:30 a.m.–9:00 a.m. The Ideal Gestational Diabetes Mellitus Meal Plan—Fact or Fiction 

Alyce M. Thomas, RD, CDN 

9:00 a.m.–9:30 a.m. Proactive Counseling for Post-Partum Risk Reduction 

Sophia A. Scarpelli-Havraniak, RN, CDE 


Diabetes Diagnosis Based on the A1C 


Chair: Richard M. Bergenstal, MD 

8:00 a.m.–8:40 a.m. Epidemiology of HbA1C for the Diagnosis of Diabetes and Prediction of its Outcomes 

Edward W. Gregg, PhD 

8:40 a.m.–9:20 a.m. Should A1C Be the Preferred Test to Diagnose Diabetes 

Robert M. Cohen, MD 

9:20 a.m.–10:00 a.m. A1C and the Glucose Tests Are Equally Valid 

Jonathan E. Shaw, MD 

B Cells in Type 1 Diabetes Mellitus 

Room 221 

Chair: Kevan C. Herold, MD 

8:00 a.m.–8:30 a.m. The Role of B Cells in the Pathogenesis of Type 1 Diabetes 

Thomas F. Tedder, PhD 

8:30 a.m.–9:00 a.m. How Do B Cells Initiate Type 1 Diabetes 

David V. Serreze, PhD 

9:00 a.m.–9:30 a.m. Treatment of Type 1 Diabetes with Rituxan—2-Year Follow-Up 

Mark D. Pescovitz, MD 

9:30 a.m.–10:00 a.m. Roll of B Cells in Initiation and Recurrent Beta Cell Destruction 

Ali Naji, MD, PhD 

Control of Adipose Tissue Development and Function 

Room 304 E 

Chair: Samuel W. Cushman, PhD 

8:00 a.m.–8:30 a.m. The Biogenesis of Brown Adipocytes 

Shingo Kajimura, PhD 

8:30 a.m.–9:00 a.m. Adipose Stem Cells and Diabetes 

Saverio Cinti, MD 

9:00 a.m.–9:30 a.m. The Twist-1/PPARdelta Axis in Brown Adipocytes 

Yong-Xu Wang, PhD 

9:30 a.m.–10:00 a.m. Immune Cells as Modulators of Adipose Tissue Function 

Guo-Ping Shi, DSc, ScD 

Role of the Kidney in the Pathogenesis of Type 2 Diabetes Mellitus 

Room 414 

Chair: Ralph A. DeFronzo, MD 

8:00 a.m.–8:30 a.m. Renal Glucose Reabsorption in Healthy and Type 2 Diabetic Subjects 

John P.H. Wilding, DM 

8:30 a.m.–9:00 a.m. The Impact of Mutations in SGLTs on Glucose Homeostasis 

Ernest M. Wright, DSc 

9:00 a.m.–9:30 a.m. Effects of SGLT2 Blockers on Kidney Function(s) in Early Diabetes 

Scott C. Thomson, MD 

9:30 a.m.–10:00 a.m. Effects of Glucotoxicity on In Vivo Insulin Secretion and Action 

R. Paul Robertson, MD 

70



8:00 a.m.–10:00 a.m. 

(continued) 


Room 304 A 

Chair: John C. Hutton, PhD 

8:00 a.m.–8:30 a.m. Insulin Secretion by the Pancreatic Beta Cell 

Louis H. Philipson, MD, PhD 

8:30 a.m.–9:00 a.m. SUR1 to EPAC2 

Susumu Seino, MD, PhD 

9:00 a.m.–9:30 a.m. Zinc Transporters and Beta Cell Function 

Frans C. Schuit, MD, PhD 

9:30 a.m.–10:00 a.m. Regulation of Beta Cell Function by Gq-Type Heterotrimeric G Proteins 

Jurgen Wess, PhD 

10:15 a.m.–12:15 p.m. 

Physiological Aspects of Hypoglycemia 

Room 208 

Chair: Geremia B. Bolli, MD 

10:15 a.m.–10:45 a.m. Glucose Sensing 

Barry E. Levin, MD 

10:45 a.m.–11:15 a.m. Brain Metabolism in Hypoglycemia—Animal Data 

Robert S. Sherwin, MD 

11:15 a.m.–11:45 a.m. Brain Metabolism in Human Hypoglycemia 

Elizabeth R. Seaquist, MD 

11:45 a.m.–12:15 p.m. Brain Damage and Subsequent Brain Pathology 

Marit R. Bjorgaas, MD 

Non-Caloric/Non-Nutritive Sweeteners—What’s New 

Room 224 

Chair: Hope S. Warshaw, RD, CDE, BC-ADM 

10:15 a.m.–10:55 a.m. What are the New Products Available for Consumers 

Beth Hubrich, MS, RD 

10:55 a.m.–11:35 a.m. Development and Implementation of Legislative and Regulatory Policy—How Safety of 

Non-Nutritive Sweeteners Is Determined 

Alan M. Rulis, PhD 

11:35 a.m.–12:15 p.m. Non-Nutritive Sweeteners—Effects on Food Intake and Appetite, and the Putative Mechanisms 

France Bellisle, PhD 

Results of the ACCORD Clinical Trial 


Chair: Denise Simons-Morton, MD, PhD 

10:15 a.m.–10:35 a.m. Main Results of the ACCORD Blood Pressure Trial 

William C. Cushman, MD 

10:35 a.m.–10:55 a.m. Main Results of the ACCORD Lipid Trial 

Henry N. Ginsberg, MD 

10:55 a.m.–11:15 a.m. Effect of 3.7 Years of Intensive Glycemic Control on Cardiovascular Outcomes after 5 Years of 

Total Follow-Up 


11:15 a.m.–11:35 a.m. Effect of Intensive Glycemia Treatment on Development and Progression of Microvascular Outcomes 

in the ACCORD Trial 

Faramarz Ismail-Beigi, MD, PhD 

11:35 a.m.–11:55 a.m. Effects of Intensive Glycemia and Blood Pressure Treatment and Dyslipidemia Management with Fenofibrate 

on Progression of Diabetic Retinopathy in the ACCORD Trial 

Emily Y. Chew, MD 


71



10:15 a.m.–12:15 p.m. 

(continued) 

What Has Genetics Taught Us From Gene to Human Physiology 

Room 311 

Chair: Rudolph L. Leibel, MD 

10:15 a.m.–10:45 a.m. Newer Molecular Genetics of Diabetes 

Rudolph L. Leibel, MD 

10:45 a.m.–11:15 a.m. MODY in Type 2 Diabetes Mellitus Revisited 

Philippe Froguel, MD, PhD 

11:15 a.m.–11:45 a.m. FTO and Obesity 

Timothy M. Frayling, PhD 

11:45 a.m.–12:15 p.m. Human Obesity and Insulin Resistance—Lessons from Experiments of Nature 

Stephen O’Rahilly, MD 


72

DAY-AT-A-GLANCE PROGRAm - American Diabetes Association

Create successful ePaper yourself

Delete template?

Save as template?